
<html lang="en"     class="pb-page"  data-request-id="33c0f3f3-636a-40ab-a2e3-f51bebb5f43c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2010.53.issue-5;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm901558p"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion" /></meta><meta name="dc.Creator" content="Caterina  Carmi" /></meta><meta name="dc.Creator" content="Andrea  Cavazzoni" /></meta><meta name="dc.Creator" content="Stefano  Vezzosi" /></meta><meta name="dc.Creator" content="Fabrizio  Bordi" /></meta><meta name="dc.Creator" content="Federica  Vacondio" /></meta><meta name="dc.Creator" content="Claudia  Silva" /></meta><meta name="dc.Creator" content="Silvia  Rivara" /></meta><meta name="dc.Creator" content="Alessio  Lodola" /></meta><meta name="dc.Creator" content="Roberta R.  Alfieri" /></meta><meta name="dc.Creator" content="Silvia  La Monica" /></meta><meta name="dc.Creator" content="Maricla  Galetti" /></meta><meta name="dc.Creator" content="Andrea  Ardizzoni" /></meta><meta name="dc.Creator" content="Pier Giorgio  Petronini" /></meta><meta name="dc.Creator" content="Marco  Mor" /></meta><meta name="dc.Description" content="Irreversible EGFR inhibitors can circumvent acquired resistance to first-generation reversible, ATP-competitive inhibitors in the treatment of non-small-cell lung cancer. They contain both a driver..." /></meta><meta name="Description" content="Irreversible EGFR inhibitors can circumvent acquired resistance to first-generation reversible, ATP-competitive inhibitors in the treatment of non-small-cell lung cancer. They contain both a driver..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 12, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm901558p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm901558p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm901558p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm901558p" /></link>
        
    
    

<title>Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm901558p" /></meta><meta property="og:title" content="Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0012.jpeg" /></meta><meta property="og:description" content="Irreversible EGFR inhibitors can circumvent acquired resistance to first-generation reversible, ATP-competitive inhibitors in the treatment of non-small-cell lung cancer. They contain both a driver group, which assures target recognition, and a warhead, generally an acrylamide or propargylamide fragment that binds covalently to Cys797 within the kinase domain of EGFR. We performed a systematic exploration of the role for the warhead group, introducing different cysteine-trapping fragments at position 6 of a traditional 4-anilinoquinazoline scaffold. We found that different reactive groups, including epoxyamides (compounds 3−6) and phenoxyacetamides (compounds 7−9), were able to irreversibly inhibit EGFR. In particular, at significant lower concentrations than gefitinib (1), (2R,3R)-N-(4-(3-bromoanilino)quinazolin-6-yl)-3-(piperidin-1-ylmethyl)oxirane-2-carboxamide (6) inhibited EGFR autophosphorylation and downstream signaling pathways, suppressed proliferation, and induced apoptosis in gefitinib-resistant NSCLC H1975 cells, harboring the T790M mutation in EGFR." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm901558p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm901558p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm901558p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm901558p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm901558p&amp;href=/doi/10.1021/jm901558p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2038-2050</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm901518t" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm901559e" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Caterina++Carmi">Caterina Carmi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Cavazzoni">Andrea Cavazzoni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefano++Vezzosi">Stefano Vezzosi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fabrizio++Bordi">Fabrizio Bordi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Federica++Vacondio">Federica Vacondio</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claudia++Silva">Claudia Silva</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Rivara">Silvia Rivara</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alessio++Lodola">Alessio Lodola</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roberta+R.++Alfieri">Roberta R. Alfieri</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++La+Monica">Silvia La Monica</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maricla++Galetti">Maricla Galetti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Ardizzoni">Andrea Ardizzoni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pier+Giorgio++Petronini">Pier Giorgio Petronini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marco++Mor">Marco Mor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Dipartimento di Medicina Sperimentale, Università degli Studi di Parma, Via Volturno 39, I-43125 Parma, Italy</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Oncologia Medica, Azienda Ospedaliero—Universitaria di Parma, V.le Gramsci 14, I-43126 Parma, Italy</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: +39 0521 905062. Fax: +39 0521 905006. E-mail: <a href="/cdn-cgi/l/email-protection#36575a5345455f59185a5952595a577643585f4644185f42"><span class="__cf_email__" data-cfemail="17767b7264647e78397b7873787b765762797e6765397e63">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm901558p&amp;href=/doi/10.1021%2Fjm901558p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2038–2050</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 12, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 October 2009</li><li><span class="item_label"><b>Published</b> online</span>12 February 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm901558p" title="DOI URL">https://doi.org/10.1021/jm901558p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2038%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DCaterina%2BCarmi%252C%2BAndrea%2BCavazzoni%252C%2BStefano%2BVezzosi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D5%26contentID%3Djm901558p%26title%3DNovel%2BIrreversible%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitors%2Bby%2BChemical%2BModulation%2Bof%2Bthe%2BCysteine-Trap%2BPortion%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2050%26publicationDate%3DMarch%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm901558p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3729</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">35</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm901558p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Caterina&quot;,&quot;last_name&quot;:&quot;Carmi&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Cavazzoni&quot;},{&quot;first_name&quot;:&quot;Stefano&quot;,&quot;last_name&quot;:&quot;Vezzosi&quot;},{&quot;first_name&quot;:&quot;Fabrizio&quot;,&quot;last_name&quot;:&quot;Bordi&quot;},{&quot;first_name&quot;:&quot;Federica&quot;,&quot;last_name&quot;:&quot;Vacondio&quot;},{&quot;first_name&quot;:&quot;Claudia&quot;,&quot;last_name&quot;:&quot;Silva&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Rivara&quot;},{&quot;first_name&quot;:&quot;Alessio&quot;,&quot;last_name&quot;:&quot;Lodola&quot;},{&quot;first_name&quot;:&quot;Roberta&quot;,&quot;last_name&quot;:&quot;R. Alfieri&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;La Monica&quot;},{&quot;first_name&quot;:&quot;Maricla&quot;,&quot;last_name&quot;:&quot;Galetti&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Ardizzoni&quot;},{&quot;first_name&quot;:&quot;Pier&quot;,&quot;last_name&quot;:&quot;Giorgio Petronini&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;Mor&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;2038-2050&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm901558p&quot;},&quot;abstract&quot;:&quot;Irreversible EGFR inhibitors can circumvent acquired resistance to first-generation reversible, ATP-competitive inhibitors in the treatment of non-small-cell lung cancer. They contain both a driver group, which assures target recognition, and a warhead, generally an acrylamide or propargylamide fragment that binds covalently to Cys797 within the kinase domain of EGFR. We performed a systematic exploration of the role for the warhead group, introducing different cysteine-trapping fragments at position 6 of a traditional 4-anilinoquinazoline scaffold. We found that different reactive groups, including epoxyamides (compounds 3−6) and phenoxyacetamides (compounds 7−9), were able to irreversibly inhibit EGFR. In particular, at significant lower concentrations than gefitinib (1), (2R,3R)-N-(4-(3-bromoanilino)quinazolin-6-yl)-3-(piperidin-1-ylmethyl)oxirane-2-carboxamide (6) inhibited EGFR autophosphorylation and downstream signaling pathways, suppressed proliferation, and induced apoptosis in gefitinib-resistant NS&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901558p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901558p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901558p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901558p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901558p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901558p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm901558p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901558p&amp;href=/doi/10.1021/jm901558p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm901558p" /></input><a href="/doi/pdf/10.1021/jm901558p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm901558p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm901558p%26sid%3Dliteratum%253Aachs%26pmid%3D20151670%26genre%3Darticle%26aulast%3DCarmi%26date%3D2010%26atitle%3DNovel%2BIrreversible%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BInhibitors%2Bby%2BChemical%2BModulation%2Bof%2Bthe%2BCysteine-Trap%2BPortion%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D5%26spage%3D2038%26epage%3D2050%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Irreversible EGFR inhibitors can circumvent acquired resistance to first-generation reversible, ATP-competitive inhibitors in the treatment of non-small-cell lung cancer. They contain both a driver group, which assures target recognition, and a warhead, generally an acrylamide or propargylamide fragment that binds covalently to Cys797 within the kinase domain of EGFR. We performed a systematic exploration of the role for the warhead group, introducing different cysteine-trapping fragments at position 6 of a traditional 4-anilinoquinazoline scaffold. We found that different reactive groups, including epoxyamides (compounds <b>3</b>−<b>6</b>) and phenoxyacetamides (compounds <b>7</b>−<b>9</b>), were able to irreversibly inhibit EGFR. In particular, at significant lower concentrations than gefitinib (<b>1</b>), (2<i>R</i>,3<i>R</i>)-<i>N</i>-(4-(3-bromoanilino)quinazolin-6-yl)-3-(piperidin-1-ylmethyl)oxirane-2-carboxamide (<b>6</b>) inhibited EGFR autophosphorylation and downstream signaling pathways, suppressed proliferation, and induced apoptosis in gefitinib-resistant NSCLC H1975 cells, harboring the T790M mutation in EGFR.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62358" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62358" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The epidermal growth factor receptor (EGFR<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>) <div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: EGFR, epidermal growth factor receptor; erbB2, human epidermal growth factor receptor 2; TK, tyrosine kinase; NSCLC, non-small-cell lung cancer; IGF-1R, insulin-like growth factor 1 receptor; PI3K, phosphoinositide-3 kinase; mTOR, mammalian target of rapamycin; MAPK, mitogen activated protein kinase; GSH, glutathione; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; HBTU, <i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate; DCC, <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide; rmsd, root-mean-square deviation.</p></div> is a validated target in cancer treatment strategies. EGFR is a member of the erbB receptor family (erbB1/EGFR, erbB2/HER2, erbB3/HER3, and erbB4/HER4) of tyrosine kinase (TK) that is overexpressed in several human solid tumors and is often associated with more aggressive disease and poorer clinical outcome.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Inhibition of the erbB-family receptor tyrosine kinases represented a major advance in the treatment of solid tumors, as demonstrated by the promising clinical activity of the EGFR tyrosine kinase inhibitors <b>1</b><a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> (gefitinib, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) and <i>N</i>-4-(3-ethynylanilino)-6,7-bis(2-methoxyethoxy)quinazoline<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> (erlotinib, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). These 4-anilinoquinazoline tyrosine kinase inhibitors compete with ATP in a reversible manner, binding to the kinase domain of the target. Although these drugs have been extremely effective in specific patient populations with tumor-containing mutated oncogenic forms of tyrosine kinases,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> the accumulating clinical experience on non-small-cell lung cancers (NSCLCs) indicates that most patients develop resistance.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In approximately half of NSCLC cases that showed an initial response to reversible EGFR tyrosine kinase inhibitors and subsequently progressed, resistance was associated with the emergence of a secondary mutation within the EGFR kinase domain: substitution of threonine 790 with methionine (T790M).<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> Threonine 790 is the gatekeeper residue in EGFR; its key location at the entrance of a hydrophobic pocket in the back of the ATP binding cleft makes it an important determinant of inhibitor specificity in protein kinases. Substitution of this residue in EGFR with the bulkier methionine causes resistance to tyrosine kinase reversible inhibitors, including gefitinib and erlotinib, and this had been attributed to an increased enzyme affinity for ATP.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Additional mechanisms of resistance to reversible EGFR inhibitors have been described, such as the activation of alternative tyrosine kinase receptors (IGF-1R), amplification of the MET gene, and constitutive activation of signaling pathways downstream of EGFR.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of reversible and irreversible EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A second generation of 4-anilinoquinazolines and 4-anilino-3-cyanoquinolines<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> carrying a Michael acceptor group at the 6-position, such as an acrylamide or propargylamide fragment, that irreversibly alkylates a cysteine residue (Cys797) close to the ATP binding site of EGFR<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> has been shown to overcome resistance.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a> Several of these inhibitors, such as <i>N</i>-[4-(3-chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]quinazolin-6-yl]-2-propenamide<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (CI-1033, canertinib, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) and (<i>E</i>)-<i>N</i>-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl}-4-(dimethylamino)-2-butenamide<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (HKI-272, neratinib, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), are currently undergoing clinical testing in patients that initially responded to erlotinib and gefitinib and subsequently relapsed.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Irreversible kinase inhibitors possess several advantages over conventional reversible ATP-competitive inhibitors. Considering that the targeted cysteine residue is conserved within the erbB-receptor family (Cys797 in EGFR, Cys805 in erbB2, and Cys803 in erbB4) and that only a limited group of kinases has a cysteine at the corresponding position, irreversible inhibitors are highly selective for erbB-family TK. Furthermore, covalent bond formation can circumvent competition with ATP, which under physiological conditions is in the millimolar range. On the other hand, the intrinsic reactivity of cysteine-reactive groups can incur augmented metabolic degradation, toxicity, or lack of target specificity. Despite the potential advantages of covalent binding kinase inhibitors, a drawback is that they might indiscriminately react with non-target-related proteins, giving rise to increased and unexpected toxicity.</div><div class="NLM_p">EGFR tyrosine kinase irreversible inhibitors reported in the literature are mostly characterized by a 4-anilinoquinazoline or 4-anilino-3-cyanoquinoline core structure (driver group) carrying a reactive center (warhead) able to covalently interact with the target protein by Michael addition or alkylation with the conserved, solvent exposed cysteine residue present in the enzyme. However, only a limited number of reactive warheads has been considered so far, such as acrylamide, propargylamide, vinylsulphonamide, chloroacetamide, and lipoic acid derivatives.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25 ref26 ref27">(22-27)</a> A more systematic structure−activity relationship study on different cysteine-reactive groups is required to provide new chemical starting points for further optimization of the efficacy/toxicity ratio.</div><div class="NLM_p">To date, many warheads have been integrated as reactive fragments into large collections of molecules that exhibit a wide spectrum of biological activities.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> All of them establish covalent, reversible, or irreversible interactions with nucleophilic residues exposed on the protein surface or into inner protein cavities. There are a variety of drugs, either approved or in clinical development, that covalently bind therapeutic targets, including ones that target cysteine protease, such as cathepsin and caspase,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> MMP13,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> thyroid hormone receptor,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and FAAH.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">Considering the acrylamide moiety of 6-acrylamide-4-(3-bromoanilino)quinazoline<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<b>2</b>, PD168393, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) as a reference warhead fragment, we explored the role of different reactive groups that covalently interact with cysteine residues when inserted on the 6-amino-4-(3-bromoanilino)quinazoline driver portion<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (<b>3</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Combining knowledge from existing drugs and late-stage clinical candidates that modify their target proteins through a covalent interaction, as well as from known EGFR tyrosine kinase inhibitors, we designed new irreversible EGFR inhibitors <b>4</b>−<b>14</b> carrying different cysteine-reactive groups at position 6 (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In particular, we linked the 6-amino-4-(3-bromoanilino)quinazoline driving portion of <b>5</b> with a number of warheads characterized by different reaction mechanisms toward nucleophiles: (i) nucleophilic addition (epoxides <b>4</b>, <b>5</b>, and <b>6</b>); (ii) nucleophilic substitution with in situ release of a leaving group (phenoxymethylamides <b>7</b>, <b>8</b>, and <b>9</b>); (iii) carbamoylation (carbamate <b>10</b>); (iv) Pinner reaction with formation of a thioimidate adduct (nitrile <b>11</b>); (v) disulfide bond formation (isothiazolinone <b>12</b>, benzisothiazolinone <b>13</b>, and thiadiazole <b>14</b>). The covalent interactions could be reversible or irreversible, depending on the reaction products and conditions. Moreover, warhead reactivity was also tentatively modulated by the introduction of electron-withdrawing groups (<b>7</b> vs <b>8</b> and <b>9</b>). In order to test nonspecific toxicity of the considered warheads, we synthesized compounds <b>15</b> and <b>16</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) where two of the cysteine-trap portions within the series were linked to a naphthalene nucleus not able to recognize the molecular target because it is lacking the structural elements required for interaction with the ATP-binding site of EGFR.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>3</b>−<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) H<sub>2</sub>SO<sub>4</sub>, formic acid, reflux; (ii) SOCl<sub>2</sub>, dioxane, reflux; (iii) 3-bromoaniline, <i>i</i>-PrOH, 60 °C; (iv) Fe, AcOH, EtOH/H<sub>2</sub>O, reflux. (v) Method A: dichloromethylene dimethyliminium chloride, NaHCO<sub>3</sub>, <b>17</b> (for <b>4</b>) or <b>18</b> (for <b>5</b>), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C. Method B: HBTU, DMF, <b>19</b>, room temp (for <b>6</b>). Method C: PCl<sub>5</sub>, <b>20</b> (for <b>7</b>) or <b>21</b> (for <b>8</b>) or <b>22</b> (for <b>9</b>) or <b>24</b> (for <b>11</b>), CH<sub>2</sub>Cl<sub>2</sub>, reflux. Method D: DCC, <b>23</b> (for <b>10</b>) or <b>25</b> (for <b>12</b>) or <b>26</b> (for <b>13</b>), DMF, 0 °C to room temp. Method E: <i>t</i>-ButOK, <b>27</b> (for <b>14</b>), DMF, microwave, 100 °C.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>15</b> and <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) Method A: dichloromethylene dimethyliminium chloride, NaHCO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C. (ii) Method C: PCl<sub>5</sub>, CH<sub>2</sub>Cl<sub>2</sub>, reflux.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. EGFR Tyrosine Kinase and Autophosphorylation Inhibition in A431 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col align="center" /></col></colgroup><tbody><tr valign="top"><td align="center"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0011.gif" alt="" id="fx2" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Concentration that inhibits by 50% EGFR tyrosine kinase activity. IC<sub>50</sub> values were measured by the phosphorylation of a peptide substrate using time-resolved fluorometry (see <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a>). Mean values of three independent experiments ± SEM are reported.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Inhibition of EGFR autophosphorylation was measured in A431 intact cells by Western blot analysis. Percent inhibition at 1 μM and IC<sub>50</sub> values were measured immediately after and 8 h after removal of the compound from the medium (1 h of incubation). Mean values of at least two independent experiments ± SEM are reported.</p></div></div></div><div class="NLM_p last">The new compounds were tested as EGFR tyrosine kinase inhibitors in enzyme-based and cell-based assays. Effects on downstream signaling pathways and antiproliferative and proapoptotic activities were also investigated in the gefitinib-resistant H1975 NSCLC cell line harboring the T790M mutation. Structure−activity relationships within the series of synthesized compounds were evaluated in order to identify new irreversible EGFR inhibitors active on a mutated gefitinib-resistant cell line.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The amides (<b>4</b>−<b>16</b>) of Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> were synthesized by coupling their precursor amines (<b>3</b> or <b>31</b>) with the appropriate carboxylic acid (<b>17</b>, <b>18</b>, <b>20</b>−<b>26</b>), carboxylate (<b>19</b>), or carboxylic ester (<b>27</b>), as described in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. 6-Amino-4-(3-bromoanilino)quinazoline <b>3</b> was prepared in three steps from 4-nitroanthranilonitrile <b>28</b> as previously described (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> Briefly, <b>28</b> was refluxed in formic acid and sulfuric acid to give 6-nitro-4-oxoquinazoline <b>29</b>, which was chlorinated with thionyl chloride in dioxane and subsequently treated with 3-bromoaniline to yield 6-nitro-4-(3-bromoanilino)quinazoline <b>30</b>. Reduction of the 6-nitro group with iron and acetic acid in aqueous ethanol gave the 6-amino-4-(3-bromoanilino)quinazoline <b>3</b>.</div><div class="NLM_p">The epoxy derivatives <b>4</b> and <b>5</b> were synthesized by coupling <b>3</b> with carboxylic acids <b>17</b> and <b>18</b>, respectively, using dichloromethylene dimethyliminium chloride as the coupling reagent (method A, Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>), while <b>6</b> was obtained from <b>19</b> with <i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HBTU) (method B, Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Compounds <b>7</b>−<b>9</b> and <b>11</b> were prepared as described in method C (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) from the amine <b>3</b> and the acyl chlorides obtained from <b>20</b> (for <b>7</b>), <b>21</b> (for <b>8</b>), <b>22</b> (for <b>9</b>), or <b>24</b> (for <b>11</b>). Derivatives <b>10</b>, <b>12</b>, and <b>13</b> were synthesized employing <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide (DCC) as the coupling reagent and <b>23</b>, <b>25</b>, and <b>26</b>, respectively, as carboxylic acids (method D). Finally, amide <b>14</b> was obtained by adding potassium <i>tert</i>-butoxide to a premixed mixture of ester <b>27</b> and amine <b>3</b> and exposing the reaction mixture to microwave irradiation (method E, Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Amides <b>15</b> and <b>16</b> were synthesized by reacting 2-naphthylamine <b>31</b> with carboxylic acids <b>17</b> (method A) and <b>20</b> (method C), respectively (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><div class="NLM_p">Carboxylic acids <b>20</b>−<b>24</b> are commercially available, while <b>17</b>−<b>19</b>, <b>25</b>, <b>26</b>, and the ester <b>27</b> were prepared as shown in Schemes <a class="ref internalNav" href="#sch3" aria-label="3">3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. The (2<i>R</i>,3<i>R</i>)-epoxy diester <b>32</b><a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> was partially hydrolyzed to the desired (2<i>R</i>,3<i>R</i>)-monoethyl ester <b>17</b><a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> or selectively monoreduced to the hydroxyl ester <b>33</b>.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Mesylation of the alcohol <b>33</b> and substitution with piperidine gave the epoxy ester <b>34</b>, which was hydrolyzed to afford the desired carboxylate <b>19</b>. The (2<i>S</i>,3<i>S</i>)-monoethyl ester <b>18</b> was synthesized by partial hydrolysis of the proper (2<i>S</i>,3<i>S</i>)-epoxy diethyl ester <b>35</b>.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Warheads <b>17</b>−<b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) KOH, abs EtOH, 0 °C; (ii) 5% KHSO<sub>4</sub>, room temp; (iii) NaBH<sub>4</sub>, EtOH, 0 °C; (iv) MsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp; (v) anhydrous piperidine, KI, DMF, 0 °C to room temp.</p></p></figure><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Warheads <b>25</b>−<b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) SO<sub>2</sub>Cl<sub>2</sub>, ClCH<sub>2</sub>CH<sub>2</sub>Cl, room temp; (ii) 1 M TFA, reflux; (iii) BrCH<sub>2</sub>COOEt, Et<sub>3</sub>N, THF, room temp; (iv) HCl reflux; (v) CH<sub>2</sub>Cl<sub>2</sub>, reflux; (vi) NCCOOEt, <i>p</i>-xylene, reflux.</p></p></figure><div class="NLM_p last">The isothiazolinone derivative <b>25</b> was synthesized as shown in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. 3,3′-Dithiodipropionamide <b>36</b><a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> was cyclized with sulfuryl chloride to isothiazolinone <b>37</b>,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> which was hydrolyzed to the desired carboxylic acid <b>25</b> by refluxing in 1 M trifluoroacetic acid. The benzisothiazolinone carboxylic acid <b>26</b> and the ethyl 3-isopropyl-1,2,4-thiadiazole-5-carboxylate <b>27</b> were prepared as described in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>, according to literature methods.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Molecular Modeling</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">When irreversible enzyme inhibition is required, both warhead reactivity and compound specificity, conferred by a driver portion responsible for noncovalent recognition at the binding site, are important in the search for an effective inhibitor. Cocrystallization of <b>2</b> within the catalytic site of EGFR<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> revealed that this inhibitor covalently binds the Cys797 sulfur atom, adopting an orientation similar to that found for several kinases in complexes with reversible quinazoline inhibitors.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> To find out whether the introduction of a warhead differing from the acrylamide chemotype at the quinazoline ring was consistent with the recognition of the EGFR active site, docking simulations of compounds <b>4</b>−<b>14</b> were performed using the publicly available coordinate of the EGFR−<b>2</b> covalent adduct.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Docking runs revealed that all the inhibitors could be accommodated within EGFR active site with a binding mode resembling that of the acrylamide derivative <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> and Figure S1−S11, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), indicating that the presence of a bulky warhead directly attached, or spaced by an appropriate linker, did not affect the crystallographic-like binding mode of the quinazoline moiety.<a onclick="showRef(event, 'ref23 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref23 ref47 ref48 ref49">(23, 47-49)</a> Indeed, the two crucial hydrogen bonds between the 4-(3-bromoanilino)quinazoline driving portion and the EGFR active site, one with Met793 and the other, through a conserved water molecule, with Thr790, were formed by all the compounds within the series.</div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking of compound <b>6</b> within the EGFR kinase domain. Compound <b>6</b> (green carbons) undertakes several polar interactions (highlighted with orange lines) at the EGFR kinase active site (black carbons and white cartoons): (i) a direct hydrogen bond between the quinazoline N1 and the backbone NH of Met793; (ii) a water molecule mediated hydrogen bond between quinazoline N3 and the side chain of Thr790; (iii) a salt bridge between Asp800 and the piperidine nitrogen. The SH group of Cys797 is at 4.13 Å from the closest carbon atom of the epoxy warhead, ready for the nucleophilic attack.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Docking studies also gave information on the positions of the warheads of the new inhibitors with respect to Cys797. Reference compound <b>2</b>, docked in its noncovalent form, placed the β-carbon atom of the acrylamide portion at 4.15 Å from the sulfhydryl group of Cys797. Equally, compounds <b>4</b>−<b>14</b> placed the reactive center of the warhead at similar distances from this nucleophile (Table S2, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Although the formation of a covalent adduct can be significantly affected by dynamical effects (e.g., trajectory of the nucleophile on the electrophilic center), these docking simulations qualitatively suggested that the warheads of <b>4</b>−<b>14</b> may potentially undergo to a nucleophilic attack by Cys797.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75457" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75457" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The newly synthesized 4-(3-bromoanilino)quinazoline derivatives were tested as EGFR inhibitors in enzyme-based and cell-based assays. The effects of the compounds on the kinase activity of human EGFR were quantified by measuring the phosphorylation of a peptide substrate, using time-resolved fluorometry (see <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a>). Results are reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. In accordance with our docking hypothesis and with the SAR profile of the 4-anilinoquinazoline ring,<a onclick="showRef(event, 'ref23 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref23 ref47 ref48 ref49">(23, 47-49)</a> the ATP-binding site of EGFR was tolerant to the introduction of differently sized and shaped substituents at position 6. In the tested conditions, the reference compound <b>2</b> showed an IC<sub>50</sub> of 1.7 nM. Substitution of the acrylamide warhead of <b>2</b> with an epoxy (<b>4</b>−<b>6</b>), a carbonylic (carbamate <b>10</b> and nitrile <b>11</b>), or a (benzo)isothiazolinonic (<b>12</b> and <b>13</b>) one generally produced equally potent or more potent inhibitors. On the contrary, the phenoxyacetamide derivatives (<b>7</b>−<b>9</b>) proved less effective than <b>2</b> but yet maintained IC<sub>50</sub> values in the low nanomolar range. Only the introduction of a thiadiazole warhead (<b>14</b>) notably reduced EGFR tyrosine kinase inhibition potency.</div><div class="NLM_p">The ability of the compounds to irreversibly inhibit EGFR autophosphorylation was investigated in the A431 human epidermoid cancer cell line by Western blotting. Percent inhibitions at 1 μM are also reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Results were compared with those observed for the reference compounds <b>2</b> and <b>3</b>, recognized irreversible and reversible EGFR inhibitors, respectively. A431 cells, which overexpress wild type EGFR, were treated with each inhibitor for 1 h and then washed free of drug. The degree of EGFR autophosphorylation was measured either immediately after or 8 h after removal of the inhibitor from the medium.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> For compounds that showed the highest inhibitory potencies toward EGFR at 1 μM, dose dependency was investigated and IC<sub>50</sub> determined (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). As previously reported,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> compounds showing 80% or greater EGFR inhibition 8 h after their removal from the medium were designated as irreversible inhibitors while compounds showing 20−80% inhibition were designated as partially irreversible ones. Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> indicates that reference compound <b>2</b> and several of the newly synthesized derivatives, <b>4</b>−<b>6</b> and <b>9</b>, irreversibly inhibit EGFR activity, with inhibition values higher than 90% after an 8 h washout. On the other hand, compounds <b>7</b>−<b>8</b> and <b>10</b>−<b>14</b> were only partially irreversible under the tested conditions, with percent inhibition of EGFR autophosphorylation between 24% and 80%. As expected, the reference reversible compound <b>3</b>, which completely inhibited EGFR activity after 1 h of treatment at 1 μM, did not show any inhibitory activity 8 h after its removal from the medium.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Irreversible inhibitory action of compounds <b>4</b>−<b>9</b> on EGFR autophosphorylation. A431 cells were incubated with the investigated compound for 1 h and stimulated with EGF either immediately after or 8 h after removal of the compound from the medium. Western blot analysis was done using monoclonal antibodies directed to p-Tyr1068. <b>2</b> and <b>3</b> were used as irreversible and reversible reference compounds, respectively. Representative blots of three independent experiments are shown. Total EGFR is shown as loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>4</b>−<b>6</b>, which contain an epoxy group at position 6, irreversibly inhibited EGFR at 1 μM. In fact, their inhibitory effect persisted up to 8 h after removal from the medium, probably because this class of compounds can undergo nucleophilic attack on the epoxide by Cys797 to generate an enzyme-bond addition product. This mechanism of irreversible action through the alkylation of the Cys797 has been reported in the literature for other warheads.<a onclick="showRef(event, 'ref23 ref34'); return false;" href="javascript:void(0);" class="ref ref23 ref34">(23, 34)</a> Compounds <b>4</b>−<b>6</b> showed dose-dependent inhibition of EGFR autophosphorylation in A431 cells with IC<sub>50</sub> values comparable to that of <b>2</b>. In particular, the (2<i>R</i>,3<i>R</i>)-ethyl 3-(4-(3-bromoanilino)quinazolin-6-ylcarbamoyl)oxirane-2-carboxylate (<b>4</b>) had an IC<sub>50</sub> of 0.011 μM immediately after 1 h of treatment and and IC<sub>50</sub> of 0.145 μM 8 h after the removal of the compound from the reaction medium (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Its (2<i>S</i>,3<i>S</i>)-enantiomer <b>5</b> was slightly less potent in inhibiting EGFR after 1 h of treatment (IC<sub>50</sub> = 0.034 μM) and showed slightly higher potency 8 h after removal of the compound (IC<sub>50</sub> = 0.068 μM, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>D and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). While these limited differences may not accurately establish structure−activity relationships, we surmised that the IC<sub>50</sub> at 1 h, together with the IC<sub>50</sub> measured on the purified enzyme, reflects both reversible binding to the EGFR catalytic site, by weak interactions at the enzyme surface, and irreversible binding, due to the formation of a covalent bond with an exposed cysteine. On the other hand, the IC<sub>50</sub> measured 8 h after ligand removal would stem from the extent of irreversible covalent bonding. As observed for both acrylamide and propargylamide derivatives,<a onclick="showRef(event, 'ref22 ref50'); return false;" href="javascript:void(0);" class="ref ref22 ref50">(22, 50)</a> the introduction of a basic group in the warhead-containing side chain improved inhibitor potency. The amino group can act as (i) an intramolecular catalyst for nucleophilic additions to the cysteine-reactive center, (ii) a water-solubilizing group, since it points out of the ATP-binding pocket toward the solvent environment, and (iii) an additional site for hydrogen bond recognition with acidic residues within the EGFR binding site. Although docking of compound <b>6</b> within the EGFR active site suggests a specific role for its piperidine fragment in ligand recognition, the presence of the piperidino group does not improve the affinity toward purified EGFR enzyme with respect to the epoxy succinate <b>4</b>.</div><div class="NLM_p">On the other hand, the introduction of a piperidino group increased the inhibitory activity of compound <b>6</b> with IC<sub>50</sub> of 0.007 and 0.044 μM at 1 and 8 h after treatment, respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>E and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The binding pose, reported in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, shows that while the 4-anilinoquinazoline portion forms the conventional pattern of hydrogen bonds with the EGFR hinge region,<a onclick="showRef(event, 'ref13 ref45 ref46 ref51'); return false;" href="javascript:void(0);" class="ref ref13 ref45 ref46 ref51">(13, 45, 46, 51)</a> the protonated nitrogen of the piperidine ring can form an additional hydrogen bond with the acidic group of Asp800.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a> This interaction, rather than improving the recognition of <b>6</b> at the active site, may facilitate the nucleophilic attack at the epoxy ring by Cys797.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">The 6-phenoxyacetamide derivatives <b>7</b>−<b>9</b> are potentially able to undergo a nucleophilic attack by Cys797 on their α-methylene, with formation of a covalent adduct with the enzyme and in situ release of a phenol leaving group. Similar chemical approaches to EGFR inhibition have been tried with the α-chloro- and α-methoxyacetamides,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> showing that only the more reactive α-chloroacetamide derivatives give irreversible EGFR inhibition. We introduced the phenoxyacetamide fragment in view of its intermediate reactivity toward nucleophilic substitutions, which can be further modulated by ring substitution. Compounds <b>7</b>−<b>9</b> showed percent inhibitions at 1 μM between 92% and 97%, 1 h after treatment, and between 71% and 91%, 8 h after removal of the compound from the medium. Complete dose−inhibition curves showed that the introduction of a fluorine on the phenoxy aromatic ring did not significantly affect the inhibitory effect of <b>8</b> (IC<sub>50</sub> of 0.076 and 0.292 μM at 1 and 8 h after treatment, respectively) with respect to the unsubsituted <b>7</b> (IC<sub>50</sub> of 0.031 and 0.291 μM). Moreover, the pentafluoro substitution (compound <b>9</b>), while it gave a comparable IC<sub>50</sub> at 1 h after treatment, significantly increased EGFR inhibition after 8 h (IC<sub>50</sub> = 0.078 μM, lower than the reference compound <b>2</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>H and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Since the introduction of the electron-withdrawing fluorine is responsible for increased reactivity toward nucleophilic substitution, the remarkable potency of the pentafluoro substituted derivative <b>9</b> under these conditions can be attributed to its increased reactivity versus the nucleophilic Cys797, giving the substitution product. These results indicate that this class shows promise for chemical optimization by modification of the stereoelectronic features of the phenolic leaving group. Beyond its interest as a warhead, phenoxyacetamide derivatives could also be exploited to design and optimize leaving groups that may be pharmacologically active in a multitarget approach.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a></div><div class="NLM_p">Compound <b>10</b>, characterized by a carbamate group linked to the quinazoline driver portion through a glycine spacer, gave EGFR inhibition of 95% and 80% at 1 μM at 1 and 8 h after removal from the medium, respectively. Carbamates can form covalent adducts by carbamoylation of serine or cysteine residues, which can be slowly hydrolyzed to re-establish the enzyme in the active form.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Although EGFR average inhibition at 8 h was less than 90%, this group appeared to be worthy of consideration as a warhead or at least as a starting point for further chemical optimization.</div><div class="NLM_p">The cyanoacetamide derivative <b>11</b> inhibited EGFR autophosphorylation 1 h after treatment at 1 μM (95% inhibition), while only a residual effect persisted 8 h after washout (24% inhibition). Nitriles are known to form, through a Pinner-like reaction, covalent reversible thioimidate ester adducts with biological nucleophiles such as cysteine.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Compounds <b>10</b> and <b>11</b> both contain warheads able to establish covalent, reversible interactions with nucleophilic cysteine residues. On the other hand, even though irreversible inhibition was achieved by carbamate derivative <b>10</b>, only a residual effect was observed 8 h after treatment with compound <b>11</b>, suggesting that the thiocarbamate adduct is more stable than the thioimidate ester one. Therefore, although irreversible inhibition might be attained by chemical optimization with this class of derivatives, the nitrile warhead looks less promising than the previously cited ones, with respect to the present target.</div><div class="NLM_p">Finally, derivatives <b>12</b>−<b>14</b> can covalently react with Cys797 via disulfide bond formation, following ring-opening by breaking of the sulfenamide bond.<a onclick="showRef(event, 'ref30 ref56'); return false;" href="javascript:void(0);" class="ref ref30 ref56">(30, 56)</a> Compounds <b>12</b> and <b>13</b>, bearing an isothiazolinone and a benzisothiazolinone group, respectively, inhibited EGFR in a reversible manner, since inhibition was significantly reduced 8 h after removal from the medium (<b>12</b>, 80% and 25% inhibition at 1 and 8 h after treatment, respectively; <b>13</b>, 69% and 31%, respectively). Only the thiadiazole derivative <b>14</b> was able to produce a significant, yet partial, irreversible inhibition of EGFR, as demonstrated by 67% inhibition of autophosphorylation 8 h after treatment. This warhead has been employed to design active-site directed inhibitors of different enzymes with a cysteine in their active site.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">The design of a covalent inhibitor presents the risk that enzyme inhibition is mainly the result of high warhead reactivity, which would result in nonspecific reactions with many possible off-targets. To test the role of the 4-anilinoquinazoline driving portion, which should be to confer target selectivity to poorly reactive warheads, we synthesized compounds <b>15</b> and <b>16</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), where two of the most active cysteine-trap portions of the series were linked to a simple naphthalene nucleus. In principle, the naphthalene ring is not able to recognize the molecular target because it lacks the structural elements required for interaction with the ATP-binding site of EGFR.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> As expected, compound <b>15</b>, carrying an epoxysuccinic group analogue to compound <b>4</b>, and compound <b>16</b>, containing the same side chain as compound <b>7</b>, did not inhibit EGFR, demonstrating that target specificity of the series is due to driver-portion recognition within the EGFR active site. Interestingly, compounds <b>15</b> and <b>16</b> exhibited less than 10% inhibition of A431 cell proliferation at concentrations up to 10 μM, indicating the absence of nonspecific cellular toxicity of the considered warheads (data not shown). Moreover, the formation of conjugates with glutathione was evaluated in aqueous buffered solution by LC−UV and LC−ESI-MS (see <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a>) to assess the intrinsic reactivity of the warheads toward a thiol derivative. Neither the epoxy derivatives <b>4</b> and <b>15</b> nor the phenoxyacetamides <b>7</b> and <b>16</b> gave any measurable adduct with GSH after 1 h of incubation (data not shown). On the other hand the acrylamide <b>2</b> showed conversion of 36.2 ± 1.9% of the starting compound to its GSH conjugate ([M + H]<sup>+</sup> = 676.11) under the same conditions (mean ± SD; <i>n</i> = 3).</div><div class="NLM_p">We next tested the antiproliferative activity of compounds exhibiting highest potency as EGFR irreversible inhibitors on the gefitinib-resistant H1975 NSCLC cell line, by MTT assay. Results were compared with those of the reference compounds <b>1</b>−<b>3</b> in the same test. As reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, compound <b>4</b> exhibited a dose-dependent inhibition of H1975 cell proliferation with an IC<sub>50</sub> similar to that of <b>1</b> (IC<sub>50</sub>s of 6.76 and 8.26 μM, respectively). Interestingly, introduction of the basic piperidino group on the reactive side chain made compound <b>6</b> 4 times more active than <b>1</b> on H1975 cells (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A and Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), with an antiproliferative IC<sub>50</sub> of 1.72 μM. The 6-phenoxyacetamide derivatives <b>8</b> and <b>9</b> showed IC<sub>50</sub> on H1975 cells proliferation in the same range of the reference compound <b>1</b> (IC<sub>50</sub> of 7.82 and 11.02 μM, respectively).</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effectiveness of irreversible EGFR inhibitor <b>6</b> in H1975 NSCLC cell line. (A) Antiproliferative effects of compound <b>6</b> (▲) in comparison with <b>1</b> (●) on H1975 cell line, harboring the resistance-associated mutation T790M. Cell proliferation was determined by MTT assay, as described in the <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a>. Results are reported as the mean ± SD of three independent experiments: (∗) <i>P</i> < 0.01 for each dose versus <b>1</b>; <i>n</i> = 3. (B) Comparison of compounds <b>6</b>, <b>1</b>, and <b>2</b> in their ability to suppress EGFR autophosphorylation (p-EGFR), erbB2 autophosphorylation (p-erbB2), and phosphorylation of downstream effectors AKT (p-Akt) and MAPK (p-p44/42) in H1975 cells. Total EGFR, erbB2, AKT, and MAPK are shown as loading controls.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Viability Inhibition of H1975 Gefitinib-Resistant Cell Line<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th align="center">compd</th><th align="center">H1975 cell line, IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top"><td align="left"><b>1</b></td><td align="left">8.26 ± 1.11</td></tr><tr valign="top"><td align="left"><b>2</b></td><td align="left">0.61 ± 0.05</td></tr><tr valign="top"><td align="left"><b>3</b></td><td align="left">19.5 ± 2.46</td></tr><tr valign="top"><td align="left"><b>4</b></td><td align="left">6.76 ± 0.60</td></tr><tr valign="top"><td align="left"><b>6</b></td><td align="left">1.72 ± 0.47</td></tr><tr valign="top"><td align="left"><b>8</b></td><td align="left">7.82 ± 1.19</td></tr><tr valign="top"><td align="left"><b>9</b></td><td align="left">11.0 ± 1.08</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Concentration that inhibits by 50% the proliferation of NSCLC H1975. The cell proliferation was determined by the MTT assay after 72 h of incubation with compounds (0.1−20 μM). Mean values of three independent experiments ± SEM are reported.</p></div></div></div><div class="NLM_p">We then examined the ability of compound <b>6</b> to inhibit EGFR signaling in the NSCLC cell line H1975 harboring the T790M mutation. <b>1</b> and <b>2</b> were used as reference compounds. Results of Western blot analysis are illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B. Compound <b>6</b> produced a dose-dependent inhibition of EGFR and erbB2 autophosphorylation with complete inhibition at 1 μM. By contrast, <b>1</b> showed marginal activity on EGFR and erbB2 in H1975 cells up to 10 μM. Compound <b>6</b> was also considerably more effective than <b>1</b> in inhibiting the two major signaling pathways activated by EGFR, the PI3K/AKT/mTOR and the RAS/RAF/MAPK cascades having a central role in controlling cell survival, cell growth, and proliferation (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B).</div><div class="NLM_p">Finally, we observed that compound <b>6</b> killed more cells (25−30% at 5 μM) when compared with control or cells treated with the reference compound <b>1</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A) and was associated with caspase-3 activation (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). After 2 days of treatment at 5 μM, compound <b>6</b> significantly cleaved this proapoptotic protein from its inactive precursor form into active fragments. These results suggest that this new irreversible inhibitor can have both a cytostatic and a cytotoxic effect on the H1975 cancer cell line. On the other hand, compound <b>6</b> proved to have only a weak cytotoxic profile on a cell line where proliferation is not driven by EGFR activity, excluding off-target general cytotoxic effects. In fact, compound <b>6</b> at 10 μM inhibited less than 50% of SW620 cell proliferation, similar to what was observed for <b>1</b> and for the epoxysuccinic derivative <b>4</b>, while the acrylamide derivative <b>2</b> gave an IC<sub>50</sub> of 8.23 ± 1.08 μM (Table S3, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of compound <b>6</b> on H1975 cell death. (A) H1975 cells were treated with the indicated concentration of compound <b>1</b> and compound <b>6</b> for 72 h and then analyzed with propidium iodide/Hoechst 33342 staining to assess cell death: (∗) <i>P</i> < 0.01 for each dose versus control; <i>n</i> = 3. (B) At the same time the cleavage of procaspase-3 was assessed on lysate proteins by Western blotting. The migration position of each full-length procaspase and those of its processing products are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We report here an exploration of possible warheads for EGFR inhibition, extended to the most important classes of clinically exploitable ones. We investigated warheads that covalently react with cysteine via nucleophilic addition (epoxides <b>4</b>−<b>6</b>), nucleophilic substitution (phenoxyacetamides <b>7</b>−<b>9</b>), carbamoylation (carbamate <b>10</b>), Pinner reaction (nitrile <b>11</b>), and disulfide bond formation (isothiazolinone <b>12</b>, benzisothiazolinone <b>13</b>, thiadiazole <b>14</b>).</div><div class="NLM_p">Compounds from different chemical classes proved efficient in irreversibly inhibiting EGFR autophosphorylation.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Epoxy derivatives <b>4</b>−<b>6</b> showed potencies comparable to that of the acrylamide reference compound <b>2</b>. As expected from the structure of EGFR, the introduction of a terminal basic group (compound <b>6</b>) significantly improved inhibition of both EGFR autophosphorylation and cell proliferation, suggesting that the identified compounds could be starting points for further structure-based optimization. Compound <b>6</b> inhibited EGFR downstream signaling pathways and showed cytostatic and cytotoxic activities on gefitinib-resistant NSCLC cells (H1975). Another interesting warhead is represented by the phenoxyacetamides (<b>7</b>−<b>9</b>), which in principle can release a leaving group on nucleophilic substitution and may be considered for a multidrug approach in cancer treatment. Promising results were also observed with the carbamate <b>10</b> and the thiadiazole <b>14</b>.</div><div class="NLM_p last">In conclusion, the results described here extend the chemical diversity of new irreversible EGFR inhibitors, and similar chemical approaches could be exploited to design compounds targeting noncatalytic cysteines by covalent bond formation.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18388" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18388" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Reagents were obtained from commercial suppliers and used without further purification. Solvents were purified and stored according to standard procedures. Anhydrous reactions were conducted under a positive pressure of dry N<sub>2</sub>. Reactions were monitored by TLC, on Kieselgel 60 F 254 (DC-Alufolien, Merck). Final compounds and intermediates were purified by flash chromatography (SiO<sub>2</sub> 60, 40−63 μm). Microwave reactions were conducted using a CEM Discover synthesis unit (CEM Corp., Matthews, NC). Melting points were not corrected and were determined with a Gallenkamp melting point apparatus. The <sup>1</sup>H NMR spectra were recorded on a Bruker 300 MHz Avance spectrometer. Chemical shifts (δ scale) are reported in parts per million (ppm) relative to the central peak of the solvent. <sup>1</sup>H NMR spectra are reported in the following order: multiplicity, approximate coupling constant (<i>J</i> value) in hertz (Hz), and number of protons; signals were characterized as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), dt (doublet of triplets), q (quartet), m (multiplet), br s (broad signal). Mass spectra were recorded using an API 150 EX instrument (Applied Biosystems/MDS SCIEX, Foster City, CA). Liquid chromatography/mass spectrometry analysis was performed on a Agilent 1100 LC gradient system and on an Applied Biosystem 150-EX single quadrupole mass spectrometer equipped with a TurboIonSpray ion source working in positive ion mode. Compounds <b>1</b>,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a><b>2</b>,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and <b>3</b><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> were synthesized according to literature methods. The final compounds were analyzed on ThermoQuest (Italia) FlashEA 1112 elemental analyzer for C, H, and N. Analyses were within ±0.4% of the theoretical values (Table S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). All tested compounds were >95% pure by elemental analysis.</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> (2<i>R</i>,3<i>S</i>)-Ethyl 3-(Piperidin-1-ylmethyl)oxirane-2-carboxylate (<b>34</b>)</h3><div class="NLM_p last">A 0 °C cooled solution of (2<i>R</i>,3<i>S</i>)-ethyl 3-(hydroxymethyl)oxirane-2-carboxylate <b>33</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (405 mg, 2.77 mmol) and Et<sub>3</sub>N (582 μL, 4.16 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (12 mL) was stirred for 30 min before the dropwise addition of methanesulfonyl chloride (MsCl) (407 μL, 4.16 mmol). The mixture was then stirred for 10 min at 0 °C and for 2 h at room temperature. Then the solvent was evaporated. The resulting yellow paste was dissolved in anhydrous DMF (12 mL), and KI (23 mg, 0.14 mmol) was added. The yellow solution was cooled to 0 °C and stirred for 5 min before the dropwise addition of anhydrous piperidine (830 μL, 8.31 mmol). The resulting suspension was slowly warmed to room temperature and stirred for 7 days, diluted with saturated aqueous NaHCO<sub>3</sub> (85 mL), and extracted with Et<sub>2</sub>O. The combined organic layers were dried and evaporated to give a brown oil that was purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 100:0 to 96:4), furnishing <b>34</b> as a yellow oil (30%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.25 (t, <i>J</i> = 7.1 Hz, 3H), 1.39 (m, 2H), 1.55 (m, 4H), 2.31 (dd, <i>J</i> = 13.6, 6.4 Hz, 1H), 2.36−2.55 (m, 4H), 2.71 (dd, <i>J</i> = 13.6, 3.4 Hz, 1H), 3.19 (d, <i>J</i> = 2.0 Hz, 1H), 3.29 (m, 1H), 4.18 (m, 2H).</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Potassium (2<i>R</i>,3<i>S</i>)-3-(Piperidin-1-ylmethyl)oxirane-2-carboxylate (<b>19</b>)</h3><div class="NLM_p last">To an ice cold stirring solution of (2<i>R</i>,3<i>S</i>)-ethyl 3-(piperidin-1-ylmethyl)oxirane-2-carboxylate <b>34</b> (170 mg, 0.80 mmol) in absolute EtOH (1 mL), a solution of KOH (45 mg, 0.8 mmol) in absolute EtOH (1.5 mL) was added dropwise. The resulting mixture was stirred for 2 h at 0 °C. The solvent was removed under reduced pressure, and the residue was washed with petroleum ether. The product <b>19</b> was obtained as a pale-brown solid (83%): mp >230 °C; MS (APCI) <i>m</i>/<i>z</i> 184.2; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.49 (m, 2H), 1.63 (m, 4H), 2.32 (dd, <i>J</i> = 13.4, 6.7 Hz, 1H), 2.54 (m, 4H), 2.74 (dd, <i>J</i> = 13.4, 3.7 Hz, 1H), 3.02 (d, <i>J</i> = 2.16 Hz, 1H), 3.12 (m, 1H).</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 2-(3-Oxoisothiazolin-2-yl)acetic acid (<b>25</b>)</h3><div class="NLM_p last">A suspension of ethyl 2-(3-oxoisothiazolin-2-yl)acetate <b>37</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> (200 mg, 1.07 mmol) in 1 M trifluoroacetic acid (TFA) (25 mL, 25 mmol) was refluxed for 12 h and then evaporated. The residue was dried at 50−55 °C in vacuo to yield <b>25</b> (98%) as a white solid: mp 171−172 °C; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.41 (s, 2H), 6.19 (d, <i>J</i> = 6.2 Hz, 1H), 8.51 (d, <i>J</i> = 6.2 Hz, 1H).</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> (2<i>R</i>,3<i>R</i>)-Ethyl 3-(4-(3-Bromoanilino)quinazolin-6-ylcarbamoyl)oxirane-2-carboxylate (<b>4</b>)</h3><div id="sec6_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Method A</h4><div class="NLM_p last">Dichloromethylene dimethyliminium chloride (356 mg, 2.19 mmol) was added to a stirred solution of (2<i>R</i>,3<i>R</i>)-2,3-epoxysuccinic acid monoethyl ester <b>17</b><a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (350 mg, 2.19 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (10 mL). After the reactants were stirred for 1 h with ice-cooling, 6-amino-4-(3-bromoanilino)quinazoline <b>3</b> (458 mg, 1.46 mmol) and NaHCO<sub>3</sub> (613 mg, 7.3 mmol) were added, and the suspension was stirred for 1 h at 0 °C. The mixture was washed with water, dried, and concentrated to obtain the crude compound. Crystallization from MeOH gave the pure product <b>4</b> as white crystals (60%): mp (MeOH) >230 °C (dec); MS (APCI) <i>m</i>/<i>z</i> 458.3, 459.2; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.26 (t, <i>J</i> = 7.1 Hz, 3H), 3.82 (d, <i>J</i> = 1.7 Hz, 1H), 3.93 (d, <i>J</i> = 1.7 Hz, 1H), 4.23 (q, <i>J</i> = 7.1 Hz, 2H), 7.29 (d, <i>J</i> = 8.1 Hz, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 7.82−7.92 (m, 3H), 8.16 (br s, 1H), 8.60 (s, 1H), 8.72 (d, <i>J</i> = 1.3 Hz, 1H), 9.93 (br s, 1H), 10.80 (br s, 1H). Anal. (C<sub>20</sub>H<sub>17</sub>BrN<sub>4</sub>O<sub>4</sub>) C, H, N.</div></div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (2<i>S</i>,3<i>S</i>)-Ethyl 3-(4-(3-Bromoanilino)quinazolin-6-ylcarbamoyl)oxirane-2-carboxylate (<b>5</b>)</h3><div class="NLM_p last">6-Amino-4-(3-bromoanilino)quinazoline <b>3</b> was reacted with (2<i>S</i>,3<i>S</i>)-2,3-epoxysuccinic acid monoethyl ester <b>18</b><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> according to the procedure described in <a class="ref internalNav" href="#sec6_4_1" aria-label="Method A.">Method A.</a> The crude product was purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 99:1 to 97:3) to give <b>5</b> (66%) as a white solid: mp (MeOH) >230 °C; MS (APCI) <i>m</i>/<i>z</i> 457.9, 459.3; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.26 (t, <i>J</i> = 7.2 Hz, 3H), 3.81 (d, <i>J</i> = 1.7 Hz, 1H), 3.92 (d, <i>J</i> = 1.7 Hz, 1H), 4.23 (q, <i>J</i> = 7.1 Hz, 2H), 7.29 (d, <i>J</i> = 8.1 Hz, 1H), 7.35 (t, <i>J</i> = 7.8 Hz, 1H), 7.80−7.87 (m, 2H), 7.89 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 8.16 (s, 1H), 8.60 (s, 1H), 8.72 (s, 1H), 9.94 (br s, 1H), 10.80 (br s, 1H). Anal. (C<sub>20</sub>H<sub>17</sub>BrN<sub>4</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (2<i>R</i>,3<i>S</i>)-<i>N</i>-(4-(3-Bromoanilino)quinazolin-6-yl)-3-(piperidin-1-ylmethyl)oxirane-2-carboxamide (<b>6</b>)</h3><div id="sec6_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Method B</h4><div class="NLM_p last">To a suspension of potassium (2<i>R</i>,3<i>S</i>)-3-(piperidin-1-ylmethyl)oxirane-2-carboxylate <b>19</b> (58 mg, 0.26 mmol) in anhydrous DMF (2 mL), <i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HBTU) (205 mg, 0.54 mmol) was added at room temperature. The mixture was stirred for 40 min before the dropwise addition of 6-amino-4-(3-bromoanilino)quinazoline <b>3</b> (80 mg, 0.26 mmol) in DMF (2 mL). The reaction mixture was stirred for 16 h, the solvent was removed, and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with saturated aqueous Na<sub>2</sub>CO<sub>3</sub>. The organic phase was evaporated and the crude product purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 99:1 to 97:3) to give <b>6</b> as a pale-yellow solid (30%): mp >230 °C; MS (APCI) <i>m</i>/<i>z</i> 482.2, 484.2; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.41−1.43 (m, 2H), 1.53−1.64 (m, 4H), 2.36 (dd, <i>J</i> = 13.6, 6.7 Hz, 1H), 2.48−2.56 (m, 4H), 2.80 (dd, <i>J</i> = 13.7, 3.4 Hz, 1H), 3.30−3.34 (m, 1H), 3.39 (d, <i>J</i> = 1.89 Hz, 1H), 7.21−7.22 (m, 2H), 7.64−7.69 (m, 2H), 7.77 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 8.03 (s, 1H), 8.45 (s, 1H), 8.56 (d, <i>J</i> = 2.1 Hz, 1H). Anal. (C<sub>23</sub>H<sub>24</sub>BrN<sub>5</sub>O<sub>2</sub>) C, H, N.</div></div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>N</i>-(4-(3-Bromoanilino)quinazolin-6-yl)-2-phenoxyacetamide (<b>7</b>)</h3><div id="sec6_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Method C</h4><div class="NLM_p last">Phenoxyacetic acid <b>20</b> (361 mg, 2.37 mmol) was added to a stirred suspension of PCl<sub>5</sub> (490 mg, 2.37 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) at room temperature. The reactants were refluxed for 30 min and then cooled to room temperature, and 6-amino-4-(3-bromoanilino)quinazoline <b>3</b> (500 mg, 1.59 mmol) was added in 10 min. After refluxing for 2 h, the mixture was cooled in an ice/water bath, an amount of 2.5 mL of water was added, the mixture was stirred for 30 min, and then Na<sub>2</sub>CO<sub>3</sub> was added. The solid was filtered and purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 99:1 to 97:3) to afford <b>7</b> as a white solid (77%): mp (EtOH/water) 212 °C; MS (APCI) <i>m</i>/<i>z</i> 449.0, 451.0; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.79 (s, 2H), 6.99 (t, <i>J</i> = 7.4 Hz, 1H), 7.05 (d, <i>J</i> = 7.8 Hz, 2H), 7.27−7.36 (m, 4H), 7.80 (d, <i>J</i> = 8.9 Hz, 1H), 7.85 (d, <i>J</i> = 7.9 Hz, 1H), 7.95 (dd, <i>J</i> = 9.0, 2.1 Hz, 1H), 8.16 (s, 1H), 8.58 (s, 1H), 8.74 (d, <i>J</i> = 1.7 Hz, 1H), 9.93 (s, 1H), 10.44 (s, 1H). Anal. (C<sub>22</sub>H<sub>17</sub>BrN<sub>4</sub>O<sub>2</sub>) C, H, N.</div></div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(4-fluorophenoxy)acetamide (<b>8</b>)</h3><div class="NLM_p last">6-Amino-4-(3-bromoanilino)quinazoline <b>3</b> was reacted with 2-(4-fluorophenoxy)acetic acid <b>21</b> according to the procedure described in <a class="ref internalNav" href="#sec6_7_1" aria-label="Method C.">Method C.</a> The crude product was purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 99:1 to 97:3) to give <b>8</b> (67%) as a white solid: mp (EtOH/water) 224 °C; MS (APCI) <i>m</i>/<i>z</i> 467.3, 469.1; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.78 (s, 2H), 7.07 (dd, <i>J</i> = 9.2, 4.3 Hz, 2H), 7.15−7.21 (m, 2H), 7.27−7.37 (m, 2H), 7.85 (m, 2H), 7.95 (dd, <i>J</i> = 8.2, 1.4 Hz, 1H), 8.16 (br s, 1H), 8.59 (s, 1H), 8.74 (br s, 1H), 9.93 (br s, 1H), 10.44 (br s, 1H). Anal. (C<sub>22</sub>H<sub>16</sub>BrFN<sub>4</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(perfluorophenoxy)acetamide (<b>9</b>)</h3><div class="NLM_p last">6-Amino-4-(3-bromoanilino)quinazoline <b>3</b> was reacted with 2-(perfluorophenoxy)acetic acid <b>22</b> according to the procedure described in <a class="ref internalNav" href="#sec6_7_1" aria-label="Method C.">Method C.</a> The crude product was purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 99:1 to 97:3) to give <b>9</b> (50%) as a white solid: mp 220−221 °C; MS (APCI) <i>m</i>/<i>z</i> 539.1, 541.1; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.99 (s, 2H), 7.24−7.34 (m, 2H), 7.75−7.87 (m, 3H), 8.11 (s, 1H), 8.55 (s, 1H), 8.66 (s, 1H), 9.91 (br s, 1H), 10.50 (br s, 1H). Anal. (C<sub>22</sub>H<sub>12</sub>BrF<sub>5</sub>N<sub>4</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-(4-(3-Bromoanilino)quinazolin-6-yl)-2-cyanoacetamide (<b>11</b>)</h3><div class="NLM_p last">6-Amino-4-(3-bromoanilino)quinazoline <b>3</b> was reacted with 2-cyanoacetic acid <b>24</b> according to the procedure described in <a class="ref internalNav" href="#sec6_7_1" aria-label="Method C.">Method C.</a> The crude product was purified by silica gel chromatography (EtOAc) to give <b>11</b> (55%) as white solid: mp (EtOH/water) 263 °C; MS (APCI) <i>m</i>/<i>z</i> 382.0, 384.1; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.00 (s, 2H), 7.30−7.35 (m, 2H), 7.81−7.86 (m, 3H), 8.15 (t, <i>J</i> = 1.7 Hz, 1H), 8.59 (s, 1H), 8.70 (s, 1H), 9.95 (s, 1H), 10.64 (s, 1H). Anal. (C<sub>17</sub>H<sub>12</sub>BrN<sub>5</sub>O·1.5H<sub>2</sub>O) C, H, N.</div></div><div id="sec6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-[2-[(4-(3-Bromoanilino)quinazolin-6-yl)amino]-2-oxoethyl] Phenylcarbamate (<b>10</b>)</h3><div id="sec6_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Method D</h4><div class="NLM_p last">2-(Phenoxycarbonylamino)acetic acid <b>23</b> (375 mg, 1.92 mmol) and <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide (DCC) (416 mg, 1.04 mmol) were added to a solution of <b>3</b> (400 mg, 1.28 mmol) in anhydrous DMF (6 mL) at 0 °C. The mixture was stirred 16 h at room temperature, the solid was removed by filtration, and the filtrate was evaporated in vacuo to obtain the crude product, which was purified by silica gel chromatography (EtOAc). The pure product <b>10</b> (55%) appeared as a white solid: mp (EtOH/water) >250 °C (dec); MS (APCI) <i>m</i>/<i>z</i> 492.1; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.20 (s, 2H), 6.73−6.78 (m, 3H), 7.15 (t, <i>J</i> = 8.6 Hz, 2H), 7.32 (dt, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.37 (t, <i>J</i> = 7.9 Hz, 1H), 7.82−7.93 (m, 3H), 8.21 (s, 1H), 8.50 (s, 1H), 8.57 (d, <i>J</i> = 1.7 Hz, 1H), 8.70 (s, 1H), 9.32 (s, 1H), 9.98 (br s, 1H). Anal. (C<sub>25</sub>H<sub>20</sub>BrN<sub>3</sub>O<sub>3</sub>·0.5H<sub>2</sub>0) C, H, N.</div></div></div><div id="sec6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(3-oxoisothiazolin-2-yl)acetamide (<b>12</b>)</h3><div class="NLM_p last">6-Amino-4-(3-bromoanilino)quinazoline <b>3</b> was reacted with 2-(3-oxoisothiazolin-2-yl)acetic acid <b>25</b> according to the procedure described in <a class="ref internalNav" href="#sec6_11_1" aria-label="Method D.">Method D.</a> The crude product was purified by silica gel chromatography (EtOAc/MeOH, 99:1 to 90:10) to give <b>12</b> (40%) as a white solid: mp (EtOH/water) >230 °C; MS (APCI) <i>m</i>/<i>z</i> 456.1, 458.3; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.65 (s, 2H), 6.24 (d, <i>J</i> = 6.2 Hz, 1H), 7.28 (d, <i>J</i> = 8.0 Hz, 1H), 7.33 (t, <i>J</i> = 7.9 Hz, 1H), 7.79−7.85 (m, 3H), 8.10 (s, 1H), 8.55 (d, <i>J</i> = 6.2 Hz, 1H), 8.55 (s, 1H), 8.71 (s, 1H), 9.94 (br s, 1H), 10.69 (br s, 1H). Anal. (C<sub>19</sub>H<sub>14</sub>BrN<sub>5</sub>O<sub>2</sub>S·1.5H<sub>2</sub>O) C, H, N.</div></div><div id="sec6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(4-(3-Bromoanilino)quinazolin-6-yl)-2-(3-oxobenzo[<i>d</i>]isothiazolin-2-yl)acetamide (<b>13</b>)</h3><div class="NLM_p last">6-Amino-4-(3-bromoanilino)quinazoline <b>3</b> was reacted with 2-(3-oxobenzo[<i>d</i>]isothiazolin-2-yl)acetic acid <b>26</b> according to the procedure described in <a class="ref internalNav" href="#sec6_11_1" aria-label="Method D.">Method D.</a> The crude product was purified by silica gel chromatography (EtOAc/<i>n</i>-hexane, 99:1) to afford <b>13</b> (50%) as a white solid: mp (MeOH) 238 °C; MS (APCI) <i>m</i>/<i>z</i> 506.1, 508.1; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.75 (s, 2H), 7.25−7.31 (m, 2H), 7.43 (t, <i>J</i> = 7.5 Hz, 1H), 7.69 (t, <i>J</i> = 7.8 Hz, 1H), 7.76−7.83 (m, 3H), 7.88 (d, <i>J</i> = 7.9 Hz, 1H), 7.98 (d, <i>J</i> = 8.5 Hz, 1H), 8.09 (s, 1H), 8.54 (s, 1H), 8.72 (s, 1H), 9.89 (br s, 1H), 10.66 (br s, 1H). Anal. (C<sub>23</sub>H<sub>16</sub>BrN<sub>5</sub>O<sub>2</sub>S·0.5H<sub>2</sub>O) C, H, N.</div></div><div id="sec6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(4-(3-Bromoanilino)quinazolin-6-yl)-3-isopropyl-1,2,4-thiadiazole-5-carboxamide (<b>14</b>)</h3><div id="sec6_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Method E</h4><div class="NLM_p last">Potassium <i>tert</i>-butoxide (84 mg, 0.75 mmol) was added to a premixed mixture of ethyl 3-isopropyl-1,2,4-thiadiazole-5-carboxylate <b>27</b><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> (150 mg, 0.75 mmol) and 6-amino-4-(3-bromoanilino)quinazoline <b>3</b> (235 mg, 0.75 mmol) in anhydrous DMF (1 mL). The reaction mixture was microwaved (150 W) to 100 °C for 8 min. The solution was diluted with water and extracted with EtOAc. The organic phase was evaporated to obtain the crude compound, which was purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 99:1 to 97:3) to give <b>14</b> (50%) as pale-yellow crystals: mp (CH<sub>2</sub>Cl<sub>2</sub>) 224 °C; MS (APCI) <i>m</i>/<i>z</i> 469.0, 471.0; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.47 (d, <i>J</i> = 6.9 Hz, 6H), 3.43 (m, 1H), 7.34 (dt, <i>J</i> = 8.2, 1.5 Hz, 1H), 7.40 (t, <i>J</i> = 8.0 Hz, 1H), 7.90 (d, <i>J</i> = 8.9 Hz, 1H), 7.93 (d, <i>J</i> = 7.9 Hz, 1H), 8.20−8.23 (m, 2H), 8.68 (s, 1H), 8.93 (d, <i>J</i> = 1.8 Hz, 1H), 10.01 (s, 1H), 11.33 (br s, 1H). Anal. (C<sub>20</sub>H<sub>17</sub>BrN<sub>6</sub>OS·0.5H<sub>2</sub>O) C, H, N.</div></div></div><div id="sec6_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (2<i>R</i>,3<i>R</i>)-Ethyl 3-(Naphthalen-2-ylcarbamoyl)oxirane-2-carboxylate (<b>15</b>)</h3><div class="NLM_p last">Compound <b>15</b> was synthesized by coupling the carboxylic acid <b>17</b> and 2-naphthylamine <b>31</b> following the procedure described in <a class="ref internalNav" href="#sec6_4_1" aria-label="Method A.">Method A.</a> Purification by silica gel chromatography (<i>n</i>-hexane/EtOAc, 90:10 to 70:30) gave the pure compound (70%) as a white solid: mp (EtOH/water) 118−119 °C; MS (APCI) <i>m</i>/<i>z</i> 283.3; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 3.66 (d, <i>J</i> = 1.9 Hz, 1H), 3.85 (d, <i>J</i> = 2.0 Hz, 1H), 4.29 (m, 2H), 7.39−7.49 (m, 3H), 7.77−7.83 (m, 4H), 8.18 (d, <i>J</i> = 2.0 Hz, 1H). Anal. (C<sub>16</sub>H<sub>15</sub>NO<sub>4</sub>) C, H, N.</div></div><div id="sec6_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(Naphthalen-2-yl)-2-phenoxyacetamide (<b>16</b>)</h3><div class="NLM_p last">Compound <b>16</b> was synthesized by coupling the carboxylic acid <b>20</b> and 2-naphthylamine <b>31</b> using the procedure described in <a class="ref internalNav" href="#sec6_7_1" aria-label="Method C.">Method C.</a> Purification by silica gel chromatography (<i>n</i>-hexane/EtOAc, 70:30) gave the pure compound (80%) as a pale-yellow solid: mp (EtOH/water) 142−144 °C; MS (APCI) <i>m</i>/<i>z</i> 184.3; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.65 (s, 2H), 7.00−7.09 (m, 3H), 7.33−7.55 (m, 5H), 7.77−7.82 (m, 3H), 8,25 (d, <i>J</i> = 1.7 Hz, 1H), 8.43 (br s, 1H). Anal. (C<sub>18</sub>H<sub>15</sub>NO<sub>2</sub>) C, H, N.</div></div><div id="sec6_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Reactivity with Reduced Glutathione</h3><div class="NLM_p last">The reactivity of compounds <b>4</b>, <b>15</b>, <b>7</b>, and <b>16</b> with reduced glutathione (GSH) was evaluated in an aqueous buffered solution (phosphate buffered saline, PBS, pH 7.4), at 37 °C and compared to that of the acrylamide <b>2</b>. Briefly, 10 μL of the compound standard solution in DMSO (1 mM) was diluted with 890 μL of PBS, pH 7.4. Then an amount of 100 μL of a freshly prepared GSH solution in PBS (20 mM) was added. Conversion of the compounds and formation of conjugates at 37 °C and at different time points were measured by LC−UV and LC−ESI-MS. The LC column used was a Phenomenex Synergi Fusion (2.0 mm × 100 mm, 4 μm), and the mobile phase was a gradient of 50−10% aqueous trifluoroacetic acid (0.05%) in methanol in 10 min at the flow rate of 250 μL/min.</div></div><div id="sec6_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Kinase Assay</h3><div class="NLM_p last">Evaluation of the effects of compounds on the kinase activity of human EGFR was performed by measuring the phosphorylation of the substrate Ulight-CAGAGAIETDKEYYTVKD (JAK1) using a human recombinant enzyme expressed in insect cells<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> and the LANCE detection method,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> employing the Cerep EGFR kinase assay.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Briefly, the test compound, reference compound, or water (control) was mixed with the enzyme (0.0452 ng) in a buffer containing 40 mM Hepes/Tris (pH 7.4), 0.8 mM EGTA/Tris, 8 mM MgCl<sub>2</sub>, 1.6 mM DTT, 0.008% Tween-20, and 100 nM poly-<span class="smallcaps smallerCapital">d</span>-lysine. Thereafter, the reaction was initiated by the addition of 100 nM substrate and 10 μM ATP, and the mixture was incubated for 15 min at room temperature. For control basal measurements, the enzyme was omitted from the reaction medium. Following incubation, the reaction was stopped by the addition of 13 mM EDTA. After 5 min, the antiphopho-PT66 antibody labeled with europium chelate was added. After 60 min, the fluorescence transfer was measured at excitation wavelength of 337 nm and emission wavelength of 620 nm using a microplate reader (Envision, Perkin-Elmer). The concentration of compound that inhibited receptor phosphorylation by 50% (IC<sub>50</sub>) was calculated from inhibition curves.</div></div><div id="sec6_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Cell Culture</h3><div class="NLM_p last">The human A431 epidermoid cancer cell line was cultured in D-MEM 4.5 g/L glucose. NSCLC cell line H1975 and SW620 cell line were cultured in RPMI. All media were supplemented with 2 mmol/<span class="smallcaps smallerCapital">l</span>-glutamine, 10% FCS. A431 was from ATCC. H1975 was kindly provided by Dr. E. Giovannetti (Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands) and was maintained under standard cell culture conditions at 37 °C in a water-saturated atmosphere of 5% CO<sub>2</sub> in air.</div></div><div id="sec6_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Antibodies and Reagents</h3><div class="NLM_p last">Media were from Euroclone, and FBS was purchased from Gibco-BRL (Grand Island, NY). Monoclonal anti-EGFR, polyclonal anti-phospho-EGFR (Tyr1068), monoclonal anti-erbB2, monoclonal anti-phospho-erbB2 (Tyr 1221/1222), polyclonal Akt, polyclonal anti-phospho-Akt (Ser473), monoclonal anti-p44/42 MAPK, monoclonal anti-phospho-p44/42 MAPK (Thr202/Tyr204), and polyclonal anticaspase-3 antibodies were from Cell Signaling Technology (Beverly, MA). Horseradish peroxidase-conjugated (HRP) secondary antibodies were from Pierce. The enhanced chemiluminescence system (ECL) was from Millipore (Millipore, MA). Reagents for electrophoresis and blotting analysis were obtained from, respectively, BIO-RAD Laboratories and Millipore.</div></div><div id="sec6_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Western Blot Analysis</h3><div class="NLM_p last">Procedures for protein extraction, solubilization, and protein analysis by 1D PAGE are described elsewhere.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> 50−100 μg proteins from lysates were resolved by 5−15% SDS−PAGE and transferred to PVDF membranes (Millipore). The membranes were then incubated with primary antibody, washed, and then incubated with HRP-antimouse or HRP-antirabbit antibodies. Immunoreactive bands were visualized using an enhanced chemiluminescence system.</div></div><div id="sec6_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Autophosphorylation Assay</h3><div class="NLM_p last">Inhibition of EGFR autophosphorylation was determined as previously described using specific antiphosphotyrosine and antitotal EGFR antibodies by Western blot analysis.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div></div><div id="sec6_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Cell Growth Inhibition</h3><div class="NLM_p last">Cell viability was assessed after 3 days of treatment by tetrazolium dye [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Sigma, Dorset, U.K.] assay as previously described.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Representative results of at least three independent experiments were used for evaluation of dose−response curves, calculated from experimental points using Graph Pad Prism5 software. The concentration that inhibits 50% (IC<sub>50</sub>) (e.g., the point at which viability is 50%) was extrapolated from the dose−response curves. The compounds were renewed every 24 h.</div></div><div id="sec6_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Cell Death</h3><div class="NLM_p last">Cell death was assessed by morphology on stained (Hoechst 33342, propidium iodide) or unstained cells using light, phase contrast, and fluorescence microscopy.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Activation of caspase-3 was evaluated by Western blotting procedure as previously described.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div></div><div id="sec6_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Statistical Analysis</h3><div class="NLM_p last">Statistical significances of differences between data were estimated using the two-tailed Student’s <i>t</i> test.</div></div><div id="sec6_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Computational Studies</h3><div class="NLM_p last">Docking simulations were performed with Glide 5.0<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(64)</a> employing the crystal structure of the EGFR kinase domain covalently bound to <b>2</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BJF">2BJF</a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Molecular models of compounds <b>4</b>−<b>14</b> were built using Maestro,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(65)</a> and their geometries were optimized by energy minimization using the OPLS2003 force field<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(66)</a> in combination with GB/SA<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(67)</a> model for implicit solvent representation (water) to an energy gradient of 0.01 kcal/(mol·Å). The EGFR crystal structure was submitted to the protein preparation procedure of Maestro, which includes addition of missing side chains and hydrogens, assignment of tautomeric state of histidines maximizing the number of hydrogen bonds, and geometric optimization of the whole system to a root-mean-square displacement (rmsd) value of 0.3 Å. Docking simulations were performed starting from minimum energy conformations of compounds <b>4</b>−<b>14</b> placed in an arbitrary position within a region centered on the covalent inhibitor <b>2</b>, using enclosing and bounding boxes of 20 and 14 Å on each side, respectively. van der Waals radii of the protein atoms were not scaled, while van der Waals radii of the ligand atoms with partial atomic charges lower than |0.15| were scaled by 0.8. Standard precision (SP) mode was applied, and the first 10 poses with the highest <i>G</i>-score values were collected for each docked compound. The resulting binding poses were reranked according to the rmsd of the 4-anilinoquinazoline heavy atoms, taking the crystallized compound <b>2</b> as a reference structure.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45"><a href="/doi/suppl/10.1021/jm901558p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68114" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68114" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Combustion analytical data; docking of compounds <b>2</b>, <b>4</b>, <b>5</b>, and <b>7</b>−<b>14</b> within the EGFR active site; SW620 cells viability inhibition. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901558p/suppl_file/jm901558p_si_001.pdf">jm901558p_si_001.pdf (1.0 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm901558p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47153" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47153" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessio Lodola</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f6979a9385859f99d89a9992999a97b683989f8684d89f82"><span class="__cf_email__" data-cfemail="3958555c4a4a50561755565d565558794c5750494b17504d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Caterina Carmi</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Cavazzoni</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Medicina Sperimentale, Università degli Studi di Parma, Via Volturno 39, I-43125 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefano Vezzosi</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabrizio Bordi</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Federica Vacondio</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudia Silva</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Rivara</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roberta R. Alfieri</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Medicina Sperimentale, Università degli Studi di Parma, Via Volturno 39, I-43125 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia La Monica</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Medicina Sperimentale, Università degli Studi di Parma, Via Volturno 39, I-43125 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maricla Galetti</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Medicina Sperimentale, Università degli Studi di Parma, Via Volturno 39, I-43125 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Ardizzoni</span> - <span class="hlFld-Affiliation affiliation">Oncologia Medica, Azienda Ospedaliero—Universitaria di Parma, V.le Gramsci 14, I-43126 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pier Giorgio Petronini</span> - <span class="hlFld-Affiliation affiliation">Dipartimento di Medicina Sperimentale, Università degli Studi di Parma, Via Volturno 39, I-43125 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco Mor</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G.P. Usberti 27/A, I-43124 Parma, Italy</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33824" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33824" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Grant support was from the following: Ministero della Salute (Programma Straordinario di Ricerca Oncologica 2006), Regione Emilia Romagna; AIRC (Associazione Italiana per la Ricerca sul Cancro); Associazione Marta Nurizzo, Brugherio MI; Associazione Chiara Tassoni, Parma; A.VO.PRO.RI.T., Parma; Associazione Davide Rodella, Montichiari BS; Lega Italiana per la Lotta contro i Tumori, Sezione di Parma; and CONAD, Bologna.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00356" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00356" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 67 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwknowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwknowski&title=Untangling+the+ErbB+signalling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0lh616jEPRLKvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwknowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Teman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Naggar, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issa, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, L.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2164</span><span class="NLM_x">–</span> <span class="NLM_lpage">2170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1200%2FJCO.2006.06.6605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=17538160" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=2164-2170&author=S.+Temanauthor=H.+Kawaguchiauthor=A.+K.+El-Naggarauthor=J.+Jelinekauthor=H.+Tangauthor=D.+D.+Liuauthor=W.+Langauthor=J.+P.+Issaauthor=J.+J.+Leeauthor=L.+Mao&title=Epidermal+growth+factor+receptor+copy+number+alterations+correlate+with+poor+clinical+outcome+in+patients+with+head+and+neck+squamous+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.6605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.6605%26sid%3Dliteratum%253Aachs%26aulast%3DTeman%26aufirst%3DS.%26aulast%3DKawaguchi%26aufirst%3DH.%26aulast%3DEl-Naggar%26aufirst%3DA.%2BK.%26aulast%3DJelinek%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DD.%2BD.%26aulast%3DLang%26aufirst%3DW.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DMao%26aufirst%3DL.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520copy%2520number%2520alterations%2520correlate%2520with%2520poor%2520clinical%2520outcome%2520in%2520patients%2520with%2520head%2520and%2520neck%2520squamous%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D2164%26epage%3D2170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Sarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28Iressa%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0ljwJSQP0qolJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DSarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528Iressa%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Orio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neveu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theleman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P.</span><span> </span><span class="NLM_article-title">Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4838</span><span class="NLM_x">–</span> <span class="NLM_lpage">4848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=9354447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4838-4848&author=J.+D.+Moyerauthor=E.+G.+Barbacciauthor=K.+K.+Iwataauthor=L.+Arnoldauthor=B.+Bomanauthor=A.+Cunninghamauthor=C.+Di+Orioauthor=J.+Dotyauthor=M.+J.+Morinauthor=M.+P.+Moyerauthor=M.+Neveuauthor=V.+A.+Pollackauthor=L.+R.+Pustilnickauthor=M.+M.+Reynoldsauthor=D.+Sloanauthor=A.+Thelemanauthor=P.+Miller&title=Induction+of+apoptosis+and+cell+cycle+arrest+by+CP-358%2C774%2C+an+inhibitor+of+epidermal+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Moyer, James D.; Barbacci, Elsa G.; Iwata, Kenneth K.; Arnold, Lee; Boman, Bruce; Cunningham, Ann; Diorio, Catherine; Doty, Jonathan; Morin, Michael J.; Moyer, Mikel P.; Neveu, Mark; Pollack, Vincent A.; Pustilnik, Leslie R.; Reynolds, Margaret M.; Sloan, Don; Theleman, April; Miller, Penny</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4838-4848</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype.  CP-358774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.  This inhibition is selective for EGFR tyrosine kinase relative to other tyrosine kinases we have examd., both in assays of isolated kinases and whole cells.  At doses of 100 mg/kg, CP-358774 completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice.  CP-358774 inhibits the proliferation of DiFi human colon tumor cells at submicromolar concns. in cell culture and blocks cell cycle progression at the G1 phase.  This inhibitor produces a marked accumulation of retinoblastoma protein in its underphosphorylated form and accumulation of p27KIP1 in DiFi cells, which may contribute to the cell cycle block.  Inhibition of the EGFR also triggers apoptosis in these cells as detd. by formation of DNA fragments and other criteria.  These results indicate that CP-358774 has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation or survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghArQOnGlkbVg90H21EOLACvtfcHk0ljj09SqYuFlRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D&md5=0a6e9697bf290d8e7c44cbe2a125e0b1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DBoman%26aufirst%3DB.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DDi%2BOrio%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DM.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DNeveu%26aufirst%3DM.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DPustilnick%26aufirst%3DL.%2BR.%26aulast%3DReynolds%26aufirst%3DM.%2BM.%26aulast%3DSloan%26aufirst%3DD.%26aulast%3DTheleman%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DInduction%2520of%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520by%2520CP-358%252C774%252C%2520an%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4838%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0ljj09SqYuFlRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljj09SqYuFlRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H. E.</span><span> </span><span class="NLM_article-title"><i>KRAS</i> mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e17&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=R.+T.+Heelanauthor=M.+G.+Krisauthor=H.+E.+Varmus&title=KRAS+mutations+and+primary+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DHeelan%26aufirst%3DR.%2BT.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26atitle%3DKRAS%2520mutations%2520and%2520primary%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2895</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1158%2F1078-0432.CCR-07-2248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A280%3ADC%252BD1czitVKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2895-2899&author=J.+A.+Engelmanauthor=P.+A.+Janne&title=Mechanisms+of+acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span></div><div class="casAuthors">Engelman Jeffrey A; Janne Pasi A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2895-9</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non-small cell lung cancer patients whose tumors harbor somatic mutations in EGFR.  All patients, however, ultimately develop resistance to these agents.  Thus, there is a great need to understand how patients become resistant to develop effective therapies for these cancers.  Studies over the last few years have identified two different EGFR tyrosine kinase inhibitor resistance mechanisms, a secondary mutation in EGFR, EGFR 790M, and amplification of the MET oncogene.  These findings have led to clinical trials using newly designed targeted therapies that can overcome these resistance mechanisms and have shown promise in laboratory studies.  Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for non-small cell lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwZmvJ4PNLtd-cVm4E2RlLfW6udTcc2eYjagLPkN-55Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czitVKjug%253D%253D&md5=a3ecf68a85a0ae413c451cf8f756a976</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-2248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-2248%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D2895%26epage%3D2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liZGHuNGNbsxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Camp, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summy., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L. M.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15671571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVegtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=397-405&author=E.+R.+Campauthor=J.+Summy.author=T.+V.+Bauerauthor=W.+Liuauthor=G.+E.+Gallickauthor=L.+M.+Ellis&title=Molecular+mechanisms+of+resistance+to+therapies+targeting+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor</span></div><div class="casAuthors">Camp, E. Ramsay; Summy, Justin; Bauer, Todd W.; Liu, Wenbiao; Gallick, Gary E.; Ellis, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">397-405</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Targeted therapies that inhibit the activity of tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR) have shown activity against solid malignancies when used as single agents or in combination with chemotherapy.  Although anti-EGFR therapies are active in some patients, eventually disease in nearly all patients will become refractory to therapy.  Therefore, a better understanding of the mechanisms of resistance to anti-EGFR therapies is crit. to further improve the efficacy of this class of agents.  Mechanisms that mediate resistance to anti-EGFR therapies include the presence of redundant tyrosine kinase receptors, increased angiogenesis, and the constitutive activation of downstream mediators.  Two recent landmark publications have also shown that specific mutations in the kinase domain of EGFR in some lung carcinomas are assocd. with markedly improved response rates to an EGFR tyrosine kinase inhibitor.  Mutations in the EGFR receptor seem to play a significant role in detg. the sensitivity of tumor cells to EGFR inhibitor therapy by altering the conformation and activity of the receptor.  As the field of mol. therapeutics continues to evolve, a comprehensive understanding of resistance mechanisms will ultimately lead to refinements in the authors' regimens to provide better care for patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnp3gD31ohrVg90H21EOLACvtfcHk0ljmbrYdFxxlsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVegtbw%253D&md5=9fa2973e623dd8d50e8a28b3a12c00b1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCamp%26aufirst%3DE.%2BR.%26aulast%3DSummy.%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%2BV.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26aulast%3DEllis%26aufirst%3DL.%2BM.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520to%2520therapies%2520targeting%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D397%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Engelman, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Acquired resistance to tyrosine kinase inhibitors during cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Gene Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1016%2Fj.gde.2008.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18325754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=73-79&author=J.+F.+Engelmanauthor=J.+Settleman&title=Acquired+resistance+to+tyrosine+kinase+inhibitors+during+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to tyrosine kinase inhibitors during cancer therapy</span></div><div class="casAuthors">Engelman, Jeffrey A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-79</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Selective tyrosine kinase inhibitors have emerged as important therapeutic agents in the treatment of a variety of human malignancies.  Although several of these inhibitors have marked clin. activity, it is widely recognized that the overall value of these agents is substantially limited by the acquisition of drug resistance, which eventually arises in most, if not all treated patients.  Mechanisms of drug resistance are beginning to be elucidated through the mol. anal. of clin. specimens as well as through cell culture modeling.  By identifying resistance mechanisms, it should be possible to develop second-generation' inhibitors as well as rational drug combinations that can overcome or even prevent acquired resistance to kinase inhibitors, thereby enhancing clin. benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJCEQIe-JFI7Vg90H21EOLACvtfcHk0ljmbrYdFxxlsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVartbc%253D&md5=db27057c8cb1a4deceb779bae6d19398</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BF.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DAcquired%2520resistance%2520to%2520tyrosine%2520kinase%2520inhibitors%2520during%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Gene%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D73%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Mukherji, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J.</span><span> </span><span class="NLM_article-title">Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=293-301&author=D.+Mukherjiauthor=J.+Spicer&title=Second-generation+epidermal+growth+factor+tyrosine+kinase+inhibitors+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMukherji%26aufirst%3DD.%26aulast%3DSpicer%26aufirst%3DJ.%26atitle%3DSecond-generation%2520epidermal%2520growth%2520factor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D293%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wissnerauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0ljmbrYdFxxlsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0liEdaLsTHEptQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0liEdaLsTHEptQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branningan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harria, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoli, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branninganauthor=P.+L.+Harriaauthor=D.+R.+Driscoliauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBranningan%26aufirst%3DB.%2BW.%26aulast%3DHarria%26aufirst%3DP.%2BL.%26aulast%3DDriscoli%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">11011</span><span class="NLM_x">–</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1073%2Fpnas.0504952102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=16046538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnvVWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=V.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span></div><div class="casAuthors">Carter, Todd A.; Wodicka, Lisa M.; Shah, Neil P.; Velasco, Anne Marie; Fabian, Miles A.; Treiber, Daniel K.; Milanov, Zdravko V.; Atteridge, Corey E.; Biggs, William H., III; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Mehta, Shamal A.; Patel, Hitesh K.; Pao, William; Sawyers, Charles L.; Varmus, Harold; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11011-11016</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">To realize the full potential of targeted protein kinase inhibitors for the treatment of cancer, it is important to address the emergence of drug resistance in treated patients.  Mutant forms of BCR-ABL, KIT, and the EGF receptor (EGFR) have been found that confer resistance to the drugs imatinib, gefitinib, and erlotinib.  The mutations weaken or prevent drug binding, and interestingly, one of the most common sites of mutation in all three kinases is a highly conserved "gatekeeper" threonine residue near the kinase active site.  We have identified existing clin. compds. that bind and inhibit drug-resistant mutant variants of ABL, KIT, and EGFR.  We found that the Aurora kinase inhibitor VX-680 and the p38 inhibitor BIRB-796 inhibit the imatinib- and BMS-354825-resistant ABL(T315I) kinase.  The KIT/FLT3 inhibitor SU-11248 potently inhibits the imatinib-resistant KIT(V559D/T670I) kinase, consistent with the clin. efficacy of SU-11248 against imatinib-resistant gastrointestinal tumors, and the EGFR inhibitors EKB-569 and Cl-1033, but not GW-572016 and ZD-6474, potently inhibit the gefitinib- and erlotinib-resistant EGFR(L858R/T790M) kinase.  EKB-569 and Cl-1033 are already in clin. trials, and our results suggest that they should be considered for testing in the treatment of gefitinib/erlotinib-resistant non-small cell lung cancer.  The results highlight the strategy of screening existing clin. compds. against newly identified drug-resistant mutant variants to find compds. that may serve as starting points for the development of next-generation drugs, or that could be used directly to treat patients that have acquired resistance to first-generation targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdgFgcC03tybVg90H21EOLACvtfcHk0lhPv7w5obPirQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnvVWjurg%253D&md5=448c95c51b0cf9b5035df4065cd8f62c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0504952102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0504952102%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DV.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentration of an irreversible EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1158%2F1535-7163.MCT-07-2387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18413800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=874-879&author=N.+Godin-Heymannauthor=L.+Ulkusauthor=B.+W.+Branniganauthor=U.+McDermottauthor=J.+Lambauthor=S.+Maheswaranauthor=J.+Settlemanauthor=D.+A.+Haber&title=The+T790M+%E2%80%9Cgatekeeper%E2%80%9D+mutation+in+EGFR+mediates+resistance+to+low+concentration+of+an+irreversible+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span></div><div class="casAuthors">Godin-Heymann, Nadia; Ulkus, Lindsey; Brannigan, Brian W.; McDermott, Ultan; Lamb, Jennifer; Maheswaran, Shyamala; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-879</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine kinase inhibitors, gefitinib and erlotinib.  However, following clin. response, these patients typically relapse within a year of treatment.  In many cases, resistance is caused by an acquired secondary EGFR kinase domain mutation, T790M.  In vitro studies have shown that a new class of EGFR-irreversible inhibitors could overcome the resistance conferred by T790M.  Clin. trials are under way to examine the efficacy of one of these inhibitors, HKI-272, in patients with NSCLC who initially responded to gefitinib/erlotinib and subsequently relapsed.  To anticipate the possibility that patients who respond to irreversible inhibitors will develop secondary resistance to such inhibitors, as has been seen in other similar settings, we modeled acquired resistance to the dual EGFR/HER2-irreversible tyrosine kinase inhibitor HKI-272 in a NSCLC cell culture model.  We found that HKI-272-resistant clones fall into two biochem. groups based on the retention of EGFR phosphorylation in the presence of the drug.  Cells that retain phosphorylated EGFR have acquired the secondary mutation T790M.  Moreover, HKI-272 can overcome T790M resistance only at suprapharmacol. concns.  We further model mutations at EGFR C797 as a mechanism of resistance to irreversible EGFR inhibitors and show that although these mutants are resistant to the irreversible inhibitor, they retain erlotinib sensitivity.  Our findings suggest that HKI-272 treatment at maximally tolerated dosing may lead to the emergence of T790M-mediated resistance, whereas treatment with a more potent irreversible inhibitor could yield a resistance mutation at EGFR C797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5FtRNHnlNLVg90H21EOLACvtfcHk0lhPv7w5obPirQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D&md5=f71cd83bfabef2d7b2c5d8b6e5cfac6a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2387%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DThe%2520T790M%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutation%2520in%2520EGFR%2520mediates%2520resistance%2520to%2520low%2520concentration%2520of%2520an%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D874%26epage%3D879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Slichenmyer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">CI-1033, a pan-erbB tyrosine kinase inhibitor</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1016%2FS0093-7754%2801%2990285-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=11706399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=80-85&author=W.+J.+Slichenmyerauthor=W.+L.+Elliottauthor=D.+W.+Fry&title=CI-1033%2C+a+pan-erbB+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, a pan-erbB tyrosine kinase inhibitor</span></div><div class="casAuthors">Slichenmyer, William J.; Elliott, William L.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Overexpression of the erbB family of receptor tyrosine kinases has been implicated in a variety of tumors including breast, lung, prostate, and brain.  Most solid tumors express one or more of these receptors, which can often be related to tumor aggressiveness and poor patient prognosis.  CI-1033, a pan-erbB tyrosine kinase inhibitor, is a clin. promising agent that is active against all four members of the erbB receptor tyrosine kinase family.  In vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and sustained inhibition of tyrosine kinase activity.  This inhibition is highly selective for erbBI (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concns.  Treatment of athymic nude mice bearing xenografts of human A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, and SF-767 glioblastoma results in highly significant suppression of tumor growth.  The major toxicity in animals is diarrhea, which is more severe at higher doses.  In animal models, all side effects are reversible on cessation of treatment.  Thus, CI-1033, which is currently undergoing phase I clin. trials, holds significant potential for use in a broad range of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWblWCZGMLQLVg90H21EOLACvtfcHk0lhPv7w5obPirQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D&md5=cc0507480a4182c3e52314750347b4c2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0093-7754%2801%2990285-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0093-7754%252801%252990285-4%26sid%3Dliteratum%253Aachs%26aulast%3DSlichenmyer%26aufirst%3DW.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DCI-1033%252C%2520a%2520pan-erbB%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OverBeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the Her-2 tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=D.+Nilakantanauthor=E.+OverBeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+Her-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0liKra-13XDXeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DD.%26aulast%3DOverBeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520Her-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Gill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span> </span><span class="NLM_article-title">A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1408</span><span class="NLM_x">–</span> <span class="NLM_lpage">1422</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.2174%2F156802607781696819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=17692029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1408-1422&author=A.+L.+Gillauthor=M.+Verdonkauthor=R.+G.+Boyleauthor=R.+Taylor&title=A+comparison+of+physicochemical+property+profiles+of+marketed+oral+drugs+and+orally+bioavailable+anti-cancer+protein+kinase+inhibitors+in+clinical+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development</span></div><div class="casAuthors">Gill, Adrian L.; Verdonk, Marcel; Boyle, Robert G.; Taylor, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1408-1422</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This manuscript describes a comparison of the physicochem. properties of marketed oral drugs with those of 45 structurally confirmed orally bioavailable anti-cancer protein kinase inhibitors currently in different phases of clin. development.  It is evident from the data presented that these kinase inhibitors are on av. larger (over 110Da), more lipophilic (over 1.5 log units) and more complex (approx. two more rotatable bonds) than those of marketed oral drugs.  In contrast, hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA) counts are not significantly different.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8vw6yZzFirVg90H21EOLACvtfcHk0liKra-13XDXeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbvM&md5=03b0a1943f8d1a08ed436da75e9a296f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F156802607781696819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607781696819%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DVerdonk%26aufirst%3DM.%26aulast%3DBoyle%26aufirst%3DR.%2BG.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DA%2520comparison%2520of%2520physicochemical%2520property%2520profiles%2520of%2520marketed%2520oral%2520drugs%2520and%2520orally%2520bioavailable%2520anti-cancer%2520protein%2520kinase%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1408%26epage%3D1422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBlanc, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehn, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2734</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0005555" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2719-2734&author=H.-R.+Tsouauthor=N.+Mamuyaauthor=B.+D.+Johnsonauthor=M.+F.+Reichauthor=B.+C.+Gruberauthor=F.+Yeauthor=R.+Nilakantanauthor=R.+Shenauthor=C.+Discafaniauthor=R.+DeBlancauthor=R.+Davisauthor=F.+E.+Koehnauthor=L.+M.+Greenbergerauthor=Y.-F.+Wangauthor=A.+Wissner&title=6-Substituted-4-%283-bromophenylamino%29quinazolines+as+putative+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+human+epidermal+growth+factor+receptor+%28HER-2%29+tyrosine+kinases+with+enhanced+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm0005555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0005555%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDeBlanc%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DKoehn%26aufirst%3DF.%2BE.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3D6-Substituted-4-%25283-bromophenylamino%2529quinazolines%2520as%2520putative%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528HER-2%2529%2520tyrosine%2520kinases%2520with%2520enhanced%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2719%26epage%3D2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000372i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=429-440&author=J.+B.+Smaillauthor=H.+D.+H.+Showalterauthor=H.+Zhouauthor=A.+J.+Bridgesauthor=D.+J.+McNamaraauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+18.+6-Substituted+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+soluble%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm000372i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000372i%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252018.%25206-Substituted%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520soluble%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Mishani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abourbeh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dissoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5337</span><span class="NLM_x">–</span> <span class="NLM_lpage">5348</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0580196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5337-5348&author=E.+Mishaniauthor=G.+Abourbehauthor=O.+Jacobsonauthor=S.+Dissokiauthor=R.+B.+Danielauthor=G.+Rozenauthor=M.+Shaulauthor=A.+Levitzki&title=High-affinity+epidermal+growth+factor+receptor+%28EGFR%29+irreversible+inhibitors+with+diminished+chemical+reactivities+as+positron+emission+tomography+%28PET%29-imaging+agent+candidates+of+EGFR+overexpressing+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm0580196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0580196%26sid%3Dliteratum%253Aachs%26aulast%3DMishani%26aufirst%3DE.%26aulast%3DAbourbeh%26aufirst%3DG.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DDissoki%26aufirst%3DS.%26aulast%3DDaniel%26aufirst%3DR.%2BB.%26aulast%3DRozen%26aufirst%3DG.%26aulast%3DShaul%26aufirst%3DM.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DHigh-affinity%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520irreversible%2520inhibitors%2520with%2520diminished%2520chemical%2520reactivities%2520as%2520positron%2520emission%2520tomography%2520%2528PET%2529-imaging%2520agent%2520candidates%2520of%2520EGFR%2520overexpressing%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5337%26epage%3D5348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Antonello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarozzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morroni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrelia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6642</span><span class="NLM_x">–</span> <span class="NLM_lpage">6645</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6642-6645&author=A.+Antonelloauthor=A.+Tarozziauthor=F.+Morroniauthor=A.+Cavalliauthor=M.+Rosiniauthor=P.+Hreliaauthor=M.+L.+Bolognesiauthor=C.+Melchiorre&title=Multitarget-directed+drug+design+strategy%3A+a+novel+molecule+designed+to+block+epidermal+growth+factor+receptor+%28EGFR%29+and+to+exert+proapoptotic+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm0608762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608762%26sid%3Dliteratum%253Aachs%26aulast%3DAntonello%26aufirst%3DA.%26aulast%3DTarozzi%26aufirst%3DA.%26aulast%3DMorroni%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DHrelia%26aufirst%3DP.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMultitarget-directed%2520drug%2520design%2520strategy%253A%2520a%2520novel%2520molecule%2520designed%2520to%2520block%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520to%2520exert%2520proapoptotic%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6642%26epage%3D6645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Wissner, A.; Tsou, H.-R.; Jonson, B. D.; Hamann, P. R.; Zhang, N.</span><span> </span><span class="NLM_article-title">Substituted Quinazoline Derivatives and Their Use as Tyrosine Kinase Inhibitors</span>. PCT Int. Appl. WO99/09016,<span class="NLM_x"> </span><span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=A.+Wissner&author=H.-R.+Tsou&author=B.+D.+Jonson&author=P.+R.+Hamann&author=N.+Zhang&title=Substituted+Quinazoline+Derivatives+and+Their+Use+as+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DSubstituted%2520Quinazoline%2520Derivatives%2520and%2520Their%2520Use%2520as%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Ban, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nabeyama, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuzawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span> </span><span class="NLM_article-title">Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4415</span><span class="NLM_x">–</span> <span class="NLM_lpage">4427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1039%2Fb909504g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=19830290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=4415-4427&author=S.+H.+Banauthor=T.+Usuiauthor=W.+Nabeyamaauthor=H.+Moritaauthor=K.+Fukuzawaauthor=H.+Nakamura&title=Discovery+of+boron-conjugated+4-anilinoquinazoline+as+a+prolonged+inhibitor+of+EGFR+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase</span></div><div class="casAuthors">Ban, Hyun Seung; Usui, Taikou; Nabeyama, Wataru; Morita, Hidetoshi; Fukuzawa, Kaori; Nakamura, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4415-4427</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Boron-conjugated 4-anilinoquinazolines were designed and synthesized as inhibitors of EGFR tyrosine kinase with possible covalent bond interactions between the boron atom and the nucleophilic groups of the EGFR kinase domain.  Among the compds. synthesized, compds. I and II (X = CH:CH, 1,4-phenylene) reduced the EGF-mediated phosphorylation of EGFR tyrosine kinase and its downstream kinases including ERK and Akt in A431 cells.  The cell growth was inhibited by these compds. through arrest of G1 cell cycle, which induced apoptosis.  A time-dependent in vitro preincubation assay demonstrated the irreversible inhibition of compd. II [X = 1,4-phenylene; (III)] against EGFR tyrosine kinase.  Quantum mech. docking simulation revealed that the boronic acid moiety of compd. III formed a covalent B-O bond with Asp800 in addn. to hydrogen bonds with Asp800 and Cys797, which may cause the prolonged inhibition of compd. III toward EGFR tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod_ARjWKN7LLVg90H21EOLACvtfcHk0liJEzfDWtxGUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb%252FN&md5=b61ee61865bdff8e4706485b1f030554</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fb909504g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb909504g%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DS.%2BH.%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DNabeyama%26aufirst%3DW.%26aulast%3DMorita%26aufirst%3DH.%26aulast%3DFukuzawa%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520boron-conjugated%25204-anilinoquinazoline%2520as%2520a%2520prolonged%2520inhibitor%2520of%2520EGFR%2520tyrosine%2520kinase%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26spage%3D4415%26epage%3D4427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0liJEzfDWtxGUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Powers, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asgian, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogan Ekici, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis James, K.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of serine, cysteine, and threonine proteases</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">4639</span><span class="NLM_x">–</span> <span class="NLM_lpage">4750</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr010182v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD38XosFSnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2002&pages=4639-4750&author=J.+C.+Powersauthor=J.+L.+Asgianauthor=O.+Dogan+Ekiciauthor=K.+Ellis+James&title=Irreversible+inhibitors+of+serine%2C+cysteine%2C+and+threonine+proteases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of serine, cysteine, and threonine proteases</span></div><div class="casAuthors">Powers, James C.; Asgian, Juliana L.; Ekici, Oezlem Dogan; James, Karen Ellis</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4639-4750</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Topics discussed include alkylating, acylating, phosphonylating, and sulfonylating agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorivaxGhmhirVg90H21EOLACvtfcHk0lgalj0fVKgSgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XosFSnsr4%253D&md5=eb21ff0297b87537a7d459c92f13c75d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fcr010182v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr010182v%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DJ.%2BC.%26aulast%3DAsgian%26aufirst%3DJ.%2BL.%26aulast%3DDogan%2BEkici%26aufirst%3DO.%26aulast%3DEllis%2BJames%26aufirst%3DK.%26atitle%3DIrreversible%2520inhibitors%2520of%2520serine%252C%2520cysteine%252C%2520and%2520threonine%2520proteases%26jtitle%3DChem.%2520Rev.%26date%3D2002%26volume%3D102%26spage%3D4639%26epage%3D4750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Leung-Toung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karimian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spino, M.</span><span> </span><span class="NLM_article-title">Thiol proteases: inhibitors and potential therapeutic targets</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.2174%2F092986706776055733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=16515521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Klu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=547-581&author=R.+Leung-Toungauthor=Y.+Zhaoauthor=W.+Liauthor=T.+F.+Tamauthor=K.+Karimianauthor=M.+Spino&title=Thiol+proteases%3A+inhibitors+and+potential+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Thiol proteases: inhibitors and potential therapeutic targets</span></div><div class="casAuthors">Leung-Toung, Regis; Zhao, Yanqing; Li, Wanren; Tam, Tim F.; Karimian, Khashayar; Spino, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">547-581</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  A better understanding of the biol. roles and the pathol. consequences of thiol-dependent enzymes has emerged in recent years, and hence considerable progress has been made in identifying and delineating cysteine proteases that can be considered promising drug targets from those involved in housekeeping functions.  Cysteine proteases have been implicated in a wide variety of disease processes ranging from cardiovascular, inflammatory, viral and immunol. disorders to cancer.  The first milestone in drug development of cysteine protease inhibitors has probably been reached, as IDN-6556 (a broad spectrum caspase inhibitor) has recently received Orphan Drug label by the U.S. Food and Drug Administration for use in the treatment of the patients undergoing liver transplantation and other solid organ transplantation.  IDN-6556, which blocks apoptosis, is in Phase II human clin. trial in patients undergoing liver transplantation.  In addn., more than ten cysteine protease inhibitors are presently at various phases of clin. development/trials for diverse diseases.  This review emphasizes on the new development from the literature reports since the year 2000 in the exploration of potential cysteine proteases as prospective drug targets, and the investigation of promising inhibitors that can potentially be developed for the treatment of human diseases.  Transglutaminases, another class of thiol-dependent enzymes, are not discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYKHoAclVmbVg90H21EOLACvtfcHk0lgalj0fVKgSgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Klu7Y%253D&md5=ef25f861761e9d51092da05f9334239c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F092986706776055733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706776055733%26sid%3Dliteratum%253Aachs%26aulast%3DLeung-Toung%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTam%26aufirst%3DT.%2BF.%26aulast%3DKarimian%26aufirst%3DK.%26aulast%3DSpino%26aufirst%3DM.%26atitle%3DThiol%2520proteases%253A%2520inhibitors%2520and%2520potential%2520therapeutic%2520targets%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26spage%3D547%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Overall, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleifeld, O.</span><span> </span><span class="NLM_article-title">Towards third generation matrix metalloproteinase inhibitors for cancer theraphy</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1038%2Fsj.bjc.6603043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=16538215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFGqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=941-946&author=C.+M.+Overallauthor=O.+Kleifeld&title=Towards+third+generation+matrix+metalloproteinase+inhibitors+for+cancer+theraphy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Towards third generation matrix metalloproteinase inhibitors for cancer therapy</span></div><div class="casAuthors">Overall, C. M.; Kleifeld, O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">941-946</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The failure of matrix metalloproteinase (MMP) inhibitor drug clin. trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition.  We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are crit. in host protection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWaFApPMIKRLVg90H21EOLACvtfcHk0lgalj0fVKgSgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFGqt7g%253D&md5=5e672a6e9495ec2e283856edc6e61a60</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603043%26sid%3Dliteratum%253Aachs%26aulast%3DOverall%26aufirst%3DC.%2BM.%26aulast%3DKleifeld%26aufirst%3DO.%26atitle%3DTowards%2520third%2520generation%2520matrix%2520metalloproteinase%2520inhibitors%2520for%2520cancer%2520theraphy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D94%26spage%3D941%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Arnold, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosinski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estebanez-Perpina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletterick, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, R. K.</span><span> </span><span class="NLM_article-title">Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure−reactivity relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">5269</span><span class="NLM_x">–</span> <span class="NLM_lpage">5280</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070556y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5269-5280&author=L.+A.+Arnoldauthor=A.+Kosinskiauthor=E.+Estebanez-Perpinaauthor=R.+J.+Fletterickauthor=R.+K.+Guy&title=Inhibitors+of+the+interaction+of+a+thyroid+hormone+receptor+and+coactivators%3A+preliminary+structure%E2%88%92reactivity+relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm070556y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070556y%26sid%3Dliteratum%253Aachs%26aulast%3DArnold%26aufirst%3DL.%2BA.%26aulast%3DKosinski%26aufirst%3DA.%26aulast%3DEstebanez-Perpina%26aufirst%3DE.%26aulast%3DFletterick%26aufirst%3DR.%2BJ.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26atitle%3DInhibitors%2520of%2520the%2520interaction%2520of%2520a%2520thyroid%2520hormone%2520receptor%2520and%2520coactivators%253A%2520preliminary%2520structure%25E2%2588%2592reactivity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5269%26epage%3D5280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapper, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Synthesis and structure−reactivity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3484</span><span class="NLM_x">–</span> <span class="NLM_lpage">3498</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3484-3498&author=M.+Morauthor=A.+Lodolaauthor=S.+Rivaraauthor=F.+Vacondioauthor=A.+Durantiauthor=A.+Tontiniauthor=S.+Sanchiniauthor=G.+Piersantiauthor=J.+R.+Clapperauthor=A.+R.+Kingauthor=G.+Tarziaauthor=D.+Piomelli&title=Synthesis+and+structure%E2%88%92reactivity+relationship+of+fatty+acid+amide+hydrolase+inhibitors%3A+modulation+at+the+N-portion+of+biphenyl-3-yl+alkylcarbamates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DSanchini%26aufirst%3DS.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DClapper%26aufirst%3DJ.%2BR.%26aulast%3DKing%26aufirst%3DA.%2BR.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592reactivity%2520relationship%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%253A%2520modulation%2520at%2520the%2520N-portion%2520of%2520biphenyl-3-yl%2520alkylcarbamates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3484%26epage%3D3498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slintak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliot, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patmore, S. J.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[<i>d</i>]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">–</span> <span class="NLM_lpage">1815</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9806603" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1803-1815&author=J.+B.+Smaillauthor=B.+D.+Palmerauthor=G.+W.+Rewcastleauthor=V.+A.+Dennyauthor=D.+J.+McNamaraauthor=E.+M.+Dobrusinauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=H.+D.+H.+Showalterauthor=R.+T.+Wintersauthor=V.+R.+Leopoldauthor=D.+V.+Fryauthor=J.+M.+Nelsonauthor=V.+Slintakauthor=V.+L.+Elliotauthor=B.+J.+Robertsauthor=P.+W.+Vincentauthor=S.+J.+Patmore&title=Tyrosine+kinase+inhibitors.+15.+4-%28Phenylamino%29quinazoline+and+4-%28phenylamino%29pyrido%5Bd%5Dpyrimidine+acrylamides+as+irreversible+inhibitors+of+the+ATP+binding+site+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm9806603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9806603%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DV.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DLeopold%26aufirst%3DV.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BV.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSlintak%26aufirst%3DV.%26aulast%3DElliot%26aufirst%3DV.%2BL.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DPatmore%26aufirst%3DS.%2BJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252015.%25204-%2528Phenylamino%2529quinazoline%2520and%25204-%2528phenylamino%2529pyrido%255Bd%255Dpyrimidine%2520acrylamides%2520as%2520irreversible%2520inhibitors%2520of%2520the%2520ATP%2520binding%2520site%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1803%26epage%3D1815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-[(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3487</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00018a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3482-3487&author=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=D.+R.+Codyauthor=A.+McMichaelauthor=D.+W.+Fry&title=Tyrosine+kinase+inhibitors%3A+synthesis+and+structure-activity+relationships+for+4-%5B%28phenylmethyl%29amino%5D-+and+4-%5B%28phenylamino%29quinazolines+as+potent+adenosine+5%E2%80%B2-triphosphate+binding+site+inhibitors+of+the+tyrosine+kinase+domain+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm00018a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00018a008%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520synthesis%2520and%2520structure-activity%2520relationships%2520for%25204-%255B%2528phenylmethyl%2529amino%255D-%2520and%25204-%255B%2528phenylamino%2529quinazolines%2520as%2520potent%2520adenosine%25205%25E2%2580%25B2-triphosphate%2520binding%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3482%26epage%3D3487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Roth, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, J. J.</span><span> </span><span class="NLM_article-title">A new synthesis of aryl substituted quinazolin-4(1<i>H</i>)-ones</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2051</span><span class="NLM_x">–</span> <span class="NLM_lpage">2053</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1996&pages=2051-2053&author=G.+A.+Rothauthor=J.+J.+Tai&title=A+new+synthesis+of+aryl+substituted+quinazolin-4%281H%29-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BA.%26aulast%3DTai%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520new%2520synthesis%2520of%2520aryl%2520substituted%2520quinazolin-4%25281H%2529-ones%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1996%26volume%3D33%26spage%3D2051%26epage%3D2053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Saito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morowake, T.</span><span> </span><span class="NLM_article-title">Diethyl (2<i>S</i>,3<i>R</i>)-2-(<i>N</i>-<i>tert</i>-butoxycarbonyl)amino-3-hydroxysuccinate</span> <span class="citation_source-journal">Org. Synth.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1995&pages=184-200&author=S.+Saitoauthor=K.+Komadaauthor=T.+Morowake&title=Diethyl+%282S%2C3R%29-2-%28N-tert-butoxycarbonyl%29amino-3-hydroxysuccinate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DKomada%26aufirst%3DK.%26aulast%3DMorowake%26aufirst%3DT.%26atitle%3DDiethyl%2520%25282S%252C3R%2529-2-%2528N-tert-butoxycarbonyl%2529amino-3-hydroxysuccinate%26jtitle%3DOrg.%2520Synth.%26date%3D1995%26volume%3D73%26spage%3D184%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Korn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph-Böhner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moroder, L.</span><span> </span><span class="NLM_article-title">A convenient synthesis of optically pure (2<i>R</i>,3<i>R</i>)-2,3-epoxysuccinyl-dipeptides</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">8381</span><span class="NLM_x">–</span> <span class="NLM_lpage">8392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=8381-8392&author=A.+Kornauthor=S.+Rudolph-B%C3%B6hnerauthor=L.+Moroder&title=A+convenient+synthesis+of+optically+pure+%282R%2C3R%29-2%2C3-epoxysuccinyl-dipeptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKorn%26aufirst%3DA.%26aulast%3DRudolph-B%25C3%25B6hner%26aufirst%3DS.%26aulast%3DMoroder%26aufirst%3DL.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520optically%2520pure%2520%25282R%252C3R%2529-2%252C3-epoxysuccinyl-dipeptides%26jtitle%3DTetrahedron%26date%3D1994%26volume%3D50%26spage%3D8381%26epage%3D8392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukaiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakeya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osada, H.</span><span> </span><span class="NLM_article-title">First asymmetric total synthesis of synerazol, an antifungal antibiotic, and determination of its absolute stereochemistry</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">5643</span><span class="NLM_x">–</span> <span class="NLM_lpage">5654</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo050664x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=5643-5654&author=Y.+Hayashiauthor=M.+Shojiauthor=T.+Mukaiyamaauthor=H.+Gotohauthor=S.+Yamaguchiauthor=M.+Nakataauthor=H.+Kakeyaauthor=H.+Osada&title=First+asymmetric+total+synthesis+of+synerazol%2C+an+antifungal+antibiotic%2C+and+determination+of+its+absolute+stereochemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjo050664x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo050664x%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DShoji%26aufirst%3DM.%26aulast%3DMukaiyama%26aufirst%3DT.%26aulast%3DGotoh%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DS.%26aulast%3DNakata%26aufirst%3DM.%26aulast%3DKakeya%26aufirst%3DH.%26aulast%3DOsada%26aufirst%3DH.%26atitle%3DFirst%2520asymmetric%2520total%2520synthesis%2520of%2520synerazol%252C%2520an%2520antifungal%2520antibiotic%252C%2520and%2520determination%2520of%2520its%2520absolute%2520stereochemistry%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D5643%26epage%3D5654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Tamai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanaoka, Y.</span><span> </span><span class="NLM_article-title">Efficient synthetic method for ethyl (+)-(2<i>S</i>,3<i>S</i>)-3-[(<i>S</i>)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-2-oxiranecarboxylate (EST), a new inhibitor of cysteine proteinase</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">–</span> <span class="NLM_lpage">1104</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1987&pages=1098-1104&author=M.+Tamaiauthor=C.+Yokooauthor=M.+Murataauthor=K.+Ogumaauthor=K.+Sotaauthor=E.+Satoauthor=Y.+Kanaoka&title=Efficient+synthetic+method+for+ethyl+%28%2B%29-%282S%2C3S%29-3-%5B%28S%29-3-methyl-1-%283-methylbutylcarbamoyl%29butylcarbamoyl%5D-2-oxiranecarboxylate+%28EST%29%2C+a+new+inhibitor+of+cysteine+proteinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamai%26aufirst%3DM.%26aulast%3DYokoo%26aufirst%3DC.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DOguma%26aufirst%3DK.%26aulast%3DSota%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DE.%26aulast%3DKanaoka%26aufirst%3DY.%26atitle%3DEfficient%2520synthetic%2520method%2520for%2520ethyl%2520%2528%252B%2529-%25282S%252C3S%2529-3-%255B%2528S%2529-3-methyl-1-%25283-methylbutylcarbamoyl%2529butylcarbamoyl%255D-2-oxiranecarboxylate%2520%2528EST%2529%252C%2520a%2520new%2520inhibitor%2520of%2520cysteine%2520proteinase%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1987%26volume%3D35%26spage%3D1098%26epage%3D1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Clerici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelmi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocar, D.</span><span> </span><span class="NLM_article-title">Isothiazoles. Part 14: 3-Aminosubstituted isothiazole dioxides and their mono- and dihalogeno derivatives</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">9399</span><span class="NLM_x">–</span> <span class="NLM_lpage">9408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2003&pages=9399-9408&author=F.+Clericiauthor=A.+Continiauthor=M.+L.+Gelmiauthor=D.+Pocar&title=Isothiazoles.+Part+14%3A+3-Aminosubstituted+isothiazole+dioxides+and+their+mono-+and+dihalogeno+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClerici%26aufirst%3DF.%26aulast%3DContini%26aufirst%3DA.%26aulast%3DGelmi%26aufirst%3DM.%2BL.%26aulast%3DPocar%26aufirst%3DD.%26atitle%3DIsothiazoles.%2520Part%252014%253A%25203-Aminosubstituted%2520isothiazole%2520dioxides%2520and%2520their%2520mono-%2520and%2520dihalogeno%2520derivatives%26jtitle%3DTetrahedron%26date%3D2003%26volume%3D59%26spage%3D9399%26epage%3D9408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Lewis, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hausman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szamborski, E. C.</span><span> </span><span class="NLM_article-title">4-Isothiazolin-3-ones. A general synthesis from 3,3′-dithiodipropionamides</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1971&pages=571-580&author=S.+N.+Lewisauthor=G.+A.+Millerauthor=M.+Hausmanauthor=E.+C.+Szamborski&title=4-Isothiazolin-3-ones.+A+general+synthesis+from+3%2C3%E2%80%B2-dithiodipropionamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DS.%2BN.%26aulast%3DMiller%26aufirst%3DG.%2BA.%26aulast%3DHausman%26aufirst%3DM.%26aulast%3DSzamborski%26aufirst%3DE.%2BC.%26atitle%3D4-Isothiazolin-3-ones.%2520A%2520general%2520synthesis%2520from%25203%252C3%25E2%2580%25B2-dithiodipropionamides%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1971%26volume%3D8%26spage%3D571%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catellani, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plazzi, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barocelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiavarini, M.</span><span> </span><span class="NLM_article-title">4-(3-Oxo-1,2-benzisothiazolin-2-yl)alkanoic, -phenylalkanoic, and -phenoxyalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic properties</span> <span class="citation_source-journal">Farmaco</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=2604834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK3cXhvFWgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1989&pages=795-807&author=F.+Bordiauthor=P.+L.+Catellaniauthor=G.+Moriniauthor=P.+V.+Plazziauthor=C.+Silvaauthor=E.+Barocelliauthor=M.+Chiavarini&title=4-%283-Oxo-1%2C2-benzisothiazolin-2-yl%29alkanoic%2C+-phenylalkanoic%2C+and+-phenoxyalkanoic+acids%3A+synthesis+and+anti-inflammatory%2C+analgesic+and+antipyretic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">4-(3-Oxo-1,2-benzisothiazolin-2-yl)alkanoic, -phenylalkanoic, and -phenoxyalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic properties</span></div><div class="casAuthors">Bordi, Fabrizio; Catellani, Pier Luigi; Morini, Giovanni; Plazzi, Pier Vincenzo; Silva, Claudia; Barocelli, Elisabetta; Chiavarini, Milena</div><div class="citationInfo"><span class="NLM_cas:title">Farmaco</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">795-807</span>CODEN:
                <span class="NLM_cas:coden">FRMCE8</span>;
        ISSN:<span class="NLM_cas:issn">0014-827X</span>.
    </div><div class="casAbstract">A group of title derivs. (I, X = alkylene, phenylene, and etc.; n = 0 or 2) were prepd. by cyclization of 2-chlorocarbonylphenylsulfenylchloride with aliph. amino acids and arom. amino acid esters.  The products were hydrolyzed and amidated or oxidized and hydrolyzed.  The 41 final products and intermediates were tested for analgesic, anti-inflammatory, and antipyretic effects in rats and mice in comparison with the effects of ibuprofen, paracetamol, phenylbutazone, and 1,2-benzisothiazolin-3-one.  The compds. showed rather complex pharmacol. properties.  Their structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohab-MxWE6drVg90H21EOLACvtfcHk0liMFOBt9wfAYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhvFWgtbk%253D&md5=a4206af9903e3b9f2e4898a57a9bd31d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DCatellani%26aufirst%3DP.%2BL.%26aulast%3DMorini%26aufirst%3DG.%26aulast%3DPlazzi%26aufirst%3DP.%2BV.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DChiavarini%26aufirst%3DM.%26atitle%3D4-%25283-Oxo-1%252C2-benzisothiazolin-2-yl%2529alkanoic%252C%2520-phenylalkanoic%252C%2520and%2520-phenoxyalkanoic%2520acids%253A%2520synthesis%2520and%2520anti-inflammatory%252C%2520analgesic%2520and%2520antipyretic%2520properties%26jtitle%3DFarmaco%26date%3D1989%26volume%3D44%26spage%3D795%26epage%3D807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Buck, W.</span><span> </span><span class="NLM_article-title">Herbicidal[1,2,4]thiadiazoles</span>. U.S. Patent 5,583,092,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=W.+Buck&title=Herbicidal%5B1%2C2%2C4%5Dthiadiazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBuck%26aufirst%3DW.%26atitle%3DHerbicidal%255B1%252C2%252C4%255Dthiadiazoles%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Q.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Structure guided development of affinity probes for tyrosine kinases using chemical genetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1038%2Fnchembio866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=17334377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=229-238&author=J.+A.+Blairauthor=D.+Rauhauthor=C.+Kungauthor=C.-H.+Yunauthor=Q.-W.+Fanauthor=H.+Rodeauthor=C.+Zhangauthor=M.+J.+Eckauthor=W.+A.+Weissauthor=K.+M.+Shokat&title=Structure+guided+development+of+affinity+probes+for+tyrosine+kinases+using+chemical+genetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span></div><div class="casAuthors">Blair, Jimmy A.; Rauh, Daniel; Kung, Charles; Yun, Cai-Hong; Fan, Qi-Wen; Rode, Haridas; Zhang, Chao; Eck, Michael J.; Weiss, William A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-mol. inhibitors.  The authors report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue.  Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Cocrystal structures of two irreversible quinazoline inhibitors (I, II) bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Based on these structures, the authors developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe (III) to report the fraction of kinase necessary for cellular signaling, and the authors used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0KmYAm-skrVg90H21EOLACvtfcHk0lhWb-GeYYknYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D&md5=ce4d24a8d65d7080645bf382cd65dbca</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnchembio866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio866%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DFan%26aufirst%3DQ.-W.%26aulast%3DRode%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DStructure%2520guided%2520development%2520of%2520affinity%2520probes%2520for%2520tyrosine%2520kinases%2520using%2520chemical%2520genetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Å resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0lhWb-GeYYknYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Domarkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudouit, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiyu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahimi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jean-Claude, B. J.</span><span> </span><span class="NLM_article-title">The Combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3544</span><span class="NLM_x">–</span> <span class="NLM_lpage">3552</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0600390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD28XkslKht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3544-3552&author=J.+Domarkasauthor=F.+Dudouitauthor=C.+Williamsauthor=Q.+Qiyuauthor=R.+Banerjeeauthor=F.+Brahimiauthor=B.+J.+Jean-Claude&title=The+Combi-targeting+concept%3A+synthesis+of+stable+nitrosoureas+designed+to+inhibit+the+epidermal+growth+factor+receptor+%28EGFR%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Combi-Targeting Concept: Synthesis of Stable Nitrosoureas Designed to Inhibit the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Domarkas, Juozas; Dudouit, Fabienne; Williams, Christopher; Qiu, Qiyu; Banerjee, Ranjita; Brahimi, Fouad; Bertrand, Jacques Jean-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3544-3552</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">According to the "combi-targeting" concept, the EGFR tyrosine kinase (TK) inhibitory potency of compds. termed "combi-mols." is crit. for selective growth inhibition of tumor cells with disordered expression of EGFR or its closest family member erbB2.  Here a report is presented on the optimization of the EGFR TK inhibitory potency of the combi-mols. of the (nitroso)urea class by comparison with their aminoquinazoline and (ureido)quinazoline precursors.  This led to the discovery of a new structural parameter that influences their EGFR TK inhibitory potency, i.e., the torsion angle between the plane of the quinazoline ring and the ureido or the (nitroso)ureido moiety of the synthesized drugs.  Chloro and bromo compds. with small angles (0.5-3°) were generally stronger EGFR TK inhibitors than those with large angles (18-21°).  This was further corroborated by ligand-receptor van der Waals interaction calcns. that showed significant binding hindrance imposed by large torsion angles in the narrow ATP cleft of EGFR.  Selective antiproliferative studies in a pair of mouse fibroblast NIH3T3 cells, one of which NIH3T3/neu being transfected with the erbB2 oncogene, showed that IC50 values for inhibition of EGFR TK could be good predictors of their selective potency against the serum-stimulated growth of the erbB2-transfected cell line (Pearson r = 0.8).  On the basis of stability (t1/2), EGFR TK inhibitory potency (IC50), and selective erbB2 targeting, N-(2-chloroethyl)-N'-methyl-N'-[4-[(3-chlorophenyl)amino]-6-quinazolinyl]-N-nitrosourea, a stable (nitroso)urea, was considered to have the structural requirements for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxsPsnA7Mo27Vg90H21EOLACvtfcHk0lhWb-GeYYknYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkslKht7c%253D&md5=8467f8ee9d926318324ee4856c88b2aa</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm0600390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0600390%26sid%3Dliteratum%253Aachs%26aulast%3DDomarkas%26aufirst%3DJ.%26aulast%3DDudouit%26aufirst%3DF.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DQiyu%26aufirst%3DQ.%26aulast%3DBanerjee%26aufirst%3DR.%26aulast%3DBrahimi%26aufirst%3DF.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520Combi-targeting%2520concept%253A%2520synthesis%2520of%2520stable%2520nitrosoureas%2520designed%2520to%2520inhibit%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3544%26epage%3D3552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Mechanism of action of erb tyrosine kinase inhibitors</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1016%2FS0014-4827%2802%2900095-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=12648472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitVyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=131-139&author=D.+W.+Fry&title=Mechanism+of+action+of+erb+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of erbB tyrosine kinase inhibitors</span></div><div class="casAuthors">Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-139</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A review.  Over the last decade, drug discovery efforts have generated a myriad of compds. that inhibit the activity of the erbB family of tyrosine kinases with potencies and selectivity that have surpassed original expectations.  These characteristics, along with improved pharmaceutical properties, have enabled inhibitors from this class of agents to finally realize their therapeutic potential, and indeed, some are currently producing significant clin. responses.  Interestingly, those properties that are essential for a clin. active inhibitor of the erbB family are most readily attained with compds. that bind at the ATP site, and the most successful compds. have shown a distinct convergence to certain common chem. features.  The reasons for this trend are beginning to be realized through the generation of an increasing array of cryst. structures for protein kinases as well as advances in mol. modeling.  This has allowed a more complete understanding of the precise phys. interactions that occur between erbB tyrosine kinase inhibitors and their target(s), which, in turn, has begun to shed light on the mechanism by which these mols. attain their remarkable affinity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-o5XCjZZQdLVg90H21EOLACvtfcHk0liznF8ERdUMeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitVyltL8%253D&md5=09c10abfc9a8e91617f468393b2d449a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0014-4827%2802%2900095-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4827%252802%252900095-2%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DMechanism%2520of%2520action%2520of%2520erb%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2003%26volume%3D284%26spage%3D131%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallet, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span> </span><span class="NLM_article-title">Synthesis and structure−activity relationships of 6,7-disubstituted 4-anilinoquinazoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Halletauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=L.+M.+Greenbergerauthor=H.-R.+Tsou&title=Synthesis+and+structure%E2%88%92activity+relationships+of+6%2C7-disubstituted+4-anilinoquinazoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallet%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.-R.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinazoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Johnson, L. N.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors: contributions from structure to clinical compounds</span> <span class="citation_source-journal">Q. Rev. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1017%2FS0033583508004745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1-40&author=L.+N.+Johnson&title=Protein+kinase+inhibitors%3A+contributions+from+structure+to+clinical+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1017%2FS0033583508004745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033583508004745%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DProtein%2520kinase%2520inhibitors%253A%2520contributions%2520from%2520structure%2520to%2520clinical%2520compounds%26jtitle%3DQ.%2520Rev.%2520Biophys.%26date%3D2009%26volume%3D19%26spage%3D1%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Rachid, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahimi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jean-Claude, B. J.</span><span> </span><span class="NLM_article-title">Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure−activity relationship</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2605</span><span class="NLM_x">–</span> <span class="NLM_lpage">2608</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070144p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2605-2608&author=Z.+Rachidauthor=F.+Brahimiauthor=Q.+Qiuauthor=C.+Williamsauthor=J.+M.+Hartleyauthor=J.+A.+Hartleyauthor=B.+J.+Jean-Claude&title=Novel+nitrogen+mustard-armed+combi-molecules+for+the+selective+targeting+of+epidermal+growth+factor+receptor+overexperessing+solid+tumors%3A+discovery+of+an+unusual+structure%E2%88%92activity+relationship"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm070144p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070144p%26sid%3Dliteratum%253Aachs%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DBrahimi%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DHartley%26aufirst%3DJ.%2BM.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DNovel%2520nitrogen%2520mustard-armed%2520combi-molecules%2520for%2520the%2520selective%2520targeting%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520overexperessing%2520solid%2520tumors%253A%2520discovery%2520of%2520an%2520unusual%2520structure%25E2%2588%2592activity%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2605%26epage%3D2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=J.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+H.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DJ.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Matheson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jean-Claude, B. J.</span><span> </span><span class="NLM_article-title">Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=11181914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlOksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2001&pages=832-840&author=S.+L.+Mathesonauthor=J.+McNameeauthor=B.+J.+Jean-Claude&title=Design+of+a+chimeric+3-methyl-1%2C2%2C3-triazene+with+mixed+receptor+tyrosine+kinase+and+DNA+damaging+properties%3A+a+novel+tumour+targeting+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy</span></div><div class="casAuthors">Matheson, Stephanie L.; McNamee, James; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">832-840</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The mixed epidermal growth factor receptor (EGFR)-DNA targeting properties of SMA41, a 6-(3-methyl-1,2,3-triazen-1-yl)-4-anilinoquinazoline designed to release N4-m-tolyl-quinazoline-4,6-diamine henceforth referred to as SMA52 [an inhibitor of EGFR tyrosine kinase (TK)] and methyldiazonium (a DNA methylating species) were studied in the O6-methylguanine-DNA methyltransferase (MGMT)-proficient and high EGFR-expressing epidermoid carcinoma of the vulva cell line A431.  The effects of SMA41 were compared with those of SMA52 alone, and temozolomide (TEM), a clin. prodrug of 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) that is inactive in MGMT-proficient cells.  The results showed that (1) the chimeric SMA41 could degrade in serum-contg. medium (t1/2 of ∼30 min) to generate, as predicted, the free inhibitor SMA52 as the most abundant metabolite (∼81% yield); (2) in contrast to SMA52 alone, the chimeric SMA41 and TEM induced significant DNA damage in A431 cells after 30-min or 2-h drug exposures, as confirmed by alk. single-cell gel microelectrophoresis (comet) assay; (3) SMA41 showed 5-fold greater affinity for the ATP binding site of EGFR than independently synthesized SMA52 in an enzyme assay and blocked EGF-induced tyrosine phosphorylation and EGFR autophosphorylation in A431 cells in a dose-dependent manner; (4) these mixed targeting properties of SMA41, combined with its ability to be converted to another potent EGFR TK inhibitor (e.g., SMA52) by hydrolytic cleavage, translated into over 8-fold greater antiproliferative activity than TEM, which showed no EGFR targeting properties (IC50 competitive binding > 100 μM); (5) under continuous drug exposure (3-6-day sulforhodamine and clonogenic assays), SMA41 was almost equipotent with SMA52; however, in a short 2-h drug exposure followed by incubation in drug-free media, SMA52 showed an almost complete loss of antiproliferative activity over the whole dose range.  In contrast, SMA41 retained almost 100% of its activity, indicating a more sustained growth inhibitory activity.  The results in toto suggest that the superior antiproliferative activity of SMA41 may be due to a combination of events assocd. with its binary EGFR TK and DNA targeting properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCMceLhqIjUbVg90H21EOLACvtfcHk0liCIX18euMUMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlOksr8%253D&md5=0377f2155e213dc809999dc1572dfd3c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DS.%2BL.%26aulast%3DMcNamee%26aufirst%3DJ.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DDesign%2520of%2520a%2520chimeric%25203-methyl-1%252C2%252C3-triazene%2520with%2520mixed%2520receptor%2520tyrosine%2520kinase%2520and%2520DNA%2520damaging%2520properties%253A%2520a%2520novel%2520tumour%2520targeting%2520strategy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D296%26spage%3D832%26epage%3D840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuliani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fumarola, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span> </span><span class="NLM_article-title">Dual mechanism of action of the 5-benzylidene-hydantoin UPR1204 on lung cancer cell lines</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1158%2F1535-7163.MCT-07-0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18281519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVShsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=361-370&author=A.+Cavazzoniauthor=R.+Alfieriauthor=C.+Carmiauthor=V.+Zulianiauthor=M.+Galettiauthor=C.+Fumarolaauthor=R.+Frazziauthor=M.+Bonelliauthor=F.+Bordiauthor=A.+Lodolaauthor=M.+Morauthor=P.+G.+Petronini&title=Dual+mechanism+of+action+of+the+5-benzylidene-hydantoin+UPR1204+on+lung+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines</span></div><div class="casAuthors">Cavazzoni, Andrea; Alfieri, Roberta R.; Carmi, Caterina; Zuliani, Valentina; Galetti, Maricla; Fumarola, Claudia; Frazzi, Raffaele; Bonelli, Mara; Bordi, Fabrizio; Lodola, Alessio; Mor, Marco; Petronini, Pier Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In this study, we examd. the mechanism of action of the novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 5-benzylidene-hydantoin UPR1024, whose structure was designed to interact at the ATP-binding site of EGFR.  The compd. had antiproliferative and proapoptotic effects when tested on the non-small cell lung cancer cell line A549.  The growth inhibitory effect was assocd. with an accumulation of the cells in the S phase of the cell cycle.  Moreover, UPR1024 induced significant level of DNA strand breaks assocd. with increased expression of p53 and p21WAF1 proteins, suggesting an additive mechanism of action.  The presence of wild-type p53 improved the drug efficacy, although the effect was also detectable in p53 null cells.  We also noted apoptotic cell death after treatment with UPR1024 at concns. above 10 μmol/L for >24 h, with involvement of both the extrinsic and intrinsic pathways.  The present data show that UPR1024 may be considered a combi-mol. capable of both blocking EGFR tyrosine kinase activity and inducing genomic DNA damage.  UPR1024 or its derivs. might serve as a basis for development of drugs for the treatment of lung cancer in patients resistant to classic tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAJkd_64qRwbVg90H21EOLACvtfcHk0liCIX18euMUMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVShsr0%253D&md5=06b5a43934a731dceb0a321ae2fd22c7</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0477%26sid%3Dliteratum%253Aachs%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DZuliani%26aufirst%3DV.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DFumarola%26aufirst%3DC.%26aulast%3DFrazzi%26aufirst%3DR.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26atitle%3DDual%2520mechanism%2520of%2520action%2520of%2520the%25205-benzylidene-hydantoin%2520UPR1204%2520on%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Alvarez-Sanchez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basketter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepoittevin, J.-P.</span><span> </span><span class="NLM_article-title">Studies of chemical selectivity of hapten, reactivity, and skin sensitization potency. 3. Synthesis and studies on the reactivity toward model nucleophiles of the <sup>13</sup>C-labeled skin sensitizers, 5-chloro-2-methylisothiazol-3-one (MCI) and 2-methylisothiazol-3-one (MI)</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">636</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx0256634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=627-636&author=R.+Alvarez-Sanchezauthor=D.+Basketterauthor=C.+Peaseauthor=J.-P.+Lepoittevin&title=Studies+of+chemical+selectivity+of+hapten%2C+reactivity%2C+and+skin+sensitization+potency.+3.+Synthesis+and+studies+on+the+reactivity+toward+model+nucleophiles+of+the+13C-labeled+skin+sensitizers%2C+5-chloro-2-methylisothiazol-3-one+%28MCI%29+and+2-methylisothiazol-3-one+%28MI%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Ftx0256634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0256634%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Sanchez%26aufirst%3DR.%26aulast%3DBasketter%26aufirst%3DD.%26aulast%3DPease%26aufirst%3DC.%26aulast%3DLepoittevin%26aufirst%3DJ.-P.%26atitle%3DStudies%2520of%2520chemical%2520selectivity%2520of%2520hapten%252C%2520reactivity%252C%2520and%2520skin%2520sensitization%2520potency.%25203.%2520Synthesis%2520and%2520studies%2520on%2520the%2520reactivity%2520toward%2520model%2520nucleophiles%2520of%2520the%252013C-labeled%2520skin%2520sensitizers%252C%25205-chloro-2-methylisothiazol-3-one%2520%2528MCI%2529%2520and%25202-methylisothiazol-3-one%2520%2528MI%2529%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2003%26volume%3D16%26spage%3D627%26epage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1519</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm960789h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1519-1529&author=B.+D.+Palmerauthor=S.+Trumpp-Kallmeyerauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=H.+D.+H.+Showalterauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+11.+Soluble+analogues+of+pyrrolo-+and+pyrazoloquinazolines+as+epidermal+growth+factor+receptor+inhibitors%3A+synthesis%2C+biological+evaluation%2C+and+modeling+of+the+mode+of+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm960789h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960789h%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252011.%2520Soluble%2520analogues%2520of%2520pyrrolo-%2520and%2520pyrazoloquinazolines%2520as%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%253A%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520modeling%2520of%2520the%2520mode%2520of%2520binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1519%26epage%3D1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Mor, M.; Bordi, F.; Carmi, C.; Vezzosi, S.; Lodola, A.; Petronini, P. G.; Alfieri, R.; Cavazzoni, A.</span><span> </span><span class="NLM_article-title">Composti Inibitori Irreversibili di EGFR con Attività Antiproliferativa</span>. Italian Patent Application MI2008A002336,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=M.+Mor&author=F.+Bordi&author=C.+Carmi&author=S.+Vezzosi&author=A.+Lodola&author=P.+G.+Petronini&author=R.+Alfieri&author=A.+Cavazzoni&title=Composti+Inibitori+Irreversibili+di+EGFR+con+Attivit%C3%A0+Antiproliferativa"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMor%26aufirst%3DM.%26atitle%3DComposti%2520Inibitori%2520Irreversibili%2520di%2520EGFR%2520con%2520Attivit%25C3%25A0%2520Antiproliferativa%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Gilday, J. P.; David, M.</span><span> </span><span class="NLM_article-title">Process for the Preparation of 4-(3′-Chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline</span>. PCT Int. Appl.WO2004/024703,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=J.+P.+Gilday&author=M.+David&title=Process+for+the+Preparation+of+4-%283%E2%80%B2-Chloro-4%E2%80%B2-fluoroanilino%29-7-methoxy-6-%283-morpholinopropoxy%29quinazoline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilday%26aufirst%3DJ.%2BP.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%25204-%25283%25E2%2580%25B2-Chloro-4%25E2%2580%25B2-fluoroanilino%2529-7-methoxy-6-%25283-morpholinopropoxy%2529quinazoline%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Weber, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertics, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, G. N.</span><span> </span><span class="NLM_article-title">Immunoaffinity purification of the epidermal growth factor receptor. Stoichiometry of binding and kinetics of self-phosphorylation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">259</span><span class="NLM_x">, </span> <span class="NLM_fpage">14631</span><span class="NLM_x">–</span> <span class="NLM_lpage">14636</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=1984&pages=14631-14636&author=W.+Weberauthor=P.+J.+Berticsauthor=G.+N.+Gill&title=Immunoaffinity+purification+of+the+epidermal+growth+factor+receptor.+Stoichiometry+of+binding+and+kinetics+of+self-phosphorylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DW.%26aulast%3DBertics%26aufirst%3DP.%2BJ.%26aulast%3DGill%26aufirst%3DG.%2BN.%26atitle%3DImmunoaffinity%2520purification%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor.%2520Stoichiometry%2520of%2520binding%2520and%2520kinetics%2520of%2520self-phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1984%26volume%3D259%26spage%3D14631%26epage%3D14636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Olive, D. M.</span><span> </span><span class="NLM_article-title">Quantitative methods for the analysis of protein phosphorylation in drug development</span> <span class="citation_source-journal">Expert Rev. Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1586%2F14789450.1.3.327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15966829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsFWlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=327-341&author=D.+M.+Olive&title=Quantitative+methods+for+the+analysis+of+protein+phosphorylation+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative methods for the analysis of protein phosphorylation in drug development</span></div><div class="casAuthors">Olive, D. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-341</span>CODEN:
                <span class="NLM_cas:coden">ERPXA3</span>;
        ISSN:<span class="NLM_cas:issn">1478-9450</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Most signal transduction and cell signaling pathways are mediated by protein kinases.  Protein kinases have emerged as important cellular regulatory proteins in many aspects of neoplasia.  Protein kinase inhibitors offer the opportunity to target diseases such as cancer with chemotherapeutic agents specific for the causative mol. defect.  In order to identity possible targets and assess kinase inhibitors, quant. methods for analyzing protein phosphorylation have been developed.  This review examines some of the current formats used for quantifying kinase function for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqicz-TQoAbfbVg90H21EOLACvtfcHk0lj2ajBA1qb7fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsFWlsbY%253D&md5=bc30b08948eab0593aac338138936d23</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1586%2F14789450.1.3.327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14789450.1.3.327%26sid%3Dliteratum%253Aachs%26aulast%3DOlive%26aufirst%3DD.%2BM.%26atitle%3DQuantitative%2520methods%2520for%2520the%2520analysis%2520of%2520protein%2520phosphorylation%2520in%2520drug%2520development%26jtitle%3DExpert%2520Rev.%2520Proteomics%26date%3D2004%26volume%3D1%26spage%3D327%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><a href="http://www.cerep.fr" class="extLink">www.cerep.fr</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=www.cerep.fr."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andriani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbognani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusca, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fumarola, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzi, G.</span><span> </span><span class="NLM_article-title">Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">8439</span><span class="NLM_x">–</span> <span class="NLM_lpage">8446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=8439-8446&author=A.+Cavazzoniauthor=P.+G.+Petroniniauthor=M.+Galettiauthor=L.+Rozauthor=F.+Andrianiauthor=P.+Carbognaniauthor=M.+Ruscaauthor=C.+Fumarolaauthor=R.+Alfieriauthor=G.+Sozzi&title=Dose-dependent+effect+of+FHIT-inducible+expression+in+Calu-1+lung+cancer+cell+line"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DRoz%26aufirst%3DL.%26aulast%3DAndriani%26aufirst%3DF.%26aulast%3DCarbognani%26aufirst%3DP.%26aulast%3DRusca%26aufirst%3DM.%26aulast%3DFumarola%26aufirst%3DC.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DSozzi%26aufirst%3DG.%26atitle%3DDose-dependent%2520effect%2520of%2520FHIT-inducible%2520expression%2520in%2520Calu-1%2520lung%2520cancer%2520cell%2520line%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D8439%26epage%3D8446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit65"><span> <span class="citation_source-book">Glide</span>, version <span class="NLM_edition">5.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+5.0%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlide%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit66"><span> <span class="citation_source-book">Maestro</span>, version <span class="NLM_edition">8.5</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+version+8.5%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2008."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMaestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span> </span><span class="NLM_article-title">Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">11225</span><span class="NLM_x">–</span> <span class="NLM_lpage">11236</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja9621760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK28XmtlOitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=11225-11236&author=W.+L.+Jorgensenauthor=D.+S.+Maxwellauthor=J.+Tirado-Rives&title=Development+and+testing+of+the+OPLS+all-atom+force+field+on+conformational+energetics+and+properties+of+organic+liquids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids</span></div><div class="casAuthors">Jorgensen, William L.; Maxwell, David S.; Tirado-Rives, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11225-11236</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and testing of the OPLS all-atom force field for org. mols. and peptides are described.  Parameters for both torsional and nonbonded energetics have been derived, while the bond stretching and angle bending parameters have been adopted mostly from the AMBER all-atom force field.  The torsional parameters were detd. by fitting to rotational energy profiles obtained from ab initio MO calcns. at the RHF/6-31G*//RHF/6-31G* level for more than 50 org. mols. and ions.  The quality of the fits was high with av. errors for conformational energies of less than 0.2 kcal/mol.  The force-field results for mol. structures are also demonstrated to closely match the ab initio predictions.  The nonbonded parameters were developed in conjunction with Monte Carlo statistical mechanics simulations by computing thermodn. and structural properties for 34 pure org. liqs. including alkanes, alkenes, alcs., ethers, acetals, thiols, sulfides, disulfides, aldehydes, ketones, and amides.  Av. errors in comparison with exptl. data are 2% for heats of vaporization and densities.  The Monte Carlo simulations included sampling all internal and intermol. degrees of freedom.  It is found that such non-polar and monofunctional systems do not show significant condensed-phase effects on internal energies in going from the gas phase to the pure liqs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGotSev_b1LVg90H21EOLACvtfcHk0lh4q0zPjII7rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtlOitrs%253D&md5=fef2924a69421881390282aa309ae91b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fja9621760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9621760%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DMaxwell%26aufirst%3DD.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26atitle%3DDevelopment%2520and%2520testing%2520of%2520the%2520OPLS%2520all-atom%2520force%2520field%2520on%2520conformational%2520energetics%2520and%2520properties%2520of%2520organic%2520liquids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D11225%26epage%3D11236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Ghosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sendrovic Rapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">Generalized Born model based on a surface integral formulation</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">10983</span><span class="NLM_x">–</span> <span class="NLM_lpage">10990</span></span><div class="citationLinks">[<a href="/doi/10.1021/jp982533o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK1cXnslOhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=10983-10990&author=A.+Ghoshauthor=C.+Sendrovic+Rappauthor=R.+A.+Friesner&title=Generalized+Born+model+based+on+a+surface+integral+formulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Generalized Born Model Based on a Surface Integral Formulation</span></div><div class="casAuthors">Ghosh, Avijit; Rapp, Chaya Sendrovic; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">10983-10990</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1089-5647</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have derived a surface-area-based version of the generalized Born model (S-GB) as a well-defined approxn. to the boundary element formulation of the Poisson-Boltzmann (PB) equation.  The relationship of the surface area methodol. to the vol.-integration-based approach of Still and co-workers is elucidated.  On the basis of insights obtained from these results, we then develop empirical correction schemes which yield significant improvements in accuracy, as compared to the uncorrected GB model, in reproducing accurate solns. of the Poisson-Boltzmann equation.  A large suite of energetic comparisons of GB, cor. S-GB, and PB for multiple conformations of peptides and proteins is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP-DmhFzS_w7Vg90H21EOLACvtfcHk0lh4q0zPjII7rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnslOhs7s%253D&md5=64dcaf1cf104d017a3f907a09c598710</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjp982533o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp982533o%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DSendrovic%2BRapp%26aufirst%3DC.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DGeneralized%2520Born%2520model%2520based%2520on%2520a%2520surface%2520integral%2520formulation%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D1998%26volume%3D102%26spage%3D10983%26epage%3D10990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 35 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Matthias Gehringer, <span class="NLM_string-name hlFld-ContribAuthor">Stefan A. Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (12)
                                     , 5673-5724. <a href="https://doi.org/10.1021/acs.jmedchem.8b01153" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01153%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEmerging%252Band%252BRe-Emerging%252BWarheads%252Bfor%252BTargeted%252BCovalent%252BInhibitors%25253A%252BApplications%252Bin%252BMedicinal%252BChemistry%252Band%252BChemical%252BBiology%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D23072018%26date%3D25012019%26date%3D19122018%26volume%3D62%26issue%3D12%26spage%3D5673%26epage%3D5724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Andrea J.  Gonzales</span>, <span class="hlFld-ContribAuthor ">Julie A.  Spicer</span>, <span class="hlFld-ContribAuthor ">Helen  Lee</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Reed</span>, <span class="hlFld-ContribAuthor ">Karen  Sexton</span>, <span class="hlFld-ContribAuthor ">Irene W.  Althaus</span>, <span class="hlFld-ContribAuthor ">Tong  Zhu</span>, <span class="hlFld-ContribAuthor ">Shannon L.  Black</span>, <span class="hlFld-ContribAuthor ">Adrian  Blaser</span>, <span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Paul A.  Ellis</span>, <span class="hlFld-ContribAuthor ">Stephen  Fakhoury</span>, <span class="hlFld-ContribAuthor ">Patricia J.  Harvey</span>, <span class="hlFld-ContribAuthor ">Ken  Hook</span>, <span class="hlFld-ContribAuthor ">Florence O. J.  McCarthy</span>, <span class="hlFld-ContribAuthor ">Brian D.  Palmer</span>, <span class="hlFld-ContribAuthor ">Freddy  Rivault</span>, <span class="hlFld-ContribAuthor ">Kevin  Schlosser</span>, <span class="hlFld-ContribAuthor ">Teresa  Ellis</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Thompson</span>, <span class="hlFld-ContribAuthor ">Erin  Trachet</span>, <span class="hlFld-ContribAuthor ">R. Thomas  Winters</span>, <span class="hlFld-ContribAuthor ">Haile  Tecle</span>, and <span class="hlFld-ContribAuthor ">Alexander  Bridges</span>  . </span><span class="cited-content_cbyCitation_article-title">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (17)
                                     , 8103-8124. <a href="https://doi.org/10.1021/acs.jmedchem.6b00883" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00883</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTyrosine%252BKinase%252BInhibitors.%252B20.%252BOptimization%252Bof%252BSubstituted%252BQuinazoline%252Band%252BPyrido%25255B3%25252C4-d%25255Dpyrimidine%252BDerivatives%252Bas%252BOrally%252BActive%25252C%252BIrreversible%252BInhibitors%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BFamily%26aulast%3DSmaill%26aufirst%3DJeff%2BB.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D15062016%26date%3D22082016%26date%3D08092016%26date%3D04082016%26volume%3D59%26issue%3D17%26spage%3D8103%26epage%3D8124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Jessica E.    Reed </span><span class="hlFld-ContribAuthor "> Jeff B.    Smaill </span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 207-233. <a href="https://doi.org/10.1021/bk-2016-1239.ch008" title="DOI URL">https://doi.org/10.1021/bk-2016-1239.ch008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2016-1239.ch008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2016-1239.ch008%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Bof%252BDacomitinib%25252C%252Ba%252BPotent%252BIrreversible%252BEGFR%252BInhibitor%26aulast%3DReed%26aufirst%3DJessica%2BE.%26date%3D2016%26date%3D2016%26spage%3D207%26epage%3D233%26atitle%3DComprehensive%252BAccounts%252Bof%252BPharmaceutical%252BResearch%252Band%252BDevelopment%25253A%252BFrom%252BDiscovery%252Bto%252BLate-Stage%252BProcess%252BDevelopment%252BVolume%252B1%26aulast%3DAbdel-Magid%26aufirst%3DAhmed%2BF.%26date%3D2016%26date%3D2016%26volume%3D1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luigi  Capoferri</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Silvia  Rivara</span>, and <span class="hlFld-ContribAuthor ">Marco  Mor</span>  . </span><span class="cited-content_cbyCitation_article-title">Quantum Mechanics/Molecular Mechanics Modeling of Covalent Addition between EGFR–Cysteine 797 and N-(4-Anilinoquinazolin-6-yl) Acrylamide. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2015,</strong> <em>55 </em>
                                    (3)
                                     , 589-599. <a href="https://doi.org/10.1021/ci500720e" title="DOI URL">https://doi.org/10.1021/ci500720e</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci500720e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci500720e%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DQuantum%252BMechanics%25252FMolecular%252BMechanics%252BModeling%252Bof%252BCovalent%252BAddition%252Bbetween%252BEGFR%2525E2%252580%252593Cysteine%252B797%252Band%252BN-%2525284-Anilinoquinazolin-6-yl%252529%252BAcrylamide%26aulast%3DCapoferri%26aufirst%3DLuigi%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D04122014%26date%3D17022015%26date%3D23032015%26date%3D06022015%26volume%3D55%26issue%3D3%26spage%3D589%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bobby Fachrizal  Assiddiq</span>, <span class="hlFld-ContribAuthor ">Kah Yap  Tan</span>, <span class="hlFld-ContribAuthor ">Weiyi  Toy</span>, <span class="hlFld-ContribAuthor ">Siew Pang  Chan</span>, <span class="hlFld-ContribAuthor ">Poh Kuan  Chong</span>, and <span class="hlFld-ContribAuthor ">Yoon Pin  Lim</span>  . </span><span class="cited-content_cbyCitation_article-title">EGFR S1166 Phosphorylation Induced by a Combination of EGF and Gefitinib Has a Potentially Negative Impact on Lung Cancer Cell Growth. </span><span class="cited-content_cbyCitation_journal-name">Journal of Proteome Research</span><span> <strong>2012,</strong> <em>11 </em>
                                    (8)
                                     , 4110-4119. <a href="https://doi.org/10.1021/pr3002029" title="DOI URL">https://doi.org/10.1021/pr3002029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/pr3002029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fpr3002029%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Proteome%2520Research%26atitle%3DEGFR%252BS1166%252BPhosphorylation%252BInduced%252Bby%252Ba%252BCombination%252Bof%252BEGF%252Band%252BGefitinib%252BHas%252Ba%252BPotentially%252BNegative%252BImpact%252Bon%252BLung%252BCancer%252BCell%252BGrowth%26aulast%3DAssiddiq%26aufirst%3DBobby%2BFachrizal%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D01032012%26date%3D10072012%26date%3D03082012%26date%3D18062012%26volume%3D11%26issue%3D8%26spage%3D4110%26epage%3D4119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tjeerd  Barf</span> and <span class="hlFld-ContribAuthor ">Allard  Kaptein</span>  . </span><span class="cited-content_cbyCitation_article-title">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (14)
                                     , 6243-6262. <a href="https://doi.org/10.1021/jm3003203" title="DOI URL">https://doi.org/10.1021/jm3003203</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm3003203%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIrreversible%252BProtein%252BKinase%252BInhibitors%25253A%252BBalancing%252Bthe%252BBenefits%252Band%252BRisks%26aulast%3DBarf%26aufirst%3DTjeerd%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D07032012%26date%3D08062012%26date%3D26072012%26date%3D23052012%26volume%3D55%26issue%3D14%26spage%3D6243%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaohua  Chang</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Duanqing  Pei</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (6)
                                     , 2711-2723. <a href="https://doi.org/10.1021/jm201591k" title="DOI URL">https://doi.org/10.1021/jm201591k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201591k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BConformationally%252BConstrained%252BInhibitors%252BTargeting%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BThreonine790%252B%2525E2%252586%252592%252BMethionine790%252BMutant%26aulast%3DChang%26aufirst%3DShaohua%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D25112011%26date%3D01032012%26date%3D22032012%26date%3D16022012%26volume%3D55%26issue%3D6%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Elena  Galvani</span>, <span class="hlFld-ContribAuthor ">Federica  Vacondio</span>, <span class="hlFld-ContribAuthor ">Silvia  Rivara</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Simonetta  Russo</span>, <span class="hlFld-ContribAuthor ">Stefania  Aiello</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Bordi</span>, <span class="hlFld-ContribAuthor ">Gabriele  Costantino</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavazzoni</span>, <span class="hlFld-ContribAuthor ">Roberta R.  Alfieri</span>, <span class="hlFld-ContribAuthor ">Andrea  Ardizzoni</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, and <span class="hlFld-ContribAuthor ">Marco  Mor</span>  . </span><span class="cited-content_cbyCitation_article-title">Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (5)
                                     , 2251-2264. <a href="https://doi.org/10.1021/jm201507x" title="DOI URL">https://doi.org/10.1021/jm201507x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201507x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201507x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIrreversible%252BInhibition%252Bof%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BActivity%252Bby%252B3-Aminopropanamides%26aulast%3DCarmi%26aufirst%3DCaterina%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D08112011%26date%3D17022012%26date%3D08032012%26date%3D26012012%26volume%3D55%26issue%3D5%26spage%3D2251%26epage%3D2264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Scalvini</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>190 </em>, 114643. <a href="https://doi.org/10.1016/j.bcp.2021.114643" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114643%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DFighting%252Btertiary%252Bmutations%252Bin%252BEGFR-driven%252Blung-cancers%25253A%252BCurrent%252Badvances%252Band%252Bfuture%252Bperspectives%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DScalvini%26aufirst%3DLaura%26date%3D2021%26volume%3D190%26spage%3D114643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chieh-Kai  Chan</span>, <span class="hlFld-ContribAuthor ">Chien-Yu  Lai</span>, <span class="hlFld-ContribAuthor ">Cheng-Chung  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">TMSOTf-catalyzed synthesis of substituted quinazolines using hexamethyldisilazane as a nitrogen source under neat and microwave irradiation conditions. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (36)
                                     , 7201-7212. <a href="https://doi.org/10.1039/D0OB01507E" title="DOI URL">https://doi.org/10.1039/D0OB01507E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB01507E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB01507E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DTMSOTf-catalyzed%252Bsynthesis%252Bof%252Bsubstituted%252Bquinazolines%252Busing%252Bhexamethyldisilazane%252Bas%252Ba%252Bnitrogen%252Bsource%252Bunder%252Bneat%252Band%252Bmicrowave%252Birradiation%252Bconditions%26aulast%3DChan%26aufirst%3DChieh-Kai%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D36%26spage%3D7201%26epage%3D7212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Fumarola</span>, <span class="hlFld-ContribAuthor ">Nicole  Bozza</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Francesca  Ferlenghi</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Marseglia</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Mara  Bonelli</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Daniele  Cretella</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>, <span class="hlFld-ContribAuthor ">Roberta  Minari</span>, <span class="hlFld-ContribAuthor ">Maricla  Galetti</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Andrea  Ardizzoni</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2019,</strong> <em>9 </em><a href="https://doi.org/10.3389/fonc.2019.00179" title="DOI URL">https://doi.org/10.3389/fonc.2019.00179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2019.00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2019.00179%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DExpanding%252Bthe%252BArsenal%252Bof%252BFGFR%252BInhibitors%25253A%252BA%252BNovel%252BChloroacetamide%252BDerivative%252Bas%252Ba%252BNew%252BIrreversible%252BAgent%252BWith%252BAnti-proliferative%252BActivity%252BAgainst%252BFGFR1-Amplified%252BLung%252BCancer%252BCell%252BLines%26aulast%3DFumarola%26aufirst%3DClaudia%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Nicole  Bozza</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavazzoni</span>, <span class="hlFld-ContribAuthor ">Mara  Bonelli</span>, <span class="hlFld-ContribAuthor ">Federica  Vacondio</span>, <span class="hlFld-ContribAuthor ">Francesca  Ferlenghi</span>, <span class="hlFld-ContribAuthor ">Donatella  Callegari</span>, <span class="hlFld-ContribAuthor ">Claudia  Silva</span>, <span class="hlFld-ContribAuthor ">Silvia  Rivara</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Graziana  Digiacomo</span>, <span class="hlFld-ContribAuthor ">Claudia  Fumarola</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>. </span><span class="cited-content_cbyCitation_article-title">Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>162 </em>, 507-524. <a href="https://doi.org/10.1016/j.ejmech.2018.11.029" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.029%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBalancing%252Breactivity%252Band%252Bantitumor%252Bactivity%25253A%252Bheteroarylthioacetamide%252Bderivatives%252Bas%252Bpotent%252Band%252Btime-dependent%252Binhibitors%252Bof%252BEGFR%26aulast%3DCastelli%26aufirst%3DRiccardo%26date%3D2019%26volume%3D162%26spage%3D507%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pankaj Kumar  Singh</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>79 </em>, 163-170. <a href="https://doi.org/10.1016/j.bioorg.2018.04.001" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.04.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DMolecular%252Bdynamics%252Bguided%252Bdevelopment%252Bof%252Bindole%252Bbased%252Bdual%252Binhibitors%252Bof%252BEGFR%252B%252528T790M%252529%252Band%252Bc-MET%26aulast%3DSingh%26aufirst%3DPankaj%2BKumar%26date%3D2018%26volume%3D79%26spage%3D163%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weijie  Hou</span>, <span class="hlFld-ContribAuthor ">Yan  Ren</span>, <span class="hlFld-ContribAuthor ">Zhenhua  Zhang</span>, <span class="hlFld-ContribAuthor ">Huan  Sun</span>, <span class="hlFld-ContribAuthor ">Yongfen  Ma</span>, <span class="hlFld-ContribAuthor ">Bo  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (8)
                                     , 1740-1750. <a href="https://doi.org/10.1016/j.bmc.2018.02.022" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.02.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.02.022%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bquinazoline%252Bderivatives%252Bbearing%252Bvarious%252B6-benzamide%252Bmoieties%252Bas%252Bhighly%252Bselective%252Band%252Bpotent%252BEGFR%252Binhibitors%26aulast%3DHou%26aufirst%3DWeijie%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1740%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jon  Ainsley</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Adrian J.  Mulholland</span>, <span class="hlFld-ContribAuthor ">Christo Z.  Christov</span>, <span class="hlFld-ContribAuthor ">Tatyana G.  Karabencheva-Christova</span>. </span><span class="cited-content_cbyCitation_article-title">Combined Quantum Mechanics and Molecular Mechanics Studies of Enzymatic Reaction Mechanisms. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 1-32. <a href="https://doi.org/10.1016/bs.apcsb.2018.07.001" title="DOI URL">https://doi.org/10.1016/bs.apcsb.2018.07.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.apcsb.2018.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.apcsb.2018.07.001%26sid%3Dliteratum%253Aachs%26atitle%3DCombined%252BQuantum%252BMechanics%252Band%252BMolecular%252BMechanics%252BStudies%252Bof%252BEnzymatic%252BReaction%252BMechanisms%26aulast%3DAinsley%26aufirst%3DJon%26date%3D2018%26spage%3D1%26epage%3D32%26pub%3DElsevier%26atitle%3DComputational%252BMolecular%252BModelling%252Bin%252BStructural%252BBiology%26date%3D2018%26volume%3D113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaiyan  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Yu</span>, <span class="hlFld-ContribAuthor ">Haiyang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Huang</span>, <span class="hlFld-ContribAuthor ">Yanjun  Xu</span>, <span class="hlFld-ContribAuthor ">Lei  Gong</span>, <span class="hlFld-ContribAuthor ">Yun  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2017,</strong> <em>80 </em>
                                    (6)
                                     , 1179-1187. <a href="https://doi.org/10.1007/s00280-017-3464-9" title="DOI URL">https://doi.org/10.1007/s00280-017-3464-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-017-3464-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-017-3464-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DUncommon%252Bmutation%252Btypes%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Band%252Bresponse%252Bto%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252BChinese%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bpatients%26aulast%3DChen%26aufirst%3DKaiyan%26date%3D2017%26date%3D2017%26volume%3D80%26issue%3D6%26spage%3D1179%26epage%3D1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pankaj Kumar  Singh</span>, <span class="hlFld-ContribAuthor ">Harpreet  Singh</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Kinases inhibitors in lung cancer: From benchside to bedside. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2016,</strong> <em>1866 </em>
                                    (1)
                                     , 128-140. <a href="https://doi.org/10.1016/j.bbcan.2016.07.002" title="DOI URL">https://doi.org/10.1016/j.bbcan.2016.07.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2016.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2016.07.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DKinases%252Binhibitors%252Bin%252Blung%252Bcancer%25253A%252BFrom%252Bbenchside%252Bto%252Bbedside%26aulast%3DSingh%26aufirst%3DPankaj%2BKumar%26date%3D2016%26volume%3D1866%26issue%3D1%26spage%3D128%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ju  Hou</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Guangfa  Wang</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhonghuang  Li</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Tian</span>, <span class="hlFld-ContribAuthor ">Yonghuan  Yu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>118 </em>, 276-289. <a href="https://doi.org/10.1016/j.ejmech.2016.04.026" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.026%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Banti-tumor%252Bactivity%25252C%252Band%252Bmolecular%252Bmodeling%252Bof%252Bquinazoline%252Band%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Btargeting%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DHou%26aufirst%3DJu%26date%3D2016%26volume%3D118%26spage%3D276%26epage%3D289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Tarozzi</span>, <span class="hlFld-ContribAuthor ">Chiara  Marchetti</span>, <span class="hlFld-ContribAuthor ">Benedetta  Nicolini</span>, <span class="hlFld-ContribAuthor ">Massimo  D'Amico</span>, <span class="hlFld-ContribAuthor ">Nicole  Ticchi</span>, <span class="hlFld-ContribAuthor ">Letizia  Pruccoli</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Tumiatti</span>, <span class="hlFld-ContribAuthor ">Elena  Simoni</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Andrea  Milelli</span>, <span class="hlFld-ContribAuthor ">Anna  Minarini</span>. </span><span class="cited-content_cbyCitation_article-title">Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>117 </em>, 283-291. <a href="https://doi.org/10.1016/j.ejmech.2016.04.002" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.002%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCombined%252Binhibition%252Bof%252Bthe%252BEGFR%25252FAKT%252Bpathways%252Bby%252Ba%252Bnovel%252Bconjugate%252Bof%252Bquinazoline%252Bwith%252Bisothiocyanate%26aulast%3DTarozzi%26aufirst%3DAndrea%26date%3D2016%26volume%3D117%26spage%3D283%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ram  Khattri</span>, <span class="hlFld-ContribAuthor ">Daniel  Morris</span>, <span class="hlFld-ContribAuthor ">Caroline  Davis</span>, <span class="hlFld-ContribAuthor ">Stephanie  Bilinovich</span>, <span class="hlFld-ContribAuthor ">Andrew  Caras</span>, <span class="hlFld-ContribAuthor ">Matthew  Panzner</span>, <span class="hlFld-ContribAuthor ">Michael  Debord</span>, <span class="hlFld-ContribAuthor ">Thomas  Leeper</span>. </span><span class="cited-content_cbyCitation_article-title">An NMR-Guided Screening Method for Selective Fragment Docking and Synthesis of a Warhead Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (7)
                                     , 846. <a href="https://doi.org/10.3390/molecules21070846" title="DOI URL">https://doi.org/10.3390/molecules21070846</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21070846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21070846%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAn%252BNMR-Guided%252BScreening%252BMethod%252Bfor%252BSelective%252BFragment%252BDocking%252Band%252BSynthesis%252Bof%252Ba%252BWarhead%252BInhibitor%26aulast%3DKhattri%26aufirst%3DRam%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D7%26spage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Long  Zhang</span>, <span class="hlFld-ContribAuthor ">Yingying  Yang</span>, <span class="hlFld-ContribAuthor ">Haojie  Zhou</span>, <span class="hlFld-ContribAuthor ">Qingmei  Zheng</span>, <span class="hlFld-ContribAuthor ">Yuhao  Li</span>, <span class="hlFld-ContribAuthor ">Shansong  Zheng</span>, <span class="hlFld-ContribAuthor ">Shuyong  Zhao</span>, <span class="hlFld-ContribAuthor ">Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Chuanwen  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>102 </em>, 445-463. <a href="https://doi.org/10.1016/j.ejmech.2015.08.026" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.08.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.08.026%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-activity%252Bstudy%252Bof%252Bquinazoline%252Bderivatives%252Bleading%252Bto%252Bthe%252Bdiscovery%252Bof%252Bpotent%252BEGFR-T790M%252Binhibitors%26aulast%3DZhang%26aufirst%3DLong%26date%3D2015%26volume%3D102%26spage%3D445%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steffen  Bugge</span>, <span class="hlFld-ContribAuthor ">Ingri Ullestad  Moen</span>, <span class="hlFld-ContribAuthor ">Kent-Ove  Kragseth Sylte</span>, <span class="hlFld-ContribAuthor ">Eirik  Sundby</span>, <span class="hlFld-ContribAuthor ">Bård Helge  Hoff</span>. </span><span class="cited-content_cbyCitation_article-title">Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>94 </em>, 175-194. <a href="https://doi.org/10.1016/j.ejmech.2015.03.004" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTruncated%252Bstructures%252Bused%252Bin%252Bsearch%252Bfor%252Bnew%252Blead%252Bcompounds%252Band%252Bin%252Ba%252Bretrospective%252Banalysis%252Bof%252Bthienopyrimidine-based%252BEGFR%252Binhibitors%26aulast%3DBugge%26aufirst%3DSteffen%26date%3D2015%26volume%3D94%26spage%3D175%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai-Hao  Yin</span>, <span class="hlFld-ContribAuthor ">Yi-Han  Hsieh</span>, <span class="hlFld-ContribAuthor ">Rohidas S.  Sulake</span>, <span class="hlFld-ContribAuthor ">Su-Pei  Wang</span>, <span class="hlFld-ContribAuthor ">Jui-I.  Chao</span>, <span class="hlFld-ContribAuthor ">Chinpiao  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of gefitinib analogues with potent anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (22)
                                     , 5247-5250. <a href="https://doi.org/10.1016/j.bmcl.2014.09.056" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.09.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.09.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.09.056%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOptimization%252Bof%252Bgefitinib%252Banalogues%252Bwith%252Bpotent%252Banticancer%252Bactivity%26aulast%3DYin%26aufirst%3DKai-Hao%26date%3D2014%26volume%3D24%26issue%3D22%26spage%3D5247%26epage%3D5250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si-Ning  Li</span>, <span class="hlFld-ContribAuthor ">Huan-Qiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor inhibitors: a patent review (2010 – present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (3)
                                     , 309-321. <a href="https://doi.org/10.1517/13543776.2014.871527" title="DOI URL">https://doi.org/10.1517/13543776.2014.871527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.871527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.871527%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%252B%2525282010%252B%2525E2%252580%252593%252Bpresent%252529%26aulast%3DLi%26aufirst%3DSi-Ning%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D3%26spage%3D309%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ilija N.  Cvijetić</span>, <span class="hlFld-ContribAuthor ">Maja D.  Vitorović-Todorović</span>, <span class="hlFld-ContribAuthor ">Ivan O.  Juranić</span>, <span class="hlFld-ContribAuthor ">Branko J.  Drakulić</span>. </span><span class="cited-content_cbyCitation_article-title">Reactivity of (E)-4-aryl-4-oxo-2-butenoic acid arylamides toward 2-mercaptoethanol. A LFER study. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2013,</strong> <em>144 </em>
                                    (12)
                                     , 1815-1824. <a href="https://doi.org/10.1007/s00706-013-1084-6" title="DOI URL">https://doi.org/10.1007/s00706-013-1084-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-013-1084-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-013-1084-6%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3DReactivity%252Bof%252B%252528E%252529-4-aryl-4-oxo-2-butenoic%252Bacid%252Barylamides%252Btoward%252B2-mercaptoethanol.%252BA%252BLFER%252Bstudy%26aulast%3DCvijeti%25C4%2587%26aufirst%3DIlija%2BN.%26date%3D2013%26date%3D2013%26volume%3D144%26issue%3D12%26spage%3D1815%26epage%3D1824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Federica  Vacondio</span>, <span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Elena  Galvani</span>, <span class="hlFld-ContribAuthor ">Michele  Bassi</span>, <span class="hlFld-ContribAuthor ">Claudia  Silva</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Silvia  Rivara</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavazzoni</span>, <span class="hlFld-ContribAuthor ">Roberta R.  Alfieri</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>. </span><span class="cited-content_cbyCitation_article-title">Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (19)
                                     , 5290-5294. <a href="https://doi.org/10.1016/j.bmcl.2013.08.008" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.08.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.08.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLong-lasting%252Binhibition%252Bof%252BEGFR%252Bautophosphorylation%252Bin%252BA549%252Btumor%252Bcells%252Bby%252Bintracellular%252Baccumulation%252Bof%252Bnon-covalent%252Binhibitors%26aulast%3DVacondio%26aufirst%3DFederica%26date%3D2013%26volume%3D23%26issue%3D19%26spage%3D5290%26epage%3D5294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S  Yoshikawa</span>, <span class="hlFld-ContribAuthor ">M  Kukimoto-Niino</span>, <span class="hlFld-ContribAuthor ">L  Parker</span>, <span class="hlFld-ContribAuthor ">N  Handa</span>, <span class="hlFld-ContribAuthor ">T  Terada</span>, <span class="hlFld-ContribAuthor ">T  Fujimoto</span>, <span class="hlFld-ContribAuthor ">Y  Terazawa</span>, <span class="hlFld-ContribAuthor ">M  Wakiyama</span>, <span class="hlFld-ContribAuthor ">M  Sato</span>, <span class="hlFld-ContribAuthor ">S  Sano</span>, <span class="hlFld-ContribAuthor ">T  Kobayashi</span>, <span class="hlFld-ContribAuthor ">T  Tanaka</span>, <span class="hlFld-ContribAuthor ">L  Chen</span>, <span class="hlFld-ContribAuthor ">Z-J  Liu</span>, <span class="hlFld-ContribAuthor ">B-C  Wang</span>, <span class="hlFld-ContribAuthor ">M  Shirouzu</span>, <span class="hlFld-ContribAuthor ">S  Kawa</span>, <span class="hlFld-ContribAuthor ">K  Semba</span>, <span class="hlFld-ContribAuthor ">T  Yamamoto</span>, <span class="hlFld-ContribAuthor ">S  Yokoyama</span>. </span><span class="cited-content_cbyCitation_article-title">Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2013,</strong> <em>32 </em>
                                    (1)
                                     , 27-38. <a href="https://doi.org/10.1038/onc.2012.21" title="DOI URL">https://doi.org/10.1038/onc.2012.21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/onc.2012.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fonc.2012.21%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DStructural%252Bbasis%252Bfor%252Bthe%252Baltered%252Bdrug%252Bsensitivities%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer-associated%252Bmutants%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DYoshikawa%26aufirst%3DS%26date%3D2013%26date%3D2012%26volume%3D32%26issue%3D1%26spage%3D27%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi  Jo</span>, <span class="hlFld-ContribAuthor ">Seong  Bae</span>, <span class="hlFld-ContribAuthor ">Byeng  Son</span>, <span class="hlFld-ContribAuthor ">Chi  Kim</span>, <span class="hlFld-ContribAuthor ">Gun  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">3,4-dihydroxyphenyl acetic acid and (+)-epoxydon isolated from marine algae-derived microorganisms induce down regulation of epidermal growth factor activated mitogenic signaling cascade in Hela cells. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell International</span><span> <strong>2013,</strong> <em>13 </em>
                                    (1)
                                     , 49. <a href="https://doi.org/10.1186/1475-2867-13-49" title="DOI URL">https://doi.org/10.1186/1475-2867-13-49</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/1475-2867-13-49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2F1475-2867-13-49%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%2520International%26atitle%3D3%25252C4-dihydroxyphenyl%252Bacetic%252Bacid%252Band%252B%252528%25252B%252529-epoxydon%252Bisolated%252Bfrom%252Bmarine%252Balgae-derived%252Bmicroorganisms%252Binduce%252Bdown%252Bregulation%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Bactivated%252Bmitogenic%252Bsignaling%252Bcascade%252Bin%252BHela%252Bcells%26aulast%3DJo%26aufirst%3DMi%26date%3D2013%26volume%3D13%26issue%3D1%26spage%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Galvani</span>, <span class="hlFld-ContribAuthor ">Elisa  Giovannetti</span>, <span class="hlFld-ContribAuthor ">Francesca  Saccani</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavazzoni</span>, <span class="hlFld-ContribAuthor ">Leticia G.  Leon</span>, <span class="hlFld-ContribAuthor ">Henk  Dekker</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>, <span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Andrea  Ardizzoni</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, <span class="hlFld-ContribAuthor ">Godefridus J.  Peters</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Neoplasia</span><span> <strong>2013,</strong> <em>15 </em>
                                    (1)
                                     , 61-IN18. <a href="https://doi.org/10.1593/neo.121434" title="DOI URL">https://doi.org/10.1593/neo.121434</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1593/neo.121434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1593%2Fneo.121434%26sid%3Dliteratum%253Aachs%26jtitle%3DNeoplasia%26atitle%3DMolecular%252BMechanisms%252BUnderlying%252Bthe%252BAntitumor%252BActivity%252Bof%252B3-Aminopropanamide%252BIrreversible%252BInhibitors%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252Bin%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%26aulast%3DGalvani%26aufirst%3DElena%26date%3D2013%26volume%3D15%26issue%3D1%26spage%3D61%26epage%3DIN18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">He Ping  Yan</span>, <span class="hlFld-ContribAuthor ">Du Shu  Huang</span>, <span class="hlFld-ContribAuthor ">Ju Cheng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of 4-(3′-Chlorophenylamino)-6-Methoxy Quinazoline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Advanced Materials Research</span><span> <strong>2013,</strong> <em>634-638 </em>, 1215-1218. <a href="https://doi.org/10.4028/www.scientific.net/AMR.634-638.1215" title="DOI URL">https://doi.org/10.4028/www.scientific.net/AMR.634-638.1215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4028/www.scientific.net/AMR.634-638.1215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4028%2Fwww.scientific.net%2FAMR.634-638.1215%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Materials%2520Research%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252B4-%2525283%2525E2%252580%2525B2-Chlorophenylamino%252529-6-Methoxy%252BQuinazoline%252BDerivatives%26aulast%3DYan%26aufirst%3DHe%2BPing%26date%3D2013%26date%3D2013%26volume%3D634-638%26spage%3D1215%26epage%3D1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, <span class="hlFld-ContribAuthor ">Roberta R.  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2012,</strong> <em>84 </em>
                                    (11)
                                     , 1388-1399. <a href="https://doi.org/10.1016/j.bcp.2012.07.031" title="DOI URL">https://doi.org/10.1016/j.bcp.2012.07.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2012.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2012.07.031%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DClinical%252Bperspectives%252Bfor%252Birreversible%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252Bcancer%26aulast%3DCarmi%26aufirst%3DCaterina%26date%3D2012%26volume%3D84%26issue%3D11%26spage%3D1388%26epage%3D1399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimiliano  Tognolini</span>, <span class="hlFld-ContribAuthor ">Matteo  Incerti</span>, <span class="hlFld-ContribAuthor ">Iftiin  Hassan-Mohamed</span>, <span class="hlFld-ContribAuthor ">Carmine  Giorgio</span>, <span class="hlFld-ContribAuthor ">Simonetta  Russo</span>, <span class="hlFld-ContribAuthor ">Renato  Bruni</span>, <span class="hlFld-ContribAuthor ">Barbara  Lelli</span>, <span class="hlFld-ContribAuthor ">Luisa  Bracci</span>, <span class="hlFld-ContribAuthor ">Roberta  Noberini</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Barocelli</span>, <span class="hlFld-ContribAuthor ">Paola  Vicini</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Activity Relationships and Mechanism of Action of Eph-ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2012,</strong> <em>7 </em>
                                    (6)
                                     , 1071-1083. <a href="https://doi.org/10.1002/cmdc.201200102" title="DOI URL">https://doi.org/10.1002/cmdc.201200102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201200102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201200102%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DStructure-Activity%252BRelationships%252Band%252BMechanism%252Bof%252BAction%252Bof%252BEph-ephrin%252BAntagonists%25253A%252BInteraction%252Bof%252BCholanic%252BAcid%252Bwith%252Bthe%252BEphA2%252BReceptor%26aulast%3DTognolini%26aufirst%3DMassimiliano%26date%3D2012%26date%3D2012%26volume%3D7%26issue%3D6%26spage%3D1071%26epage%3D1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Galyna G.  Berest</span>, <span class="hlFld-ContribAuthor ">Olexii Yu.  Voskoboynik</span>, <span class="hlFld-ContribAuthor ">Sergiy I.  Kovalenko</span>, <span class="hlFld-ContribAuthor ">Olexii M.  Antypenko</span>, <span class="hlFld-ContribAuthor ">Inna S.  Nosulenko</span>, <span class="hlFld-ContribAuthor ">Andrii M.  Katsev</span>, <span class="hlFld-ContribAuthor ">Olena S.  Shandrovskaya</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2-[(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>46 </em>
                                    (12)
                                     , 6066-6074. <a href="https://doi.org/10.1016/j.ejmech.2011.10.022" title="DOI URL">https://doi.org/10.1016/j.ejmech.2011.10.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2011.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2011.10.022%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bactivity%252Bof%252Bnovel%252BN-cycloalkyl-%252528cycloalkylaryl%252529-2-%25255B%2525283-R-2-oxo-2H-%25255B1%25252C2%25252C4%25255Dtriazino%25255B2%25252C3-c%25255Dquinazoline-6-yl%252529thio%25255Dacetamides%26aulast%3DBerest%26aufirst%3DGalyna%2BG.%26date%3D2011%26volume%3D46%26issue%3D12%26spage%3D6066%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David C.  Swinney</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanism of Action (MMoA) in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2011,</strong>,, 301-317. <a href="https://doi.org/10.1016/B978-0-12-386009-5.00009-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-386009-5.00009-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-386009-5.00009-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-386009-5.00009-6%26sid%3Dliteratum%253Aachs%26atitle%3DMolecular%252BMechanism%252Bof%252BAction%252B%252528MMoA%252529%252Bin%252BDrug%252BDiscovery%26aulast%3DSwinney%26aufirst%3DDavid%2BC.%26date%3D2011%26spage%3D301%26epage%3D317%26pub%3DElsevier%26date%3D2011%26volume%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Silvia  Rivara</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Computational Methods to the Design of Fatty Acid Amide Hydrolase (FAAH) Inhibitors Based on a Carbamic Template Structure. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2011,</strong>,, 1-26. <a href="https://doi.org/10.1016/B978-0-12-386485-7.00001-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-386485-7.00001-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-386485-7.00001-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-386485-7.00001-6%26sid%3Dliteratum%253Aachs%26atitle%3DApplication%252Bof%252BComputational%252BMethods%252Bto%252Bthe%252BDesign%252Bof%252BFatty%252BAcid%252BAmide%252BHydrolase%252B%252528FAAH%252529%252BInhibitors%252BBased%252Bon%252Ba%252BCarbamic%252BTemplate%252BStructure%26aulast%3DLodola%26aufirst%3DAlessio%26date%3D2011%26spage%3D1%26epage%3D26%26pub%3DElsevier%26atitle%3DComputational%252Bchemistry%252Bmethods%252Bin%252Bstructural%252Bbiology%26date%3D2011%26volume%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of reversible and irreversible EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>3</b>−<b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) H<sub>2</sub>SO<sub>4</sub>, formic acid, reflux; (ii) SOCl<sub>2</sub>, dioxane, reflux; (iii) 3-bromoaniline, <i>i</i>-PrOH, 60 °C; (iv) Fe, AcOH, EtOH/H<sub>2</sub>O, reflux. (v) Method A: dichloromethylene dimethyliminium chloride, NaHCO<sub>3</sub>, <b>17</b> (for <b>4</b>) or <b>18</b> (for <b>5</b>), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C. Method B: HBTU, DMF, <b>19</b>, room temp (for <b>6</b>). Method C: PCl<sub>5</sub>, <b>20</b> (for <b>7</b>) or <b>21</b> (for <b>8</b>) or <b>22</b> (for <b>9</b>) or <b>24</b> (for <b>11</b>), CH<sub>2</sub>Cl<sub>2</sub>, reflux. Method D: DCC, <b>23</b> (for <b>10</b>) or <b>25</b> (for <b>12</b>) or <b>26</b> (for <b>13</b>), DMF, 0 °C to room temp. Method E: <i>t</i>-ButOK, <b>27</b> (for <b>14</b>), DMF, microwave, 100 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>15</b> and <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) Method A: dichloromethylene dimethyliminium chloride, NaHCO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C. (ii) Method C: PCl<sub>5</sub>, CH<sub>2</sub>Cl<sub>2</sub>, reflux.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Warheads <b>17</b>−<b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) KOH, abs EtOH, 0 °C; (ii) 5% KHSO<sub>4</sub>, room temp; (iii) NaBH<sub>4</sub>, EtOH, 0 °C; (iv) MsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp; (v) anhydrous piperidine, KI, DMF, 0 °C to room temp.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Warheads <b>25</b>−<b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) SO<sub>2</sub>Cl<sub>2</sub>, ClCH<sub>2</sub>CH<sub>2</sub>Cl, room temp; (ii) 1 M TFA, reflux; (iii) BrCH<sub>2</sub>COOEt, Et<sub>3</sub>N, THF, room temp; (iv) HCl reflux; (v) CH<sub>2</sub>Cl<sub>2</sub>, reflux; (vi) NCCOOEt, <i>p</i>-xylene, reflux.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking of compound <b>6</b> within the EGFR kinase domain. Compound <b>6</b> (green carbons) undertakes several polar interactions (highlighted with orange lines) at the EGFR kinase active site (black carbons and white cartoons): (i) a direct hydrogen bond between the quinazoline N1 and the backbone NH of Met793; (ii) a water molecule mediated hydrogen bond between quinazoline N3 and the side chain of Thr790; (iii) a salt bridge between Asp800 and the piperidine nitrogen. The SH group of Cys797 is at 4.13 Å from the closest carbon atom of the epoxy warhead, ready for the nucleophilic attack.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Irreversible inhibitory action of compounds <b>4</b>−<b>9</b> on EGFR autophosphorylation. A431 cells were incubated with the investigated compound for 1 h and stimulated with EGF either immediately after or 8 h after removal of the compound from the medium. Western blot analysis was done using monoclonal antibodies directed to p-Tyr1068. <b>2</b> and <b>3</b> were used as irreversible and reversible reference compounds, respectively. Representative blots of three independent experiments are shown. Total EGFR is shown as loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effectiveness of irreversible EGFR inhibitor <b>6</b> in H1975 NSCLC cell line. (A) Antiproliferative effects of compound <b>6</b> (▲) in comparison with <b>1</b> (●) on H1975 cell line, harboring the resistance-associated mutation T790M. Cell proliferation was determined by MTT assay, as described in the <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a>. Results are reported as the mean ± SD of three independent experiments: (∗) <i>P</i> < 0.01 for each dose versus <b>1</b>; <i>n</i> = 3. (B) Comparison of compounds <b>6</b>, <b>1</b>, and <b>2</b> in their ability to suppress EGFR autophosphorylation (p-EGFR), erbB2 autophosphorylation (p-erbB2), and phosphorylation of downstream effectors AKT (p-Akt) and MAPK (p-p44/42) in H1975 cells. Total EGFR, erbB2, AKT, and MAPK are shown as loading controls.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/medium/jm-2009-01558p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of compound <b>6</b> on H1975 cell death. (A) H1975 cells were treated with the indicated concentration of compound <b>1</b> and compound <b>6</b> for 72 h and then analyzed with propidium iodide/Hoechst 33342 staining to assess cell death: (∗) <i>P</i> < 0.01 for each dose versus control; <i>n</i> = 3. (B) At the same time the cleavage of procaspase-3 was assessed on lysate proteins by Western blotting. The migration position of each full-length procaspase and those of its processing products are indicated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-5/jm901558p/production/images/large/jm-2009-01558p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901558p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 67 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwknowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwknowski&title=Untangling+the+ErbB+signalling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0ljIIhzYX6wIdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwknowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Teman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Naggar, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jelinek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issa, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, L.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2164</span><span class="NLM_x">–</span> <span class="NLM_lpage">2170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1200%2FJCO.2006.06.6605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=17538160" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=2164-2170&author=S.+Temanauthor=H.+Kawaguchiauthor=A.+K.+El-Naggarauthor=J.+Jelinekauthor=H.+Tangauthor=D.+D.+Liuauthor=W.+Langauthor=J.+P.+Issaauthor=J.+J.+Leeauthor=L.+Mao&title=Epidermal+growth+factor+receptor+copy+number+alterations+correlate+with+poor+clinical+outcome+in+patients+with+head+and+neck+squamous+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.6605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.6605%26sid%3Dliteratum%253Aachs%26aulast%3DTeman%26aufirst%3DS.%26aulast%3DKawaguchi%26aufirst%3DH.%26aulast%3DEl-Naggar%26aufirst%3DA.%2BK.%26aulast%3DJelinek%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DD.%2BD.%26aulast%3DLang%26aufirst%3DW.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DMao%26aufirst%3DL.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520copy%2520number%2520alterations%2520correlate%2520with%2520poor%2520clinical%2520outcome%2520in%2520patients%2520with%2520head%2520and%2520neck%2520squamous%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2007%26volume%3D25%26spage%3D2164%26epage%3D2170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Sarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28Iressa%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0ljIIhzYX6wIdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DSarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528Iressa%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacci, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Orio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neveu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theleman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P.</span><span> </span><span class="NLM_article-title">Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4838</span><span class="NLM_x">–</span> <span class="NLM_lpage">4848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=9354447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4838-4848&author=J.+D.+Moyerauthor=E.+G.+Barbacciauthor=K.+K.+Iwataauthor=L.+Arnoldauthor=B.+Bomanauthor=A.+Cunninghamauthor=C.+Di+Orioauthor=J.+Dotyauthor=M.+J.+Morinauthor=M.+P.+Moyerauthor=M.+Neveuauthor=V.+A.+Pollackauthor=L.+R.+Pustilnickauthor=M.+M.+Reynoldsauthor=D.+Sloanauthor=A.+Thelemanauthor=P.+Miller&title=Induction+of+apoptosis+and+cell+cycle+arrest+by+CP-358%2C774%2C+an+inhibitor+of+epidermal+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Moyer, James D.; Barbacci, Elsa G.; Iwata, Kenneth K.; Arnold, Lee; Boman, Bruce; Cunningham, Ann; Diorio, Catherine; Doty, Jonathan; Morin, Michael J.; Moyer, Mikel P.; Neveu, Mark; Pollack, Vincent A.; Pustilnik, Leslie R.; Reynolds, Margaret M.; Sloan, Don; Theleman, April; Miller, Penny</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4838-4848</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype.  CP-358774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.  This inhibition is selective for EGFR tyrosine kinase relative to other tyrosine kinases we have examd., both in assays of isolated kinases and whole cells.  At doses of 100 mg/kg, CP-358774 completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice.  CP-358774 inhibits the proliferation of DiFi human colon tumor cells at submicromolar concns. in cell culture and blocks cell cycle progression at the G1 phase.  This inhibitor produces a marked accumulation of retinoblastoma protein in its underphosphorylated form and accumulation of p27KIP1 in DiFi cells, which may contribute to the cell cycle block.  Inhibition of the EGFR also triggers apoptosis in these cells as detd. by formation of DNA fragments and other criteria.  These results indicate that CP-358774 has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation or survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghArQOnGlkbVg90H21EOLACvtfcHk0ljIIhzYX6wIdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D&md5=0a6e9697bf290d8e7c44cbe2a125e0b1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DBoman%26aufirst%3DB.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DDi%2BOrio%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DM.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DNeveu%26aufirst%3DM.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DPustilnick%26aufirst%3DL.%2BR.%26aulast%3DReynolds%26aufirst%3DM.%2BM.%26aulast%3DSloan%26aufirst%3DD.%26aulast%3DTheleman%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DInduction%2520of%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520by%2520CP-358%252C774%252C%2520an%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4838%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0ljw5SDKEHXVBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljw5SDKEHXVBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H. E.</span><span> </span><span class="NLM_article-title"><i>KRAS</i> mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e17&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=R.+T.+Heelanauthor=M.+G.+Krisauthor=H.+E.+Varmus&title=KRAS+mutations+and+primary+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DHeelan%26aufirst%3DR.%2BT.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26atitle%3DKRAS%2520mutations%2520and%2520primary%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2895</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1158%2F1078-0432.CCR-07-2248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A280%3ADC%252BD1czitVKjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2895-2899&author=J.+A.+Engelmanauthor=P.+A.+Janne&title=Mechanisms+of+acquired+resistance+to+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer</span></div><div class="casAuthors">Engelman Jeffrey A; Janne Pasi A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2895-9</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective therapies for non-small cell lung cancer patients whose tumors harbor somatic mutations in EGFR.  All patients, however, ultimately develop resistance to these agents.  Thus, there is a great need to understand how patients become resistant to develop effective therapies for these cancers.  Studies over the last few years have identified two different EGFR tyrosine kinase inhibitor resistance mechanisms, a secondary mutation in EGFR, EGFR 790M, and amplification of the MET oncogene.  These findings have led to clinical trials using newly designed targeted therapies that can overcome these resistance mechanisms and have shown promise in laboratory studies.  Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for non-small cell lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwZmvJ4PNLtd-cVm4E2RlLfW6udTcc2eYe9jMbfAwDsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czitVKjug%253D%253D&md5=a3ecf68a85a0ae413c451cf8f756a976</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-2248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-2248%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D2895%26epage%3D2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liNNABsopCXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Camp, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summy., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallick, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, L. M.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15671571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVegtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=397-405&author=E.+R.+Campauthor=J.+Summy.author=T.+V.+Bauerauthor=W.+Liuauthor=G.+E.+Gallickauthor=L.+M.+Ellis&title=Molecular+mechanisms+of+resistance+to+therapies+targeting+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor</span></div><div class="casAuthors">Camp, E. Ramsay; Summy, Justin; Bauer, Todd W.; Liu, Wenbiao; Gallick, Gary E.; Ellis, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">397-405</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Targeted therapies that inhibit the activity of tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR) have shown activity against solid malignancies when used as single agents or in combination with chemotherapy.  Although anti-EGFR therapies are active in some patients, eventually disease in nearly all patients will become refractory to therapy.  Therefore, a better understanding of the mechanisms of resistance to anti-EGFR therapies is crit. to further improve the efficacy of this class of agents.  Mechanisms that mediate resistance to anti-EGFR therapies include the presence of redundant tyrosine kinase receptors, increased angiogenesis, and the constitutive activation of downstream mediators.  Two recent landmark publications have also shown that specific mutations in the kinase domain of EGFR in some lung carcinomas are assocd. with markedly improved response rates to an EGFR tyrosine kinase inhibitor.  Mutations in the EGFR receptor seem to play a significant role in detg. the sensitivity of tumor cells to EGFR inhibitor therapy by altering the conformation and activity of the receptor.  As the field of mol. therapeutics continues to evolve, a comprehensive understanding of resistance mechanisms will ultimately lead to refinements in the authors' regimens to provide better care for patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEnp3gD31ohrVg90H21EOLACvtfcHk0liNNABsopCXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVegtbw%253D&md5=9fa2973e623dd8d50e8a28b3a12c00b1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCamp%26aufirst%3DE.%2BR.%26aulast%3DSummy.%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DT.%2BV.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGallick%26aufirst%3DG.%2BE.%26aulast%3DEllis%26aufirst%3DL.%2BM.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520to%2520therapies%2520targeting%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D397%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Engelman, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Acquired resistance to tyrosine kinase inhibitors during cancer therapy</span> <span class="citation_source-journal">Curr. Opin. Gene Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1016%2Fj.gde.2008.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18325754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=73-79&author=J.+F.+Engelmanauthor=J.+Settleman&title=Acquired+resistance+to+tyrosine+kinase+inhibitors+during+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to tyrosine kinase inhibitors during cancer therapy</span></div><div class="casAuthors">Engelman, Jeffrey A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-79</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Selective tyrosine kinase inhibitors have emerged as important therapeutic agents in the treatment of a variety of human malignancies.  Although several of these inhibitors have marked clin. activity, it is widely recognized that the overall value of these agents is substantially limited by the acquisition of drug resistance, which eventually arises in most, if not all treated patients.  Mechanisms of drug resistance are beginning to be elucidated through the mol. anal. of clin. specimens as well as through cell culture modeling.  By identifying resistance mechanisms, it should be possible to develop second-generation' inhibitors as well as rational drug combinations that can overcome or even prevent acquired resistance to kinase inhibitors, thereby enhancing clin. benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJCEQIe-JFI7Vg90H21EOLACvtfcHk0lg-BIYMXb8XHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVartbc%253D&md5=db27057c8cb1a4deceb779bae6d19398</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BF.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DAcquired%2520resistance%2520to%2520tyrosine%2520kinase%2520inhibitors%2520during%2520cancer%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Gene%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D73%26epage%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Mukherji, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spicer, J.</span><span> </span><span class="NLM_article-title">Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=293-301&author=D.+Mukherjiauthor=J.+Spicer&title=Second-generation+epidermal+growth+factor+tyrosine+kinase+inhibitors+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMukherji%26aufirst%3DD.%26aulast%3DSpicer%26aufirst%3DJ.%26atitle%3DSecond-generation%2520epidermal%2520growth%2520factor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D293%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wissnerauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0lhyKgPqGOgs_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Targeting cancer with small molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+cancer+with+small+molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lhyKgPqGOgs_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520cancer%2520with%2520small%2520molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lhyKgPqGOgs_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branningan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harria, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoli, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branninganauthor=P.+L.+Harriaauthor=D.+R.+Driscoliauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBranningan%26aufirst%3DB.%2BW.%26aulast%3DHarria%26aufirst%3DP.%2BL.%26aulast%3DDriscoli%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">11011</span><span class="NLM_x">–</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1073%2Fpnas.0504952102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=16046538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnvVWjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=V.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span></div><div class="casAuthors">Carter, Todd A.; Wodicka, Lisa M.; Shah, Neil P.; Velasco, Anne Marie; Fabian, Miles A.; Treiber, Daniel K.; Milanov, Zdravko V.; Atteridge, Corey E.; Biggs, William H., III; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Mehta, Shamal A.; Patel, Hitesh K.; Pao, William; Sawyers, Charles L.; Varmus, Harold; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11011-11016</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">To realize the full potential of targeted protein kinase inhibitors for the treatment of cancer, it is important to address the emergence of drug resistance in treated patients.  Mutant forms of BCR-ABL, KIT, and the EGF receptor (EGFR) have been found that confer resistance to the drugs imatinib, gefitinib, and erlotinib.  The mutations weaken or prevent drug binding, and interestingly, one of the most common sites of mutation in all three kinases is a highly conserved "gatekeeper" threonine residue near the kinase active site.  We have identified existing clin. compds. that bind and inhibit drug-resistant mutant variants of ABL, KIT, and EGFR.  We found that the Aurora kinase inhibitor VX-680 and the p38 inhibitor BIRB-796 inhibit the imatinib- and BMS-354825-resistant ABL(T315I) kinase.  The KIT/FLT3 inhibitor SU-11248 potently inhibits the imatinib-resistant KIT(V559D/T670I) kinase, consistent with the clin. efficacy of SU-11248 against imatinib-resistant gastrointestinal tumors, and the EGFR inhibitors EKB-569 and Cl-1033, but not GW-572016 and ZD-6474, potently inhibit the gefitinib- and erlotinib-resistant EGFR(L858R/T790M) kinase.  EKB-569 and Cl-1033 are already in clin. trials, and our results suggest that they should be considered for testing in the treatment of gefitinib/erlotinib-resistant non-small cell lung cancer.  The results highlight the strategy of screening existing clin. compds. against newly identified drug-resistant mutant variants to find compds. that may serve as starting points for the development of next-generation drugs, or that could be used directly to treat patients that have acquired resistance to first-generation targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdgFgcC03tybVg90H21EOLACvtfcHk0lgGS8I9rjWYAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnvVWjurg%253D&md5=448c95c51b0cf9b5035df4065cd8f62c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0504952102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0504952102%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DV.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentration of an irreversible EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">874</span><span class="NLM_x">–</span> <span class="NLM_lpage">879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1158%2F1535-7163.MCT-07-2387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18413800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=874-879&author=N.+Godin-Heymannauthor=L.+Ulkusauthor=B.+W.+Branniganauthor=U.+McDermottauthor=J.+Lambauthor=S.+Maheswaranauthor=J.+Settlemanauthor=D.+A.+Haber&title=The+T790M+%E2%80%9Cgatekeeper%E2%80%9D+mutation+in+EGFR+mediates+resistance+to+low+concentration+of+an+irreversible+EGFR+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor</span></div><div class="casAuthors">Godin-Heymann, Nadia; Ulkus, Lindsey; Brannigan, Brian W.; McDermott, Ultan; Lamb, Jennifer; Maheswaran, Shyamala; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-879</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine kinase inhibitors, gefitinib and erlotinib.  However, following clin. response, these patients typically relapse within a year of treatment.  In many cases, resistance is caused by an acquired secondary EGFR kinase domain mutation, T790M.  In vitro studies have shown that a new class of EGFR-irreversible inhibitors could overcome the resistance conferred by T790M.  Clin. trials are under way to examine the efficacy of one of these inhibitors, HKI-272, in patients with NSCLC who initially responded to gefitinib/erlotinib and subsequently relapsed.  To anticipate the possibility that patients who respond to irreversible inhibitors will develop secondary resistance to such inhibitors, as has been seen in other similar settings, we modeled acquired resistance to the dual EGFR/HER2-irreversible tyrosine kinase inhibitor HKI-272 in a NSCLC cell culture model.  We found that HKI-272-resistant clones fall into two biochem. groups based on the retention of EGFR phosphorylation in the presence of the drug.  Cells that retain phosphorylated EGFR have acquired the secondary mutation T790M.  Moreover, HKI-272 can overcome T790M resistance only at suprapharmacol. concns.  We further model mutations at EGFR C797 as a mechanism of resistance to irreversible EGFR inhibitors and show that although these mutants are resistant to the irreversible inhibitor, they retain erlotinib sensitivity.  Our findings suggest that HKI-272 treatment at maximally tolerated dosing may lead to the emergence of T790M-mediated resistance, whereas treatment with a more potent irreversible inhibitor could yield a resistance mutation at EGFR C797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra5FtRNHnlNLVg90H21EOLACvtfcHk0lgGS8I9rjWYAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1GmsLo%253D&md5=f71cd83bfabef2d7b2c5d8b6e5cfac6a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2387%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DThe%2520T790M%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutation%2520in%2520EGFR%2520mediates%2520resistance%2520to%2520low%2520concentration%2520of%2520an%2520irreversible%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D874%26epage%3D879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Slichenmyer, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">CI-1033, a pan-erbB tyrosine kinase inhibitor</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1016%2FS0093-7754%2801%2990285-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=11706399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=80-85&author=W.+J.+Slichenmyerauthor=W.+L.+Elliottauthor=D.+W.+Fry&title=CI-1033%2C+a+pan-erbB+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, a pan-erbB tyrosine kinase inhibitor</span></div><div class="casAuthors">Slichenmyer, William J.; Elliott, William L.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Overexpression of the erbB family of receptor tyrosine kinases has been implicated in a variety of tumors including breast, lung, prostate, and brain.  Most solid tumors express one or more of these receptors, which can often be related to tumor aggressiveness and poor patient prognosis.  CI-1033, a pan-erbB tyrosine kinase inhibitor, is a clin. promising agent that is active against all four members of the erbB receptor tyrosine kinase family.  In vitro studies of human cancer cell lines indicate that CI-1033 results in prompt, potent, and sustained inhibition of tyrosine kinase activity.  This inhibition is highly selective for erbBI (epidermal growth factor receptor), erbB2, erbB3, and erbB4 without inhibiting tyrosine kinase activity of receptors such as platelet-derived growth factor receptor, fibroblast growth factor receptor, and insulin receptor, even at high concns.  Treatment of athymic nude mice bearing xenografts of human A431 epidermoid carcinoma, H125 non-small cell lung carcinoma, and SF-767 glioblastoma results in highly significant suppression of tumor growth.  The major toxicity in animals is diarrhea, which is more severe at higher doses.  In animal models, all side effects are reversible on cessation of treatment.  Thus, CI-1033, which is currently undergoing phase I clin. trials, holds significant potential for use in a broad range of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWblWCZGMLQLVg90H21EOLACvtfcHk0lgGS8I9rjWYAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Wgu7c%253D&md5=cc0507480a4182c3e52314750347b4c2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0093-7754%2801%2990285-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0093-7754%252801%252990285-4%26sid%3Dliteratum%253Aachs%26aulast%3DSlichenmyer%26aufirst%3DW.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DCI-1033%252C%2520a%2520pan-erbB%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DSemin.%2520Oncol.%26date%3D2001%26volume%3D28%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OverBeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the Her-2 tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=D.+Nilakantanauthor=E.+OverBeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+Her-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0lhIF8wZEfFDaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DD.%26aulast%3DOverBeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520Her-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Gill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span> </span><span class="NLM_article-title">A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1408</span><span class="NLM_x">–</span> <span class="NLM_lpage">1422</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.2174%2F156802607781696819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=17692029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1408-1422&author=A.+L.+Gillauthor=M.+Verdonkauthor=R.+G.+Boyleauthor=R.+Taylor&title=A+comparison+of+physicochemical+property+profiles+of+marketed+oral+drugs+and+orally+bioavailable+anti-cancer+protein+kinase+inhibitors+in+clinical+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development</span></div><div class="casAuthors">Gill, Adrian L.; Verdonk, Marcel; Boyle, Robert G.; Taylor, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1408-1422</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This manuscript describes a comparison of the physicochem. properties of marketed oral drugs with those of 45 structurally confirmed orally bioavailable anti-cancer protein kinase inhibitors currently in different phases of clin. development.  It is evident from the data presented that these kinase inhibitors are on av. larger (over 110Da), more lipophilic (over 1.5 log units) and more complex (approx. two more rotatable bonds) than those of marketed oral drugs.  In contrast, hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA) counts are not significantly different.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8vw6yZzFirVg90H21EOLACvtfcHk0lhIF8wZEfFDaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbvM&md5=03b0a1943f8d1a08ed436da75e9a296f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2174%2F156802607781696819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607781696819%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DVerdonk%26aufirst%3DM.%26aulast%3DBoyle%26aufirst%3DR.%2BG.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DA%2520comparison%2520of%2520physicochemical%2520property%2520profiles%2520of%2520marketed%2520oral%2520drugs%2520and%2520orally%2520bioavailable%2520anti-cancer%2520protein%2520kinase%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1408%26epage%3D1422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBlanc, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehn, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2734</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0005555" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2719-2734&author=H.-R.+Tsouauthor=N.+Mamuyaauthor=B.+D.+Johnsonauthor=M.+F.+Reichauthor=B.+C.+Gruberauthor=F.+Yeauthor=R.+Nilakantanauthor=R.+Shenauthor=C.+Discafaniauthor=R.+DeBlancauthor=R.+Davisauthor=F.+E.+Koehnauthor=L.+M.+Greenbergerauthor=Y.-F.+Wangauthor=A.+Wissner&title=6-Substituted-4-%283-bromophenylamino%29quinazolines+as+putative+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+human+epidermal+growth+factor+receptor+%28HER-2%29+tyrosine+kinases+with+enhanced+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm0005555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0005555%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDeBlanc%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DKoehn%26aufirst%3DF.%2BE.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3D6-Substituted-4-%25283-bromophenylamino%2529quinazolines%2520as%2520putative%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528HER-2%2529%2520tyrosine%2520kinases%2520with%2520enhanced%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2719%26epage%3D2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000372i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=429-440&author=J.+B.+Smaillauthor=H.+D.+H.+Showalterauthor=H.+Zhouauthor=A.+J.+Bridgesauthor=D.+J.+McNamaraauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+18.+6-Substituted+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+soluble%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm000372i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000372i%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252018.%25206-Substituted%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520soluble%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Mishani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abourbeh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dissoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levitzki, A.</span><span> </span><span class="NLM_article-title">High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5337</span><span class="NLM_x">–</span> <span class="NLM_lpage">5348</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0580196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5337-5348&author=E.+Mishaniauthor=G.+Abourbehauthor=O.+Jacobsonauthor=S.+Dissokiauthor=R.+B.+Danielauthor=G.+Rozenauthor=M.+Shaulauthor=A.+Levitzki&title=High-affinity+epidermal+growth+factor+receptor+%28EGFR%29+irreversible+inhibitors+with+diminished+chemical+reactivities+as+positron+emission+tomography+%28PET%29-imaging+agent+candidates+of+EGFR+overexpressing+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm0580196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0580196%26sid%3Dliteratum%253Aachs%26aulast%3DMishani%26aufirst%3DE.%26aulast%3DAbourbeh%26aufirst%3DG.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DDissoki%26aufirst%3DS.%26aulast%3DDaniel%26aufirst%3DR.%2BB.%26aulast%3DRozen%26aufirst%3DG.%26aulast%3DShaul%26aufirst%3DM.%26aulast%3DLevitzki%26aufirst%3DA.%26atitle%3DHigh-affinity%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520irreversible%2520inhibitors%2520with%2520diminished%2520chemical%2520reactivities%2520as%2520positron%2520emission%2520tomography%2520%2528PET%2529-imaging%2520agent%2520candidates%2520of%2520EGFR%2520overexpressing%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5337%26epage%3D5348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Antonello, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarozzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morroni, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hrelia, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6642</span><span class="NLM_x">–</span> <span class="NLM_lpage">6645</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608762" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6642-6645&author=A.+Antonelloauthor=A.+Tarozziauthor=F.+Morroniauthor=A.+Cavalliauthor=M.+Rosiniauthor=P.+Hreliaauthor=M.+L.+Bolognesiauthor=C.+Melchiorre&title=Multitarget-directed+drug+design+strategy%3A+a+novel+molecule+designed+to+block+epidermal+growth+factor+receptor+%28EGFR%29+and+to+exert+proapoptotic+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm0608762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608762%26sid%3Dliteratum%253Aachs%26aulast%3DAntonello%26aufirst%3DA.%26aulast%3DTarozzi%26aufirst%3DA.%26aulast%3DMorroni%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DHrelia%26aufirst%3DP.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMultitarget-directed%2520drug%2520design%2520strategy%253A%2520a%2520novel%2520molecule%2520designed%2520to%2520block%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520to%2520exert%2520proapoptotic%2520effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6642%26epage%3D6645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Wissner, A.; Tsou, H.-R.; Jonson, B. D.; Hamann, P. R.; Zhang, N.</span><span> </span><span class="NLM_article-title">Substituted Quinazoline Derivatives and Their Use as Tyrosine Kinase Inhibitors</span>. PCT Int. Appl. WO99/09016,<span class="NLM_x"> </span><span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=A.+Wissner&author=H.-R.+Tsou&author=B.+D.+Jonson&author=P.+R.+Hamann&author=N.+Zhang&title=Substituted+Quinazoline+Derivatives+and+Their+Use+as+Tyrosine+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DSubstituted%2520Quinazoline%2520Derivatives%2520and%2520Their%2520Use%2520as%2520Tyrosine%2520Kinase%2520Inhibitors%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Ban, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nabeyama, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuzawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, H.</span><span> </span><span class="NLM_article-title">Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4415</span><span class="NLM_x">–</span> <span class="NLM_lpage">4427</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1039%2Fb909504g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=19830290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=4415-4427&author=S.+H.+Banauthor=T.+Usuiauthor=W.+Nabeyamaauthor=H.+Moritaauthor=K.+Fukuzawaauthor=H.+Nakamura&title=Discovery+of+boron-conjugated+4-anilinoquinazoline+as+a+prolonged+inhibitor+of+EGFR+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase</span></div><div class="casAuthors">Ban, Hyun Seung; Usui, Taikou; Nabeyama, Wataru; Morita, Hidetoshi; Fukuzawa, Kaori; Nakamura, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4415-4427</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Boron-conjugated 4-anilinoquinazolines were designed and synthesized as inhibitors of EGFR tyrosine kinase with possible covalent bond interactions between the boron atom and the nucleophilic groups of the EGFR kinase domain.  Among the compds. synthesized, compds. I and II (X = CH:CH, 1,4-phenylene) reduced the EGF-mediated phosphorylation of EGFR tyrosine kinase and its downstream kinases including ERK and Akt in A431 cells.  The cell growth was inhibited by these compds. through arrest of G1 cell cycle, which induced apoptosis.  A time-dependent in vitro preincubation assay demonstrated the irreversible inhibition of compd. II [X = 1,4-phenylene; (III)] against EGFR tyrosine kinase.  Quantum mech. docking simulation revealed that the boronic acid moiety of compd. III formed a covalent B-O bond with Asp800 in addn. to hydrogen bonds with Asp800 and Cys797, which may cause the prolonged inhibition of compd. III toward EGFR tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod_ARjWKN7LLVg90H21EOLACvtfcHk0ljGyLX6DR6ufg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Gksb%252FN&md5=b61ee61865bdff8e4706485b1f030554</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fb909504g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb909504g%26sid%3Dliteratum%253Aachs%26aulast%3DBan%26aufirst%3DS.%2BH.%26aulast%3DUsui%26aufirst%3DT.%26aulast%3DNabeyama%26aufirst%3DW.%26aulast%3DMorita%26aufirst%3DH.%26aulast%3DFukuzawa%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520boron-conjugated%25204-anilinoquinazoline%2520as%2520a%2520prolonged%2520inhibitor%2520of%2520EGFR%2520tyrosine%2520kinase%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2009%26volume%3D7%26spage%3D4415%26epage%3D4427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0lhiKcmjRlUFJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Powers, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asgian, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dogan Ekici, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis James, K.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of serine, cysteine, and threonine proteases</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">4639</span><span class="NLM_x">–</span> <span class="NLM_lpage">4750</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr010182v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD38XosFSnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2002&pages=4639-4750&author=J.+C.+Powersauthor=J.+L.+Asgianauthor=O.+Dogan+Ekiciauthor=K.+Ellis+James&title=Irreversible+inhibitors+of+serine%2C+cysteine%2C+and+threonine+proteases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of serine, cysteine, and threonine proteases</span></div><div class="casAuthors">Powers, James C.; Asgian, Juliana L.; Ekici, Oezlem Dogan; James, Karen Ellis</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4639-4750</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Topics discussed include alkylating, acylating, phosphonylating, and sulfonylating agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorivaxGhmhirVg90H21EOLACvtfcHk0lhiKcmjRlUFJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XosFSnsr4%253D&md5=eb21ff0297b87537a7d459c92f13c75d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fcr010182v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr010182v%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DJ.%2BC.%26aulast%3DAsgian%26aufirst%3DJ.%2BL.%26aulast%3DDogan%2BEkici%26aufirst%3DO.%26aulast%3DEllis%2BJames%26aufirst%3DK.%26atitle%3DIrreversible%2520inhibitors%2520of%2520serine%252C%2520cysteine%252C%2520and%2520threonine%2520proteases%26jtitle%3DChem.%2520Rev.%26date%3D2002%26volume%3D102%26spage%3D4639%26epage%3D4750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Leung-Toung, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karimian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spino, M.</span><span> </span><span class="NLM_article-title">Thiol proteases: inhibitors and potential therapeutic targets</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">581</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.2174%2F092986706776055733" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=16515521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xit1Klu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=547-581&author=R.+Leung-Toungauthor=Y.+Zhaoauthor=W.+Liauthor=T.+F.+Tamauthor=K.+Karimianauthor=M.+Spino&title=Thiol+proteases%3A+inhibitors+and+potential+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Thiol proteases: inhibitors and potential therapeutic targets</span></div><div class="casAuthors">Leung-Toung, Regis; Zhao, Yanqing; Li, Wanren; Tam, Tim F.; Karimian, Khashayar; Spino, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">547-581</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  A better understanding of the biol. roles and the pathol. consequences of thiol-dependent enzymes has emerged in recent years, and hence considerable progress has been made in identifying and delineating cysteine proteases that can be considered promising drug targets from those involved in housekeeping functions.  Cysteine proteases have been implicated in a wide variety of disease processes ranging from cardiovascular, inflammatory, viral and immunol. disorders to cancer.  The first milestone in drug development of cysteine protease inhibitors has probably been reached, as IDN-6556 (a broad spectrum caspase inhibitor) has recently received Orphan Drug label by the U.S. Food and Drug Administration for use in the treatment of the patients undergoing liver transplantation and other solid organ transplantation.  IDN-6556, which blocks apoptosis, is in Phase II human clin. trial in patients undergoing liver transplantation.  In addn., more than ten cysteine protease inhibitors are presently at various phases of clin. development/trials for diverse diseases.  This review emphasizes on the new development from the literature reports since the year 2000 in the exploration of potential cysteine proteases as prospective drug targets, and the investigation of promising inhibitors that can potentially be developed for the treatment of human diseases.  Transglutaminases, another class of thiol-dependent enzymes, are not discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYKHoAclVmbVg90H21EOLACvtfcHk0lhiKcmjRlUFJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xit1Klu7Y%253D&md5=ef25f861761e9d51092da05f9334239c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F092986706776055733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706776055733%26sid%3Dliteratum%253Aachs%26aulast%3DLeung-Toung%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DTam%26aufirst%3DT.%2BF.%26aulast%3DKarimian%26aufirst%3DK.%26aulast%3DSpino%26aufirst%3DM.%26atitle%3DThiol%2520proteases%253A%2520inhibitors%2520and%2520potential%2520therapeutic%2520targets%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26spage%3D547%26epage%3D581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Overall, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleifeld, O.</span><span> </span><span class="NLM_article-title">Towards third generation matrix metalloproteinase inhibitors for cancer theraphy</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1038%2Fsj.bjc.6603043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=16538215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFGqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=941-946&author=C.+M.+Overallauthor=O.+Kleifeld&title=Towards+third+generation+matrix+metalloproteinase+inhibitors+for+cancer+theraphy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Towards third generation matrix metalloproteinase inhibitors for cancer therapy</span></div><div class="casAuthors">Overall, C. M.; Kleifeld, O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">941-946</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The failure of matrix metalloproteinase (MMP) inhibitor drug clin. trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition.  We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are crit. in host protection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWaFApPMIKRLVg90H21EOLACvtfcHk0lhiKcmjRlUFJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFGqt7g%253D&md5=5e672a6e9495ec2e283856edc6e61a60</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603043%26sid%3Dliteratum%253Aachs%26aulast%3DOverall%26aufirst%3DC.%2BM.%26aulast%3DKleifeld%26aufirst%3DO.%26atitle%3DTowards%2520third%2520generation%2520matrix%2520metalloproteinase%2520inhibitors%2520for%2520cancer%2520theraphy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D94%26spage%3D941%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Arnold, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosinski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estebanez-Perpina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletterick, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, R. K.</span><span> </span><span class="NLM_article-title">Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure−reactivity relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">5269</span><span class="NLM_x">–</span> <span class="NLM_lpage">5280</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070556y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5269-5280&author=L.+A.+Arnoldauthor=A.+Kosinskiauthor=E.+Estebanez-Perpinaauthor=R.+J.+Fletterickauthor=R.+K.+Guy&title=Inhibitors+of+the+interaction+of+a+thyroid+hormone+receptor+and+coactivators%3A+preliminary+structure%E2%88%92reactivity+relationships"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm070556y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070556y%26sid%3Dliteratum%253Aachs%26aulast%3DArnold%26aufirst%3DL.%2BA.%26aulast%3DKosinski%26aufirst%3DA.%26aulast%3DEstebanez-Perpina%26aufirst%3DE.%26aulast%3DFletterick%26aufirst%3DR.%2BJ.%26aulast%3DGuy%26aufirst%3DR.%2BK.%26atitle%3DInhibitors%2520of%2520the%2520interaction%2520of%2520a%2520thyroid%2520hormone%2520receptor%2520and%2520coactivators%253A%2520preliminary%2520structure%25E2%2588%2592reactivity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5269%26epage%3D5280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duranti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanchini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clapper, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piomelli, D.</span><span> </span><span class="NLM_article-title">Synthesis and structure−reactivity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">3484</span><span class="NLM_x">–</span> <span class="NLM_lpage">3498</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3484-3498&author=M.+Morauthor=A.+Lodolaauthor=S.+Rivaraauthor=F.+Vacondioauthor=A.+Durantiauthor=A.+Tontiniauthor=S.+Sanchiniauthor=G.+Piersantiauthor=J.+R.+Clapperauthor=A.+R.+Kingauthor=G.+Tarziaauthor=D.+Piomelli&title=Synthesis+and+structure%E2%88%92reactivity+relationship+of+fatty+acid+amide+hydrolase+inhibitors%3A+modulation+at+the+N-portion+of+biphenyl-3-yl+alkylcarbamates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DDuranti%26aufirst%3DA.%26aulast%3DTontini%26aufirst%3DA.%26aulast%3DSanchini%26aufirst%3DS.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DClapper%26aufirst%3DJ.%2BR.%26aulast%3DKing%26aufirst%3DA.%2BR.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DPiomelli%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592reactivity%2520relationship%2520of%2520fatty%2520acid%2520amide%2520hydrolase%2520inhibitors%253A%2520modulation%2520at%2520the%2520N-portion%2520of%2520biphenyl-3-yl%2520alkylcarbamates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3484%26epage%3D3498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slintak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliot, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patmore, S. J.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[<i>d</i>]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">–</span> <span class="NLM_lpage">1815</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9806603" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1803-1815&author=J.+B.+Smaillauthor=B.+D.+Palmerauthor=G.+W.+Rewcastleauthor=V.+A.+Dennyauthor=D.+J.+McNamaraauthor=E.+M.+Dobrusinauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=H.+D.+H.+Showalterauthor=R.+T.+Wintersauthor=V.+R.+Leopoldauthor=D.+V.+Fryauthor=J.+M.+Nelsonauthor=V.+Slintakauthor=V.+L.+Elliotauthor=B.+J.+Robertsauthor=P.+W.+Vincentauthor=S.+J.+Patmore&title=Tyrosine+kinase+inhibitors.+15.+4-%28Phenylamino%29quinazoline+and+4-%28phenylamino%29pyrido%5Bd%5Dpyrimidine+acrylamides+as+irreversible+inhibitors+of+the+ATP+binding+site+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm9806603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9806603%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DV.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DLeopold%26aufirst%3DV.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BV.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSlintak%26aufirst%3DV.%26aulast%3DElliot%26aufirst%3DV.%2BL.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DPatmore%26aufirst%3DS.%2BJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252015.%25204-%2528Phenylamino%2529quinazoline%2520and%25204-%2528phenylamino%2529pyrido%255Bd%255Dpyrimidine%2520acrylamides%2520as%2520irreversible%2520inhibitors%2520of%2520the%2520ATP%2520binding%2520site%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1803%26epage%3D1815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-[(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3482</span><span class="NLM_x">–</span> <span class="NLM_lpage">3487</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00018a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3482-3487&author=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=D.+R.+Codyauthor=A.+McMichaelauthor=D.+W.+Fry&title=Tyrosine+kinase+inhibitors%3A+synthesis+and+structure-activity+relationships+for+4-%5B%28phenylmethyl%29amino%5D-+and+4-%5B%28phenylamino%29quinazolines+as+potent+adenosine+5%E2%80%B2-triphosphate+binding+site+inhibitors+of+the+tyrosine+kinase+domain+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm00018a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00018a008%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520synthesis%2520and%2520structure-activity%2520relationships%2520for%25204-%255B%2528phenylmethyl%2529amino%255D-%2520and%25204-%255B%2528phenylamino%2529quinazolines%2520as%2520potent%2520adenosine%25205%25E2%2580%25B2-triphosphate%2520binding%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3482%26epage%3D3487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Roth, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, J. J.</span><span> </span><span class="NLM_article-title">A new synthesis of aryl substituted quinazolin-4(1<i>H</i>)-ones</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2051</span><span class="NLM_x">–</span> <span class="NLM_lpage">2053</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1996&pages=2051-2053&author=G.+A.+Rothauthor=J.+J.+Tai&title=A+new+synthesis+of+aryl+substituted+quinazolin-4%281H%29-ones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BA.%26aulast%3DTai%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520new%2520synthesis%2520of%2520aryl%2520substituted%2520quinazolin-4%25281H%2529-ones%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1996%26volume%3D33%26spage%3D2051%26epage%3D2053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Saito, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morowake, T.</span><span> </span><span class="NLM_article-title">Diethyl (2<i>S</i>,3<i>R</i>)-2-(<i>N</i>-<i>tert</i>-butoxycarbonyl)amino-3-hydroxysuccinate</span> <span class="citation_source-journal">Org. Synth.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1995&pages=184-200&author=S.+Saitoauthor=K.+Komadaauthor=T.+Morowake&title=Diethyl+%282S%2C3R%29-2-%28N-tert-butoxycarbonyl%29amino-3-hydroxysuccinate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DS.%26aulast%3DKomada%26aufirst%3DK.%26aulast%3DMorowake%26aufirst%3DT.%26atitle%3DDiethyl%2520%25282S%252C3R%2529-2-%2528N-tert-butoxycarbonyl%2529amino-3-hydroxysuccinate%26jtitle%3DOrg.%2520Synth.%26date%3D1995%26volume%3D73%26spage%3D184%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Korn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph-Böhner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moroder, L.</span><span> </span><span class="NLM_article-title">A convenient synthesis of optically pure (2<i>R</i>,3<i>R</i>)-2,3-epoxysuccinyl-dipeptides</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">8381</span><span class="NLM_x">–</span> <span class="NLM_lpage">8392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=8381-8392&author=A.+Kornauthor=S.+Rudolph-B%C3%B6hnerauthor=L.+Moroder&title=A+convenient+synthesis+of+optically+pure+%282R%2C3R%29-2%2C3-epoxysuccinyl-dipeptides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKorn%26aufirst%3DA.%26aulast%3DRudolph-B%25C3%25B6hner%26aufirst%3DS.%26aulast%3DMoroder%26aufirst%3DL.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520optically%2520pure%2520%25282R%252C3R%2529-2%252C3-epoxysuccinyl-dipeptides%26jtitle%3DTetrahedron%26date%3D1994%26volume%3D50%26spage%3D8381%26epage%3D8392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukaiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotoh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakeya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osada, H.</span><span> </span><span class="NLM_article-title">First asymmetric total synthesis of synerazol, an antifungal antibiotic, and determination of its absolute stereochemistry</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">5643</span><span class="NLM_x">–</span> <span class="NLM_lpage">5654</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo050664x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=5643-5654&author=Y.+Hayashiauthor=M.+Shojiauthor=T.+Mukaiyamaauthor=H.+Gotohauthor=S.+Yamaguchiauthor=M.+Nakataauthor=H.+Kakeyaauthor=H.+Osada&title=First+asymmetric+total+synthesis+of+synerazol%2C+an+antifungal+antibiotic%2C+and+determination+of+its+absolute+stereochemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjo050664x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo050664x%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DShoji%26aufirst%3DM.%26aulast%3DMukaiyama%26aufirst%3DT.%26aulast%3DGotoh%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DS.%26aulast%3DNakata%26aufirst%3DM.%26aulast%3DKakeya%26aufirst%3DH.%26aulast%3DOsada%26aufirst%3DH.%26atitle%3DFirst%2520asymmetric%2520total%2520synthesis%2520of%2520synerazol%252C%2520an%2520antifungal%2520antibiotic%252C%2520and%2520determination%2520of%2520its%2520absolute%2520stereochemistry%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D5643%26epage%3D5654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Tamai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sota, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanaoka, Y.</span><span> </span><span class="NLM_article-title">Efficient synthetic method for ethyl (+)-(2<i>S</i>,3<i>S</i>)-3-[(<i>S</i>)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-2-oxiranecarboxylate (EST), a new inhibitor of cysteine proteinase</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">–</span> <span class="NLM_lpage">1104</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1987&pages=1098-1104&author=M.+Tamaiauthor=C.+Yokooauthor=M.+Murataauthor=K.+Ogumaauthor=K.+Sotaauthor=E.+Satoauthor=Y.+Kanaoka&title=Efficient+synthetic+method+for+ethyl+%28%2B%29-%282S%2C3S%29-3-%5B%28S%29-3-methyl-1-%283-methylbutylcarbamoyl%29butylcarbamoyl%5D-2-oxiranecarboxylate+%28EST%29%2C+a+new+inhibitor+of+cysteine+proteinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamai%26aufirst%3DM.%26aulast%3DYokoo%26aufirst%3DC.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DOguma%26aufirst%3DK.%26aulast%3DSota%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DE.%26aulast%3DKanaoka%26aufirst%3DY.%26atitle%3DEfficient%2520synthetic%2520method%2520for%2520ethyl%2520%2528%252B%2529-%25282S%252C3S%2529-3-%255B%2528S%2529-3-methyl-1-%25283-methylbutylcarbamoyl%2529butylcarbamoyl%255D-2-oxiranecarboxylate%2520%2528EST%2529%252C%2520a%2520new%2520inhibitor%2520of%2520cysteine%2520proteinase%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1987%26volume%3D35%26spage%3D1098%26epage%3D1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Clerici, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelmi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pocar, D.</span><span> </span><span class="NLM_article-title">Isothiazoles. Part 14: 3-Aminosubstituted isothiazole dioxides and their mono- and dihalogeno derivatives</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">9399</span><span class="NLM_x">–</span> <span class="NLM_lpage">9408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2003&pages=9399-9408&author=F.+Clericiauthor=A.+Continiauthor=M.+L.+Gelmiauthor=D.+Pocar&title=Isothiazoles.+Part+14%3A+3-Aminosubstituted+isothiazole+dioxides+and+their+mono-+and+dihalogeno+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClerici%26aufirst%3DF.%26aulast%3DContini%26aufirst%3DA.%26aulast%3DGelmi%26aufirst%3DM.%2BL.%26aulast%3DPocar%26aufirst%3DD.%26atitle%3DIsothiazoles.%2520Part%252014%253A%25203-Aminosubstituted%2520isothiazole%2520dioxides%2520and%2520their%2520mono-%2520and%2520dihalogeno%2520derivatives%26jtitle%3DTetrahedron%26date%3D2003%26volume%3D59%26spage%3D9399%26epage%3D9408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Lewis, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hausman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szamborski, E. C.</span><span> </span><span class="NLM_article-title">4-Isothiazolin-3-ones. A general synthesis from 3,3′-dithiodipropionamides</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1971&pages=571-580&author=S.+N.+Lewisauthor=G.+A.+Millerauthor=M.+Hausmanauthor=E.+C.+Szamborski&title=4-Isothiazolin-3-ones.+A+general+synthesis+from+3%2C3%E2%80%B2-dithiodipropionamides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DS.%2BN.%26aulast%3DMiller%26aufirst%3DG.%2BA.%26aulast%3DHausman%26aufirst%3DM.%26aulast%3DSzamborski%26aufirst%3DE.%2BC.%26atitle%3D4-Isothiazolin-3-ones.%2520A%2520general%2520synthesis%2520from%25203%252C3%25E2%2580%25B2-dithiodipropionamides%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1971%26volume%3D8%26spage%3D571%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catellani, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plazzi, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barocelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiavarini, M.</span><span> </span><span class="NLM_article-title">4-(3-Oxo-1,2-benzisothiazolin-2-yl)alkanoic, -phenylalkanoic, and -phenoxyalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic properties</span> <span class="citation_source-journal">Farmaco</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=2604834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK3cXhvFWgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1989&pages=795-807&author=F.+Bordiauthor=P.+L.+Catellaniauthor=G.+Moriniauthor=P.+V.+Plazziauthor=C.+Silvaauthor=E.+Barocelliauthor=M.+Chiavarini&title=4-%283-Oxo-1%2C2-benzisothiazolin-2-yl%29alkanoic%2C+-phenylalkanoic%2C+and+-phenoxyalkanoic+acids%3A+synthesis+and+anti-inflammatory%2C+analgesic+and+antipyretic+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">4-(3-Oxo-1,2-benzisothiazolin-2-yl)alkanoic, -phenylalkanoic, and -phenoxyalkanoic acids: synthesis and anti-inflammatory, analgesic and antipyretic properties</span></div><div class="casAuthors">Bordi, Fabrizio; Catellani, Pier Luigi; Morini, Giovanni; Plazzi, Pier Vincenzo; Silva, Claudia; Barocelli, Elisabetta; Chiavarini, Milena</div><div class="citationInfo"><span class="NLM_cas:title">Farmaco</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">795-807</span>CODEN:
                <span class="NLM_cas:coden">FRMCE8</span>;
        ISSN:<span class="NLM_cas:issn">0014-827X</span>.
    </div><div class="casAbstract">A group of title derivs. (I, X = alkylene, phenylene, and etc.; n = 0 or 2) were prepd. by cyclization of 2-chlorocarbonylphenylsulfenylchloride with aliph. amino acids and arom. amino acid esters.  The products were hydrolyzed and amidated or oxidized and hydrolyzed.  The 41 final products and intermediates were tested for analgesic, anti-inflammatory, and antipyretic effects in rats and mice in comparison with the effects of ibuprofen, paracetamol, phenylbutazone, and 1,2-benzisothiazolin-3-one.  The compds. showed rather complex pharmacol. properties.  Their structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohab-MxWE6drVg90H21EOLACvtfcHk0lj6CCmNSpGb5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhvFWgtbk%253D&md5=a4206af9903e3b9f2e4898a57a9bd31d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DCatellani%26aufirst%3DP.%2BL.%26aulast%3DMorini%26aufirst%3DG.%26aulast%3DPlazzi%26aufirst%3DP.%2BV.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DChiavarini%26aufirst%3DM.%26atitle%3D4-%25283-Oxo-1%252C2-benzisothiazolin-2-yl%2529alkanoic%252C%2520-phenylalkanoic%252C%2520and%2520-phenoxyalkanoic%2520acids%253A%2520synthesis%2520and%2520anti-inflammatory%252C%2520analgesic%2520and%2520antipyretic%2520properties%26jtitle%3DFarmaco%26date%3D1989%26volume%3D44%26spage%3D795%26epage%3D807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Buck, W.</span><span> </span><span class="NLM_article-title">Herbicidal[1,2,4]thiadiazoles</span>. U.S. Patent 5,583,092,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=W.+Buck&title=Herbicidal%5B1%2C2%2C4%5Dthiadiazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBuck%26aufirst%3DW.%26atitle%3DHerbicidal%255B1%252C2%252C4%255Dthiadiazoles%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Blair, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Q.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Structure guided development of affinity probes for tyrosine kinases using chemical genetics</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1038%2Fnchembio866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=17334377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=229-238&author=J.+A.+Blairauthor=D.+Rauhauthor=C.+Kungauthor=C.-H.+Yunauthor=Q.-W.+Fanauthor=H.+Rodeauthor=C.+Zhangauthor=M.+J.+Eckauthor=W.+A.+Weissauthor=K.+M.+Shokat&title=Structure+guided+development+of+affinity+probes+for+tyrosine+kinases+using+chemical+genetics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided development of affinity probes for tyrosine kinases using chemical genetics</span></div><div class="casAuthors">Blair, Jimmy A.; Rauh, Daniel; Kung, Charles; Yun, Cai-Hong; Fan, Qi-Wen; Rode, Haridas; Zhang, Chao; Eck, Michael J.; Weiss, William A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-238</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-mol. inhibitors.  The authors report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue.  Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Cocrystal structures of two irreversible quinazoline inhibitors (I, II) bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src).  Based on these structures, the authors developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe (III) to report the fraction of kinase necessary for cellular signaling, and the authors used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG0KmYAm-skrVg90H21EOLACvtfcHk0ljDcHpTxB98xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtFKnsr0%253D&md5=ce4d24a8d65d7080645bf382cd65dbca</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnchembio866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio866%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DJ.%2BA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DFan%26aufirst%3DQ.-W.%26aulast%3DRode%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DStructure%2520guided%2520development%2520of%2520affinity%2520probes%2520for%2520tyrosine%2520kinases%2520using%2520chemical%2520genetics%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2007%26volume%3D3%26spage%3D229%26epage%3D238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Å resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0ljDcHpTxB98xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Domarkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudouit, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiyu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banerjee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahimi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jean-Claude, B. J.</span><span> </span><span class="NLM_article-title">The Combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3544</span><span class="NLM_x">–</span> <span class="NLM_lpage">3552</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0600390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD28XkslKht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3544-3552&author=J.+Domarkasauthor=F.+Dudouitauthor=C.+Williamsauthor=Q.+Qiyuauthor=R.+Banerjeeauthor=F.+Brahimiauthor=B.+J.+Jean-Claude&title=The+Combi-targeting+concept%3A+synthesis+of+stable+nitrosoureas+designed+to+inhibit+the+epidermal+growth+factor+receptor+%28EGFR%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Combi-Targeting Concept: Synthesis of Stable Nitrosoureas Designed to Inhibit the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Domarkas, Juozas; Dudouit, Fabienne; Williams, Christopher; Qiu, Qiyu; Banerjee, Ranjita; Brahimi, Fouad; Bertrand, Jacques Jean-Claude</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3544-3552</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">According to the "combi-targeting" concept, the EGFR tyrosine kinase (TK) inhibitory potency of compds. termed "combi-mols." is crit. for selective growth inhibition of tumor cells with disordered expression of EGFR or its closest family member erbB2.  Here a report is presented on the optimization of the EGFR TK inhibitory potency of the combi-mols. of the (nitroso)urea class by comparison with their aminoquinazoline and (ureido)quinazoline precursors.  This led to the discovery of a new structural parameter that influences their EGFR TK inhibitory potency, i.e., the torsion angle between the plane of the quinazoline ring and the ureido or the (nitroso)ureido moiety of the synthesized drugs.  Chloro and bromo compds. with small angles (0.5-3°) were generally stronger EGFR TK inhibitors than those with large angles (18-21°).  This was further corroborated by ligand-receptor van der Waals interaction calcns. that showed significant binding hindrance imposed by large torsion angles in the narrow ATP cleft of EGFR.  Selective antiproliferative studies in a pair of mouse fibroblast NIH3T3 cells, one of which NIH3T3/neu being transfected with the erbB2 oncogene, showed that IC50 values for inhibition of EGFR TK could be good predictors of their selective potency against the serum-stimulated growth of the erbB2-transfected cell line (Pearson r = 0.8).  On the basis of stability (t1/2), EGFR TK inhibitory potency (IC50), and selective erbB2 targeting, N-(2-chloroethyl)-N'-methyl-N'-[4-[(3-chlorophenyl)amino]-6-quinazolinyl]-N-nitrosourea, a stable (nitroso)urea, was considered to have the structural requirements for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxsPsnA7Mo27Vg90H21EOLACvtfcHk0lgZyik_KmGXpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkslKht7c%253D&md5=8467f8ee9d926318324ee4856c88b2aa</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm0600390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0600390%26sid%3Dliteratum%253Aachs%26aulast%3DDomarkas%26aufirst%3DJ.%26aulast%3DDudouit%26aufirst%3DF.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DQiyu%26aufirst%3DQ.%26aulast%3DBanerjee%26aufirst%3DR.%26aulast%3DBrahimi%26aufirst%3DF.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520Combi-targeting%2520concept%253A%2520synthesis%2520of%2520stable%2520nitrosoureas%2520designed%2520to%2520inhibit%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3544%26epage%3D3552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Mechanism of action of erb tyrosine kinase inhibitors</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1016%2FS0014-4827%2802%2900095-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=12648472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitVyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=131-139&author=D.+W.+Fry&title=Mechanism+of+action+of+erb+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of erbB tyrosine kinase inhibitors</span></div><div class="casAuthors">Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-139</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A review.  Over the last decade, drug discovery efforts have generated a myriad of compds. that inhibit the activity of the erbB family of tyrosine kinases with potencies and selectivity that have surpassed original expectations.  These characteristics, along with improved pharmaceutical properties, have enabled inhibitors from this class of agents to finally realize their therapeutic potential, and indeed, some are currently producing significant clin. responses.  Interestingly, those properties that are essential for a clin. active inhibitor of the erbB family are most readily attained with compds. that bind at the ATP site, and the most successful compds. have shown a distinct convergence to certain common chem. features.  The reasons for this trend are beginning to be realized through the generation of an increasing array of cryst. structures for protein kinases as well as advances in mol. modeling.  This has allowed a more complete understanding of the precise phys. interactions that occur between erbB tyrosine kinase inhibitors and their target(s), which, in turn, has begun to shed light on the mechanism by which these mols. attain their remarkable affinity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-o5XCjZZQdLVg90H21EOLACvtfcHk0lgZyik_KmGXpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitVyltL8%253D&md5=09c10abfc9a8e91617f468393b2d449a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0014-4827%2802%2900095-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4827%252802%252900095-2%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DMechanism%2520of%2520action%2520of%2520erb%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2003%26volume%3D284%26spage%3D131%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallet, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span> </span><span class="NLM_article-title">Synthesis and structure−activity relationships of 6,7-disubstituted 4-anilinoquinazoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Halletauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=L.+M.+Greenbergerauthor=H.-R.+Tsou&title=Synthesis+and+structure%E2%88%92activity+relationships+of+6%2C7-disubstituted+4-anilinoquinazoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallet%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.-R.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinazoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Johnson, L. N.</span><span> </span><span class="NLM_article-title">Protein kinase inhibitors: contributions from structure to clinical compounds</span> <span class="citation_source-journal">Q. Rev. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1017%2FS0033583508004745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1-40&author=L.+N.+Johnson&title=Protein+kinase+inhibitors%3A+contributions+from+structure+to+clinical+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1017%2FS0033583508004745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033583508004745%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DProtein%2520kinase%2520inhibitors%253A%2520contributions%2520from%2520structure%2520to%2520clinical%2520compounds%26jtitle%3DQ.%2520Rev.%2520Biophys.%26date%3D2009%26volume%3D19%26spage%3D1%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Rachid, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahimi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jean-Claude, B. J.</span><span> </span><span class="NLM_article-title">Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure−activity relationship</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2605</span><span class="NLM_x">–</span> <span class="NLM_lpage">2608</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070144p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2605-2608&author=Z.+Rachidauthor=F.+Brahimiauthor=Q.+Qiuauthor=C.+Williamsauthor=J.+M.+Hartleyauthor=J.+A.+Hartleyauthor=B.+J.+Jean-Claude&title=Novel+nitrogen+mustard-armed+combi-molecules+for+the+selective+targeting+of+epidermal+growth+factor+receptor+overexperessing+solid+tumors%3A+discovery+of+an+unusual+structure%E2%88%92activity+relationship"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm070144p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070144p%26sid%3Dliteratum%253Aachs%26aulast%3DRachid%26aufirst%3DZ.%26aulast%3DBrahimi%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DQ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DHartley%26aufirst%3DJ.%2BM.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DNovel%2520nitrogen%2520mustard-armed%2520combi-molecules%2520for%2520the%2520selective%2520targeting%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520overexperessing%2520solid%2520tumors%253A%2520discovery%2520of%2520an%2520unusual%2520structure%25E2%2588%2592activity%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2605%26epage%3D2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=J.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+H.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DJ.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Matheson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jean-Claude, B. J.</span><span> </span><span class="NLM_article-title">Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=11181914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtlOksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2001&pages=832-840&author=S.+L.+Mathesonauthor=J.+McNameeauthor=B.+J.+Jean-Claude&title=Design+of+a+chimeric+3-methyl-1%2C2%2C3-triazene+with+mixed+receptor+tyrosine+kinase+and+DNA+damaging+properties%3A+a+novel+tumour+targeting+strategy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy</span></div><div class="casAuthors">Matheson, Stephanie L.; McNamee, James; Jean-Claude, Bertrand J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">832-840</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The mixed epidermal growth factor receptor (EGFR)-DNA targeting properties of SMA41, a 6-(3-methyl-1,2,3-triazen-1-yl)-4-anilinoquinazoline designed to release N4-m-tolyl-quinazoline-4,6-diamine henceforth referred to as SMA52 [an inhibitor of EGFR tyrosine kinase (TK)] and methyldiazonium (a DNA methylating species) were studied in the O6-methylguanine-DNA methyltransferase (MGMT)-proficient and high EGFR-expressing epidermoid carcinoma of the vulva cell line A431.  The effects of SMA41 were compared with those of SMA52 alone, and temozolomide (TEM), a clin. prodrug of 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) that is inactive in MGMT-proficient cells.  The results showed that (1) the chimeric SMA41 could degrade in serum-contg. medium (t1/2 of ∼30 min) to generate, as predicted, the free inhibitor SMA52 as the most abundant metabolite (∼81% yield); (2) in contrast to SMA52 alone, the chimeric SMA41 and TEM induced significant DNA damage in A431 cells after 30-min or 2-h drug exposures, as confirmed by alk. single-cell gel microelectrophoresis (comet) assay; (3) SMA41 showed 5-fold greater affinity for the ATP binding site of EGFR than independently synthesized SMA52 in an enzyme assay and blocked EGF-induced tyrosine phosphorylation and EGFR autophosphorylation in A431 cells in a dose-dependent manner; (4) these mixed targeting properties of SMA41, combined with its ability to be converted to another potent EGFR TK inhibitor (e.g., SMA52) by hydrolytic cleavage, translated into over 8-fold greater antiproliferative activity than TEM, which showed no EGFR targeting properties (IC50 competitive binding > 100 μM); (5) under continuous drug exposure (3-6-day sulforhodamine and clonogenic assays), SMA41 was almost equipotent with SMA52; however, in a short 2-h drug exposure followed by incubation in drug-free media, SMA52 showed an almost complete loss of antiproliferative activity over the whole dose range.  In contrast, SMA41 retained almost 100% of its activity, indicating a more sustained growth inhibitory activity.  The results in toto suggest that the superior antiproliferative activity of SMA41 may be due to a combination of events assocd. with its binary EGFR TK and DNA targeting properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCMceLhqIjUbVg90H21EOLACvtfcHk0lgYj5baW3M44Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtlOksr8%253D&md5=0377f2155e213dc809999dc1572dfd3c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DS.%2BL.%26aulast%3DMcNamee%26aufirst%3DJ.%26aulast%3DJean-Claude%26aufirst%3DB.%2BJ.%26atitle%3DDesign%2520of%2520a%2520chimeric%25203-methyl-1%252C2%252C3-triazene%2520with%2520mixed%2520receptor%2520tyrosine%2520kinase%2520and%2520DNA%2520damaging%2520properties%253A%2520a%2520novel%2520tumour%2520targeting%2520strategy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D296%26spage%3D832%26epage%3D840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuliani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fumarola, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span> </span><span class="NLM_article-title">Dual mechanism of action of the 5-benzylidene-hydantoin UPR1204 on lung cancer cell lines</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1158%2F1535-7163.MCT-07-0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=18281519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVShsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=361-370&author=A.+Cavazzoniauthor=R.+Alfieriauthor=C.+Carmiauthor=V.+Zulianiauthor=M.+Galettiauthor=C.+Fumarolaauthor=R.+Frazziauthor=M.+Bonelliauthor=F.+Bordiauthor=A.+Lodolaauthor=M.+Morauthor=P.+G.+Petronini&title=Dual+mechanism+of+action+of+the+5-benzylidene-hydantoin+UPR1204+on+lung+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines</span></div><div class="casAuthors">Cavazzoni, Andrea; Alfieri, Roberta R.; Carmi, Caterina; Zuliani, Valentina; Galetti, Maricla; Fumarola, Claudia; Frazzi, Raffaele; Bonelli, Mara; Bordi, Fabrizio; Lodola, Alessio; Mor, Marco; Petronini, Pier Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In this study, we examd. the mechanism of action of the novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 5-benzylidene-hydantoin UPR1024, whose structure was designed to interact at the ATP-binding site of EGFR.  The compd. had antiproliferative and proapoptotic effects when tested on the non-small cell lung cancer cell line A549.  The growth inhibitory effect was assocd. with an accumulation of the cells in the S phase of the cell cycle.  Moreover, UPR1024 induced significant level of DNA strand breaks assocd. with increased expression of p53 and p21WAF1 proteins, suggesting an additive mechanism of action.  The presence of wild-type p53 improved the drug efficacy, although the effect was also detectable in p53 null cells.  We also noted apoptotic cell death after treatment with UPR1024 at concns. above 10 μmol/L for >24 h, with involvement of both the extrinsic and intrinsic pathways.  The present data show that UPR1024 may be considered a combi-mol. capable of both blocking EGFR tyrosine kinase activity and inducing genomic DNA damage.  UPR1024 or its derivs. might serve as a basis for development of drugs for the treatment of lung cancer in patients resistant to classic tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAJkd_64qRwbVg90H21EOLACvtfcHk0lgYj5baW3M44Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVShsr0%253D&md5=06b5a43934a731dceb0a321ae2fd22c7</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0477%26sid%3Dliteratum%253Aachs%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DZuliani%26aufirst%3DV.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DFumarola%26aufirst%3DC.%26aulast%3DFrazzi%26aufirst%3DR.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26atitle%3DDual%2520mechanism%2520of%2520action%2520of%2520the%25205-benzylidene-hydantoin%2520UPR1204%2520on%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Alvarez-Sanchez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basketter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepoittevin, J.-P.</span><span> </span><span class="NLM_article-title">Studies of chemical selectivity of hapten, reactivity, and skin sensitization potency. 3. Synthesis and studies on the reactivity toward model nucleophiles of the <sup>13</sup>C-labeled skin sensitizers, 5-chloro-2-methylisothiazol-3-one (MCI) and 2-methylisothiazol-3-one (MI)</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">636</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx0256634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=627-636&author=R.+Alvarez-Sanchezauthor=D.+Basketterauthor=C.+Peaseauthor=J.-P.+Lepoittevin&title=Studies+of+chemical+selectivity+of+hapten%2C+reactivity%2C+and+skin+sensitization+potency.+3.+Synthesis+and+studies+on+the+reactivity+toward+model+nucleophiles+of+the+13C-labeled+skin+sensitizers%2C+5-chloro-2-methylisothiazol-3-one+%28MCI%29+and+2-methylisothiazol-3-one+%28MI%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Ftx0256634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx0256634%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarez-Sanchez%26aufirst%3DR.%26aulast%3DBasketter%26aufirst%3DD.%26aulast%3DPease%26aufirst%3DC.%26aulast%3DLepoittevin%26aufirst%3DJ.-P.%26atitle%3DStudies%2520of%2520chemical%2520selectivity%2520of%2520hapten%252C%2520reactivity%252C%2520and%2520skin%2520sensitization%2520potency.%25203.%2520Synthesis%2520and%2520studies%2520on%2520the%2520reactivity%2520toward%2520model%2520nucleophiles%2520of%2520the%252013C-labeled%2520skin%2520sensitizers%252C%25205-chloro-2-methylisothiazol-3-one%2520%2528MCI%2529%2520and%25202-methylisothiazol-3-one%2520%2528MI%2529%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2003%26volume%3D16%26spage%3D627%26epage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1519</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm960789h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1519-1529&author=B.+D.+Palmerauthor=S.+Trumpp-Kallmeyerauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=H.+D.+H.+Showalterauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+11.+Soluble+analogues+of+pyrrolo-+and+pyrazoloquinazolines+as+epidermal+growth+factor+receptor+inhibitors%3A+synthesis%2C+biological+evaluation%2C+and+modeling+of+the+mode+of+binding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm960789h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960789h%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252011.%2520Soluble%2520analogues%2520of%2520pyrrolo-%2520and%2520pyrazoloquinazolines%2520as%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%253A%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520modeling%2520of%2520the%2520mode%2520of%2520binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1519%26epage%3D1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Mor, M.; Bordi, F.; Carmi, C.; Vezzosi, S.; Lodola, A.; Petronini, P. G.; Alfieri, R.; Cavazzoni, A.</span><span> </span><span class="NLM_article-title">Composti Inibitori Irreversibili di EGFR con Attività Antiproliferativa</span>. Italian Patent Application MI2008A002336,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=M.+Mor&author=F.+Bordi&author=C.+Carmi&author=S.+Vezzosi&author=A.+Lodola&author=P.+G.+Petronini&author=R.+Alfieri&author=A.+Cavazzoni&title=Composti+Inibitori+Irreversibili+di+EGFR+con+Attivit%C3%A0+Antiproliferativa"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMor%26aufirst%3DM.%26atitle%3DComposti%2520Inibitori%2520Irreversibili%2520di%2520EGFR%2520con%2520Attivit%25C3%25A0%2520Antiproliferativa%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Gilday, J. P.; David, M.</span><span> </span><span class="NLM_article-title">Process for the Preparation of 4-(3′-Chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline</span>. PCT Int. Appl.WO2004/024703,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=J.+P.+Gilday&author=M.+David&title=Process+for+the+Preparation+of+4-%283%E2%80%B2-Chloro-4%E2%80%B2-fluoroanilino%29-7-methoxy-6-%283-morpholinopropoxy%29quinazoline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilday%26aufirst%3DJ.%2BP.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%25204-%25283%25E2%2580%25B2-Chloro-4%25E2%2580%25B2-fluoroanilino%2529-7-methoxy-6-%25283-morpholinopropoxy%2529quinazoline%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Weber, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertics, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, G. N.</span><span> </span><span class="NLM_article-title">Immunoaffinity purification of the epidermal growth factor receptor. Stoichiometry of binding and kinetics of self-phosphorylation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">259</span><span class="NLM_x">, </span> <span class="NLM_fpage">14631</span><span class="NLM_x">–</span> <span class="NLM_lpage">14636</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=1984&pages=14631-14636&author=W.+Weberauthor=P.+J.+Berticsauthor=G.+N.+Gill&title=Immunoaffinity+purification+of+the+epidermal+growth+factor+receptor.+Stoichiometry+of+binding+and+kinetics+of+self-phosphorylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DW.%26aulast%3DBertics%26aufirst%3DP.%2BJ.%26aulast%3DGill%26aufirst%3DG.%2BN.%26atitle%3DImmunoaffinity%2520purification%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor.%2520Stoichiometry%2520of%2520binding%2520and%2520kinetics%2520of%2520self-phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1984%26volume%3D259%26spage%3D14631%26epage%3D14636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Olive, D. M.</span><span> </span><span class="NLM_article-title">Quantitative methods for the analysis of protein phosphorylation in drug development</span> <span class="citation_source-journal">Expert Rev. Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm901558p&amp;key=10.1586%2F14789450.1.3.327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm901558p&amp;key=15966829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsFWlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=327-341&author=D.+M.+Olive&title=Quantitative+methods+for+the+analysis+of+protein+phosphorylation+in+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative methods for the analysis of protein phosphorylation in drug development</span></div><div class="casAuthors">Olive, D. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-341</span>CODEN:
                <span class="NLM_cas:coden">ERPXA3</span>;
        ISSN:<span class="NLM_cas:issn">1478-9450</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Most signal transduction and cell signaling pathways are mediated by protein kinases.  Protein kinases have emerged as important cellular regulatory proteins in many aspects of neoplasia.  Protein kinase inhibitors offer the opportunity to target diseases such as cancer with chemotherapeutic agents specific for the causative mol. defect.  In order to identity possible targets and assess kinase inhibitors, quant. methods for analyzing protein phosphorylation have been developed.  This review examines some of the current formats used for quantifying kinase function for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqicz-TQoAbfbVg90H21EOLACvtfcHk0lglGQAcMxlEEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsFWlsbY%253D&md5=bc30b08948eab0593aac338138936d23</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1586%2F14789450.1.3.327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14789450.1.3.327%26sid%3Dliteratum%253Aachs%26aulast%3DOlive%26aufirst%3DD.%2BM.%26atitle%3DQuantitative%2520methods%2520for%2520the%2520analysis%2520of%2520protein%2520phosphorylation%2520in%2520drug%2520development%26jtitle%3DExpert%2520Rev.%2520Proteomics%26date%3D2004%26volume%3D1%26spage%3D327%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><a href="http://www.cerep.fr" class="extLink">www.cerep.fr</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=www.cerep.fr."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andriani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbognani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusca, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fumarola, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzi, G.</span><span> </span><span class="NLM_article-title">Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">8439</span><span class="NLM_x">–</span> <span class="NLM_lpage">8446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=8439-8446&author=A.+Cavazzoniauthor=P.+G.+Petroniniauthor=M.+Galettiauthor=L.+Rozauthor=F.+Andrianiauthor=P.+Carbognaniauthor=M.+Ruscaauthor=C.+Fumarolaauthor=R.+Alfieriauthor=G.+Sozzi&title=Dose-dependent+effect+of+FHIT-inducible+expression+in+Calu-1+lung+cancer+cell+line"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DRoz%26aufirst%3DL.%26aulast%3DAndriani%26aufirst%3DF.%26aulast%3DCarbognani%26aufirst%3DP.%26aulast%3DRusca%26aufirst%3DM.%26aulast%3DFumarola%26aufirst%3DC.%26aulast%3DAlfieri%26aufirst%3DR.%26aulast%3DSozzi%26aufirst%3DG.%26atitle%3DDose-dependent%2520effect%2520of%2520FHIT-inducible%2520expression%2520in%2520Calu-1%2520lung%2520cancer%2520cell%2520line%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D8439%26epage%3D8446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit65"><span> <span class="citation_source-book">Glide</span>, version <span class="NLM_edition">5.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+5.0%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2005."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlide%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit66"><span> <span class="citation_source-book">Maestro</span>, version <span class="NLM_edition">8.5</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+version+8.5%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2008."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMaestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span> </span><span class="NLM_article-title">Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">11225</span><span class="NLM_x">–</span> <span class="NLM_lpage">11236</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja9621760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK28XmtlOitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=11225-11236&author=W.+L.+Jorgensenauthor=D.+S.+Maxwellauthor=J.+Tirado-Rives&title=Development+and+testing+of+the+OPLS+all-atom+force+field+on+conformational+energetics+and+properties+of+organic+liquids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids</span></div><div class="casAuthors">Jorgensen, William L.; Maxwell, David S.; Tirado-Rives, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11225-11236</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and testing of the OPLS all-atom force field for org. mols. and peptides are described.  Parameters for both torsional and nonbonded energetics have been derived, while the bond stretching and angle bending parameters have been adopted mostly from the AMBER all-atom force field.  The torsional parameters were detd. by fitting to rotational energy profiles obtained from ab initio MO calcns. at the RHF/6-31G*//RHF/6-31G* level for more than 50 org. mols. and ions.  The quality of the fits was high with av. errors for conformational energies of less than 0.2 kcal/mol.  The force-field results for mol. structures are also demonstrated to closely match the ab initio predictions.  The nonbonded parameters were developed in conjunction with Monte Carlo statistical mechanics simulations by computing thermodn. and structural properties for 34 pure org. liqs. including alkanes, alkenes, alcs., ethers, acetals, thiols, sulfides, disulfides, aldehydes, ketones, and amides.  Av. errors in comparison with exptl. data are 2% for heats of vaporization and densities.  The Monte Carlo simulations included sampling all internal and intermol. degrees of freedom.  It is found that such non-polar and monofunctional systems do not show significant condensed-phase effects on internal energies in going from the gas phase to the pure liqs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGotSev_b1LVg90H21EOLACvtfcHk0litWiDcBTRztw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtlOitrs%253D&md5=fef2924a69421881390282aa309ae91b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fja9621760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9621760%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DMaxwell%26aufirst%3DD.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26atitle%3DDevelopment%2520and%2520testing%2520of%2520the%2520OPLS%2520all-atom%2520force%2520field%2520on%2520conformational%2520energetics%2520and%2520properties%2520of%2520organic%2520liquids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D11225%26epage%3D11236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Ghosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sendrovic Rapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesner, R. A.</span><span> </span><span class="NLM_article-title">Generalized Born model based on a surface integral formulation</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">10983</span><span class="NLM_x">–</span> <span class="NLM_lpage">10990</span></span><div class="citationLinks">[<a href="/doi/10.1021/jp982533o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm901558p&amp;key=1%3ACAS%3A528%3ADyaK1cXnslOhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=10983-10990&author=A.+Ghoshauthor=C.+Sendrovic+Rappauthor=R.+A.+Friesner&title=Generalized+Born+model+based+on+a+surface+integral+formulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Generalized Born Model Based on a Surface Integral Formulation</span></div><div class="casAuthors">Ghosh, Avijit; Rapp, Chaya Sendrovic; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">10983-10990</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1089-5647</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have derived a surface-area-based version of the generalized Born model (S-GB) as a well-defined approxn. to the boundary element formulation of the Poisson-Boltzmann (PB) equation.  The relationship of the surface area methodol. to the vol.-integration-based approach of Still and co-workers is elucidated.  On the basis of insights obtained from these results, we then develop empirical correction schemes which yield significant improvements in accuracy, as compared to the uncorrected GB model, in reproducing accurate solns. of the Poisson-Boltzmann equation.  A large suite of energetic comparisons of GB, cor. S-GB, and PB for multiple conformations of peptides and proteins is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP-DmhFzS_w7Vg90H21EOLACvtfcHk0litWiDcBTRztw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnslOhs7s%253D&md5=64dcaf1cf104d017a3f907a09c598710</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjp982533o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp982533o%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DSendrovic%2BRapp%26aufirst%3DC.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DGeneralized%2520Born%2520model%2520based%2520on%2520a%2520surface%2520integral%2520formulation%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D1998%26volume%3D102%26spage%3D10983%26epage%3D10990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BJF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BJF','PDB','2BJF'); return false;">PDB: 2BJF</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i45"><a href="/doi/suppl/10.1021/jm901558p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_14183"></div></div></div></div></div><hr /></hr><p class="last">Combustion analytical data; docking of compounds <b>2</b>, <b>4</b>, <b>5</b>, and <b>7</b>−<b>14</b> within the EGFR active site; SW620 cells viability inhibition. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901558p/suppl_file/jm901558p_si_001.pdf">jm901558p_si_001.pdf (1.0 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm901558p&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-5%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm901558p" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm901558p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a64632ec43ce8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
